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 Metabolism profiling and enzyme induction and inhibition tests are 
performed in drug discovery to select drug candidates with favourable metabolism 
profiles and eliminate potential liabilities. While primary human hepatocytes (PHH) 
are the gold standard for metabolism testing as they possess the complete repertoire 
of drug metabolizing enzymes, co-factors, and intact cellular machinery amenable to 
induction, they are not routinely used for screening assays due to high cost, limited 
supply and donor-to-donor variability. As such, pharmaceutical scientists are 
constantly searching for alternative models to overcome these limitations. This thesis 
aimed to evaluate the alternative in vivo model, zebrafish, and in vitro model, 
hepatocyte-like cells (HLCs) derived from two different stem cell sources, for drug 
metabolism testing in drug discovery.  
 Zebrafish liver microsomes isolated from adult zebrafish were used to 
demonstrate that zebrafish possess Cyp3a functional activity through testosterone 6β-
hydroxylation activity. Zebrafish was similar to human in forming the same major 
hydroxytestosterone metabolites but more similar to rat in generating multiple 
hydroxytestosterone metabolites. It was also shown that zebrafish was able to form 
the reactive metabolite, N-acetyl-p-benzoquinone imine from acetaminophen. Cyp3a 
and Phase II testosterone glucuronidation activities were also observed in five days 
post fertilization (d.p.f.) larvae.  
 A high-throughput luminescence-based in vivo Cyp3a assay coupling 5 d.p.f. 
larvae with Luciferin IPA in a 96-well plate was established and used to assess the 
effects of eight FDA-listed hCYP3A4 inducers and six inhibitors on Cyp3a activity in 
zebrafish. Cyp3a activity was inducible by six of the eight inducers while cyp3a65 
gene was upregulated by all compounds, albeit only statistically significant for 
rifampicin, rufinamide and prednisone. Zebrafish was similar to the rat model 
whereby a lack of induction of Cyp3a activity by rifampicin and strong induction by 
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dexamethasone was observed. Induction by carbamazepine and dexamethasone was 
shown to be mediated via the Pxr pathway. A good concordance in the extent of 
Cyp3a inhibition at 50 µM of the inhibitors tested was seen between zebrafish and 
human.  
 The basal expression of 24 drug disposition-related genes of HLC derived 
from human fetal liver multipotent progenitor cells (hFLMPC) and human amniotic 
epithelial cells (hAEC) were compared to adult Caucasian PHH and Asian liver cells, 
and two commonly used hepatoma cell lines, HuH-7 and HepaRG. HLC (hFLMPC) 
expressed Phase II and drug transporter genes in comparable levels to Caucasian 
PHH, while many genes were undetected in HLC (hAEC). The overall metabolic 
profile of HLC (hFLMPC) was also better than HuH-7 which expressed low levels of 
most of the genes evaluated but nevertheless, still distinct from PHH. HLC 
(hFLMPC) possessed functional CYP3A4 metabolic activity which was inducible.  
 In conclusion, both alternative models hold promises for drug metabolism 
testing in drug discovery as they not only possessed the most important CYP activity 
in the metabolism of pharmaceutical drugs, but zebrafish could be used in a high-
throughput manner to assess inducibility or inhibitory potential of compounds, with a 
good degree of concordance to human, while HLC (hFLMPC) has potential to be 
used for screening applications due to its relatively homogenous inter-individual 
metabolic profiles. With further characterization, validation and innovation, these 
models would not only overcome current limitations in drug metabolism research but 
also add value to the drug discovery workflow when positioned strategically.   
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 CHAPTER 1: INTRODUCTION 
1.1. Drug metabolism, transport and regulation  
 
 Drug metabolism is a process in which drugs are chemically altered and 
rendered polar for excretion from the body through urine or bile. This detoxification 
process converts a drug into inactive metabolites so that the drug does not stay too 
long in the body and cause adverse events due to prolonged pharmacological action 
or toxicological effect. In some other instances, a drug may be metabolized into 
active metabolites which also exert pharmacological effects, such as the O-
demethylation of codeine to form morphine. Drug metabolism occurs largely in the 
liver, even though extrahepatic metabolism also occurs at other sites such as the 
gastrointestinal mucosa or brain.  
 In the liver, drug metabolism can be categorized into Phase I and II 
metabolism. In Phase I metabolism, drugs are functionalized via reactions such as 
oxidation, reduction or hydrolysis, primarily catalyzed by a superfamily of enzymes 
known as the cytochrome P450 (CYP).  Out of the 57 CYP genes in human, 15 CYPs 
belonging to the CYP1, 2 and 3 families are responsible for the metabolism of 
xenobiotics (Guengerich, 2005). In Phase II metabolism, the primary metabolites 
generated from Phase I metabolism are conjugated with hydrophilic endogenous 
substrates by enzymes such as the sulfotransferases (SULT), N-acetyltransferases 
(NAT), UDP-glucuronosyltransferases (UGT), and glutathione-S-transferases (GST). 
It is also possible that a drug is subjected directly to Phase II metabolism, without 
undergoing Phase I metabolism and vice versa.  
 Movement of drugs or metabolites into and out of hepatocytes can occur via 
passive diffusion and/or active carrier-mediated transport. The membrane transporters 
involved in the active uptake or efflux of drugs and metabolites in the hepatocytes 
include P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), multidrug 
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resistance protein 2 (MRP2), organic anion transporting polypeptide (OATP), bile 
salt export pump (BSEP), and many more.  
 The above Phase I and II drug metabolizing enzymes (DMEs) and membrane 
transporters are regulated by a battery of transcription factors such as the pregnane X 
receptor (PXR), constitutive androstane receptor (CAR), aryl hydrocarbon receptor 
(AhR), farnesoid X receptor (FXR) and Vitamin D receptor (VDR), among many 
others. These transcription factors are typically activated by ligands which can be 
endogenous substrates or xenobiotics. A good summary of the downstream DME and 
transporter genes regulated by the various transcription factors upon ligand activation 
is available in Table 1 of a review by Nakata et al. (2006) while examples of drugs 
acting as ligands for these transcription factors can be found in Table 1 of a review by 
Urquhart et al. (2007). These tables are also presented in Appendix II: Supplementary 
information of this thesis.  
 
1.2. Drug-drug interactions  
 
 The DMEs, particularly the CYP enzymes, and membrane transporters can be 
inhibited or induced by drugs or xenobiotics. Drug-drug interactions (DDIs) may 
occur when patients are on multiple medications, posing significant challenges in 
pharmacotherapy. CYP enzyme inducers causing accelerated metabolism may lead to 
inadequate plasma concentration level of a co-administered victim drug, 
compromising therapy. If the metabolites generated are toxic, increased generation of 
such metabolites may potentially lead to toxicity. On the other hand, CYP inhibitors 
cause accumulation of parent drugs due to a reduction in clearance of the drugs. This 
may be dangerous as well, especially if the drug has a narrow therapeutic window or 
if prolonged pharmacological action leads to undesirable effects. Using warfarin, an 
anticoagulant largely metabolized by CYP2C9, as an example, co-administration with 
rifampicin, a strong CYP enzyme inducer may increased risk of blood clot formation 
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in patients due to subtherapeutic dosing (Heimark et al., 1987). Conversely, patients 
are at higher risk of bleeding if warfarin is co-administered with CYP inhibitors such 
as amiodarone (Heimark et al., 1992). As such, patients who are prescribed warfarin 
have to be closely monitored by their doctors and pharmacists to prevent any adverse 
drug events arising from drug-drug, drug-food or drug-herb interactions.   
 Induction or inhibition of transporters also affect drug disposition or cause 
adverse drug reactions (ADRs). Inhibition of uptake transporters at the 
gastrointestinal mucosa decreases absorption of drugs while an inhibition of uptake 
transporters at the hepatocytes causes an increase plasma drug concentration due to 
lowered drug clearance. DDI involving transporters have been observed clinically. 
Induction of P-gp transporters at the intestinal barrier by concomitant administration 
of rifampicin have been shown to impair oral absorption of digoxin (Greiner et al., 
1999). Gemfibrozil and cyclosporin, both OATP1B1 inhibitors, caused an increase in 
statin plasma concentration and led to higher risk of myotoxicity (Neuvonen et al., 
2006).  
 DDI through induction is typically mediated via the ligand-activated 
pathways such as PXR, CAR or AhR which upregulate a series of downstream DME 
and transporter genes. In some cases, non-receptor mediated induction can also occur 
via post-transcriptional stabilization of mRNA or inhibition of the proteasome 
ubiquitin degradation pathway (Lin and Lu, 1998; Tompkins and Wallace, 2007).  
Kinetic activation via homotropic or heterotropic ligand binding at the active site of 
enzyme could also account for non-receptor mediated induction (Atkins, 2004; 
Atkins, 2005). On the other hand, the mechanism of CYP inhibition can be grossly 
classified as reversible, quasi-irreversible or irreversible, whereby reversible 
inhibition, which may be competitive or non-competitive, is the most common form 
encountered in DDI. Quasi-irreversible inhibition requires the formation of a 
metabolite which forms a stable complex with the CYP enzyme called metabolic-
intermediate complex. This complexation can be reversed and the CYP function 
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restored by incubation with highly lipophilic compounds to displace the metabolic 
intermediate from the active site (Lin and Lu, 1998). Irreversible inhibition, also 
known as mechanism-based inactivation, also requires a catalytic step to first 
generate a metabolite. In this case, the metabolite irreversibly alters the heme or 
protein and hence, inactivates the enzyme. Some may classify CYP inhibition into 
two categories, that is, reversible or time-dependent inhibition (TDI), whereby quasi-
irreversible and irreversible inhibitions are subsets of TDI. TDI is a kinetic definition 
as it defines that a compound demonstrates an increase in the extent of inhibition 
when it is incubated with the enzyme before addition of the substrate (Grimm et al., 
2009).  
 
1.3. Drug-induced toxicities related to drug metabolism and transport 
 
 For selected drugs, the metabolism of the parent drug to its metabolites plays 
an important role in drug-induced toxicities (Mitchell et al., 1973; Guengerich, 2006). 
The classical example of drug-induced hepatotoxicity is the biotransformation of 
acetaminophen via Phase I metabolism to its reactive electrophilic quinoneimine 
metabolite that binds to cellular proteins causing cell death (Dahlin et al., 1984). The 
Phase II acylglucuronide metabolites of several carboxylate drugs such as zomepirac 
have also been shown to form adducts with proteins as well (Bailey and Dickinson, 
1996). Inhibition of the BSEP transporter by troglitazone and bosentan has been 
proposed to be responsible for causing cholestasis in patients taking these drugs 
(Fattinger et al., 2001; Funk et al., 2001). 





1.4. Drug metabolism and toxicity screening in drug discovery and development 
 
 As a result of the above prominent and important DDI issues, it is 
recommended that pharmaceutical companies screen their compounds for potential 
DDI issues during drug discovery and development. The U.S. Food and Drug 
Administration (FDA) has issued an updated guidance document for the 
pharmaceutical industries entitled ‘Guidance for Industry: Drug Interaction Studies 
— Study Design, Data Analysis, Implications for Dosing, and Labeling 
Recommendations’  (FDA, 2012). Similarly, the European Medicines Agency (EMA) 
also provided an updated 'Guideline on the Investigation of Drug Interactions' which 
took effect from Jan 2013 onwards (EMA, 2012). 
 Metabolism studies are performed in drug discovery as part of the process to 
filter and select drug candidates with favourable absorption, distribution, metabolism, 
and excretion (ADME) profiles and eliminate candidates with potential liabilities. In 
the drug development phase, metabolism studies are conducted to understand the 
disposition of a drug in greater detail (Iyer and Zhang, 2008). The importance of 
performing drug metabolism and toxicity studies in early drug discovery and 
development is becoming more apparent as a study showed that from 1991 to 2000, 
the trend of drug attrition has tilted towards drug toxicity rather than limitations due 
to pharmacokinetics and bioavailability (Kola and Landis, 2004). As such, many 
pharmaceutical companies are investing in early drug metabolism and toxicity 
profiling based on the ‘fail early and fail cheap’ philosophy.  
 In general, in vitro metabolism studies conducted in the drug discovery 
process on new chemical entities (NCEs) or lead compounds are described below 
(Iyer and Zhang, 2008): 
(1) Metabolite profiling studies using liver microsomes, S-9 fraction or hepatocytes 
to understand the metabolic profile of the compound across different 
toxicological model species and human. 
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(2) Detailed reaction phenotyping to identify specific enzymes responsible for the 
metabolism of the compound.  
(3) Inhibition studies to investigate if the compound is an inhibitor of CYP enzymes. 
(4) Induction studies to investigate if the compound is an inducer of CYP enzymes. 
Studies (2)-(4) identify potential metabolism-related DDIs which would affect the 
safety and efficacy of drugs and are typically performed using recombinant enzymes, 
specific chemical inhibitors or inducers, inhibitory antibodies or hepatocytes.  
 With the increased knowledge on DDI involving membrane transporters in 
the past decade, it is also now recommended that investigational drugs are evaluated 
to determine if they are substrates, inhibitors or inducers of transporters. In vitro bi-
directional transport assays using cell lines overexpressing a particular transporter is 
currently the methods employed to achieve these aims (FDA, 2012).   
 In light of the contribution of reactive metabolites to drug toxicity, 
pharmaceutical scientists are also now exploring the inclusion of reactive metabolite 
screening in the drug development workflow. Existing in vitro or in vivo assays are 
able to detect covalent binding or reactive metabolites but knowledge and the tools 
linking reactive metabolites to serious ADRs are still lacking. Therefore, much 
remains to be explored in this field but its importance in reducing liability is 
definitely recognized and gaining attention in drug discovery and development (Park 
et al., 2011).  
 If a compound passes the battery of in vitro tests in the drug discovery phase, 
it then advances to the preclinical development stage where a more definitive in vivo 
ADME and toxicity characterization is performed using animal models. Small 
animals such as rats are most widely used for pharmacokinetics and toxicity testing. 
A compound demonstrating promising results will then be evaluated in bigger 





1.5. Current models used for drug metabolism testing 
 
 In vitro models used in drug metabolism testing can be categorized into 
subcellular fractions or metabolically competent cellular models. Subcellular models 
such as recombinant enzymes, liver microsomes and S9 fractions are simple, fuss-free 
and 'clean' without many confounding factors, and enable one to garner a quick 
overview on the metabolic stability of compounds. The major limitation of these 
models however is that they can be used to assess only Phase I metabolism, UGT 
activities and enzyme inhibition.  
 In this respect, cellular models then overcome the limitations encountered 
with subcellular fractions. Primary human hepatocytes (PHH) are the gold standard in 
vitro cellular model for metabolism testing as they possess the complete repertoire of 
all the drug metabolizing enzymes, co-factors as well as the cellular machinery which 
is amenable to induction by drugs. PHH are however not routinely used for screening 
assays in early drug discovery due to their limited supply and donor-to-donor 
variability (Gomez-Lechon et al., 2008) except for the assessment of CYP induction 
properties of investigational drugs which requires testing in PHH from at least three 
different donors (FDA, 2012).   
 In vivo models such as rat, dog or primates are currently not used in early 
drug discovery screening and only reserved for preclinical studies during drug 
development stages as these animal studies are low in throughput, expensive and also 
entail ethical issues when large numbers and larger animals are used for scientific 





1.6. The pursuit of alternative models for drug metabolism testing 
 
 In view of the above challenges, pharmaceutical scientists are constantly in 
search for newer alternative models which can provide the following advantages: 
(1) High-throughput in vivo models for screening in early drug discovery 
(2) Unlimited source of hepatocytes with a stable metabolic genotype and phenotype 
comparable to that of PHH 
 
1.6.1. Alternative in vivo model - zebrafish (Danio rerio) 
 
 Alternative models such as the zebrafish (Danio rerio) has been explored 
increasingly in recent years as an alternative in vivo pharmacological and 
toxicological screening model in early drug discovery (Parng, 2005; Rubinstein, 
2006; McGrath and Li, 2008; Eimon and Rubinstein, 2009). It has also been 
suggested to bridge in vitro cell-based model and in vivo mammalian model for 
toxicity screening (Sukardi et al., 2011). The popularity of zebrafish larva stems from 
it being a small vertebrate that is amenable to high-throughput screening, its 
transparency enabling visual inspection of toxicological effects, and ease of 
maintenance and handling as compared to mammalian animals. The fast 
developmental growth in which the zebrafish develops fully functional organ systems 
within three to five days post fertilization (d.p.f.) (Westerfield, 2000) increases 
throughputness. Its high fecundity where each female can produce 100-200 eggs per 
mating provides large numbers of embryo for screening applications. Only small 
amounts of compounds are required for testing and this relieves the constraints of 
availability of candidate compounds in early drug discovery. The use of zebrafish is 
also in line with the 3R (reduce, refine and replace) approach of animal use for 
scientific purpose advocated by the Institutional Animal Care and Use Committees.   
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1.6.2. Alternative in vitro model – hepatocyte-like cells (HLCs) derived from 
stem cells 
 
 Hepatoma or immortalized cell lines such as HuH-7, HepG2 and THLE-2 
have been explored as alternative models to provide unlimited supply of hepatocytes 
for metabolism testing (Castell et al., 2006; Donato et al., 2008). However, the 
expression of DMEs in these cell lines are low or even absent when compared against 
PHH, as seen from a recent study systematically characterizing the basal gene 
expression of 251 DMEs in four hepatoma cell lines (Guo et al., 2011). A promising 
hepatoma cell line, the HepaRG, which appears to have metabolic activity similar to 
PHH, has only recently emerged (Aninat et al., 2006; Hart et al., 2010; Andersson et 
al., 2012). 
 Advances in stem cell technology have opened up exciting opportunities as 
an alternative sustainable source of hepatocytes as stem cells have the potential to 
differentiate into any cell type. Stem cells have been explored for use in drug 
development as ‘bio-tools’ for early drug target studies, pharmacokinetic or safety 
assessment, and as screening models to discover NCEs (Sartipy et al., 2007; Jensen et 
al., 2009). Hepatocyte-like cells (HLCs) have been successfully differentiated from 
various stem cells such as the human embryonic stem cell (hESC), mesenchymal 
stem cell (MSC), umbilical cord, human fetal liver multipotent progenitor cells 
(hFLMPC), human amniotic epithelial cells (hAEC) and also from the newest stem 
cell source, induced pluripotent stem cells (iPSC) (Guguen-Guillouzo et al., 2009; 




1.7. Research gaps 
 
1.7.1. Alternative in vivo model - zebrafish (Danio rerio) 
 
 To be a suitable alternative in vivo model for ADME and toxicity testing, the 
drug metabolizing phenotype of zebrafish should be representative of human or 
current animal models such as rat. The zebrafish has a total of ninety-four cyp genes 
(Goldstone et al., 2010). A number of the zebrafish Cyps such as cyp3a65 (Tseng et 
al., 2005), cyp3c1 (Corley-Smith et al., 2006), cyp2j1(Wang et al., 2007), cyp2k6 
(Wang-Buhler et al., 2005) and cyp26d1 (Gu et al., 2005) have been studied but these 
were primarily performed at the mRNA expression level. The function of these Cyp 
enzymes in the metabolism of pharmaceutical drugs by zebrafish has not been 
evaluated until recently, where a few studies were performed using ibuprofen (Jones 
et al., 2009) and CYP probe substrates such as phenacetin, dextromethorphan, 
diclofenac, bupropion and testosterone (Alderton et al., 2010). Phase II enzymes such 
as SULT and UGT have been characterized at the gene expression level (Huang and 
Wu, 2010; Liu et al., 2010) and enzyme activity demonstrated with a few substrates 
(Yasuda et al., 2009; Thompson et al., 2010). 
 From current literatures, it is apparent that there is a knowledge gap in 
understanding the metabolism of drugs in zebrafish compared against current 
mammalian models such as rat or human. Knowledge about Cyp3a activity in 
zebrafish, CYP3A4 metabolic activity being the most commonly encountered 
reaction in human and responsible for the metabolism of ~50% pharmaceutical drugs 
(Guengerich, 2006), is lacking. Moreover, little is known about DDI issues such as 
induction or inhibition in zebrafish and its ability to generate reactive metabolites 
remains to be investigated. These research gaps need to be addressed in order to 
assess the suitability of using zebrafish as an alternative in vivo model or as an 
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intermediate model between current in vitro cell-based and in vivo mammalian 
models for drug metabolism testing.  
 
1.7.2. Alternative in vitro model – hepatocyte-like cells (HLCs) derived from 
stem cells 
 
 To be a suitable alternative in vitro model for ADME and toxicity testing, the 
inherent drug metabolizing phenotype of a HLC should be as similar to PHH as 
possible. The metabolism profiles of HLCs from sources such as fetal and adult liver, 
umbilical cord matrix and hESC have been evaluated preliminarily and shown to 
express certain CYP genes and some CYP activity (Guguen-Guillouzo et al., 2009). 
HLCs differentiated from hFLMPC were shown to express CYP3A4 gene and possess 
CYP2B6 activity which is inducible by phenobarbital (Dan et al., 2006). HLCs from 
hAEC were recently shown to be able to metabolize testosterone and express 
inducible fetal CYPs (Marongiu et al., 2011). 
 Although HLCs derived from stem cells is a promising alternative model of 
PHH, a thorough and systematic evaluation of their metabolic profiles is lacking. 
Typically, expression and functional tests of only a few CYP genes are characterized 
with little elucidation on the Phase II metabolism, transporters and DDI aspects in 
these cells. These research gaps need to be addressed to truly assess the suitability of 





1.8. Research objectives 
 
 The overarching objective of this thesis is to evaluate the alternative in vivo 
model, zebrafish, and in vitro model, hepatocyte-like cells (HLCs) derived from stem 
cells for drug metabolism testing in drug discovery. This is achieved by evaluating 
their drug metabolism profiles in comparison with current gold standard or commonly 
used models. The specific aims are described below: 
 
(1) In zebrafish, the focus is to elucidate and compare its functional Cyp3a 
activity with human and rat, and to assess the potential of the Cyp3a 
activity to be induced or inhibited by the respective human CYP3A4 
inducers and inhibitors. Chapter 2 of the thesis sets out to isolate and evaluate 
the CYP contents in zebrafish liver microsomes (ZLM) with and without bile 
salt or hemoglobin contamination as there is currently no commercially available 
ZLM or recombinant zebrafish Cyps for studying drug metabolism in zebrafish. 
The ZLM isolated is then used to assess zebrafish Cyp3a functional activity and 
reactive metabolite formation capability, in comparison with human and rat, in 
Chapter 3. In this same chapter, the functional Cyp3a and Phase II metabolic 
activities are also evaluated in 5 days post fertilization (d.p.f.) zebrafish larva. 
After establishing that zebrafish possesses Cyp3a functional activity, Chapter 4 
proceeds to establish and evaluate a high-throughput in vivo Cyp3a assay in 
zebrafish by coupling 5 d.p.f. larvae with a commercially available 
luminescence-based human CYP3A4 assay kit. Using the assay developed in this 
chapter, Chapter 5 and 6 assess the inducibility and inhibition of the Cyp3a 





(2) In the HLCs, the approach taken is to obtain a holistic drug disposition-
related (Phase I and II DMEs, transporters and transcription factors) 
transcript profile and compare it with the gold standard PHH and 
immortalized cell lines commonly used for drug metabolism studies. The 
basal CYP3A4 activity and inducibility of the HLCs are also investigated. 
Chapter 7 of the thesis sets to achieve the above by assessing HLCs derived from 
two different stem cell sources, the hFLMPC and hAEC, and comparing them to 





CHAPTER 2: ISOLATION AND EVALUATION OF ZEBRAFISH LIVER 




 Various methods can be used to investigate the xenobiotic metabolism profile 
of zebrafish such as using liver microsomes, hepatocytes, liver slices or whole fish. 
Although metabolic functional assay performed in vivo using adult zebrafish or 
zebrafish larvae is ideal as it represents an intact biological system, the interpretation 
of results may be confounded by other pharmacokinetic processes such as systemic 
absorption and its impact on drug bioavailability. As such, an in vitro model would 
serve as a better tool for the accurate characterization of the function of zebrafish Cyp 
enzymes to address the gap on its xenobiotic metabolism. Compared to liver slices 
and hepatocytes, liver microsomes are a favourable choice as they are robust, contain 
the complete ensemble of Cyp isozymes, can be stored long term and circumvent 
confounding factors such as drug absorption. 
While the isolation of zebrafish liver microsomes (ZLM) may appear to be 
straightforward, an in-house preliminary study conducted using a method commonly 
employed to isolate rat liver microsomes (RLM) (Hill, 2003) showed otherwise. The 
isolated ZLM did not contain CYP450 but instead, contained a high amount of 
metabolically inactive CYP420. While the successful isolation of fish liver 
microsomes was previously reported, the microsomes were derived from distinct and 
intact livers of medium or big-sized fishes such as the rainbow trout, Bermuda chub 
and yellow snapper (Stegeman et al., 1979; Vodicnik et al., 1981; Stegeman et al., 
1997; Leitao et al., 2000). On the contrary, the zebrafish is a small-sized fish 
averaging 3-5 cm in length and its liver is made up of soft tissues enveloping the gut. 
Based on the observed challenges in isolating ZLM, we hypothesized that bile salt 
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and hemoglobin contamination occurred during zebrafish liver isolation leading to 
denaturation of CYP450 and an intense spectra signal at 420 nm, respectively, and 
mitigation of these contaminations would produce metabolically active ZLM. This 
chapter thus aimed to isolate and evaluate the CYP contents in ZLM with and 





2.2. Materials and methods 
 
2.2.1. Chemicals and reagents 
 
 Sodium pyrophosphate, Tris.Cl, ethylene diamine tetra-acetic acid (EDTA),  
tergitol and safranin O were purchased from Sigma–Aldrich (St. Louis, MO, USA). 
Potassium chloride was purchased from Merck Millipore (Merck KGaA, Darmstadt, 
Germany). Water was purified using a Milli-Q water purification system (Millipore, 
Bedford, MA, USA). All other chemicals and reagents used in the experiments were 
of analytical grade. 
 
2.2.2. Animal husbandry 
 
 Adult zebrafish were purchased from Mainland Fish Farm, Singapore and 
acclimatized for a period of 2 to 5 days at the central aquarium at the Department of 
Biological Sciences, National University of Singapore (NUS) prior to liver 
dissection. Sprague-Dawley rats (SD rats) were obtained from the Animal Resources 
Centre, Australia. The SD rats were fed with food and water ad libitum and 
acclimatized at the A*STAR Biological Resource Centre (Singapore) for at least 
1 week before experimentation. All experiments were conducted in compliance with 
the guidelines of the Institutional Animal Care and Use Committee of NUS.    
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2.2.3. Preparation of liver microsomes 
 
 All procedures were conducted on ice using cold buffers. Three buffers, 
namely the homogenizing buffer (0.1 M Tris.Cl (pH 7.4), 10 mM EDTA, 150 mM 
potassium chloride), pyrophosphate buffer (0.1 M sodium pyrophosphate (pH 7.4), 
10 mM EDTA) and microsomal buffer (0.05 M Tris.Cl (pH 7.5), 10 mM EDTA, 
20% glycerol) were prepared according to Hill (Hill, 2003). RLM was pooled from 
two male SD rats and microsome isolation were performed as described by Hill (Hill, 
2003). Livers from zebrafish were isolated on ice promptly and stored temporarily on 
dry ice in between isolation and transferred to -80°C freezer for storage till ZLM 
isolation. Slight volume modifications to the protocol were made for ZLM isolation 
in which 1.5 mL pyrophosphate buffer and 0.4 mL microsomal buffer were used to 
resuspend the pellet in the intermediate and final ultracentrifugation steps, 
respectively.  
   
2.2.4. Effects of bile contamination on male ZLM 
 
 To investigate the effects of bile contamination during liver isolation, 97 
male zebrafish livers were carefully isolated on ice, taking care not to rupture the 
nearby gallbladder of the fish. Each liver was rinsed with 60 µL of homogenizing 
buffer and dabbed dry with lint-free Kimwipes (Kimberly-Clark Professional, 
Canada). 47 rinsed livers were each mixed with one gallbladder sac isolated from the 
zebrafish and pooled together to constitute the test group with bile contamination 
while 50 rinsed livers were pooled to constitute the control group without bile 
contamination. The isolation experiments yielded the male ZLM with bile (MZLM 





2.2.5. Effects of hemoglobin contamination on male ZLM 
 
 To investigate the effects of hemoglobin contamination during liver 
isolation, 95 male zebrafish livers were carefully isolated on ice, taking care not to 
rupture the nearby gallbladder of the fish. For the test group with hemoglobin 
contamination, 45 livers were pooled together without any rinsing. For the control 
group with reduced hemoglobin contamination, the remaining 50 livers were each 
rinsed with 60 µL of homogenizing buffer and dabbed dry with lint-free Kimwipes. 
The isolation experiments yielded the rinsed male ZLM (rinsed MZLM) and 
unrinsed male ZLM (unrinsed MZLM) microsomal fractions.  
 
2.2.6. Zebrafish hemoglobin isolation 
 
 100 µL male zebrafish blood was pooled from the decapitated zebrafishes 
after liver isolation. The blood sample was then centrifuged at 8,000 g for 6 min at 
4°C. The supernatant was removed and erythrocyte pellet rinsed 4 times with 100 µL 
0.9% NaCl and hemolysed with 500 µL Milli-Q water. The hemoglobin thus 





2.2.7. Protein and CYP quantification 
 
 Protein concentrations of the various ZLM fractions (MZLM with bile, 
MZLM without bile, rinsed MZLM and unrinsed MZLM), RLM and zebrafish 
hemoglobin were determined by the Bradford assay method using the Bio-rad 
protein assay kit from Bio-rad Laboratories (Hercules, CA, USA) with bovine serum 
albumin as standard. The various ZLM fractions, RLM and hemoglobin were then 
subjected to CYP concentration determination at a standardized protein 
concentration of 0.194 mg/mL using the carbon monoxide (CO) differential scanning 
method adapted to a 96-well format and the following equations as described by 
Guengerich et al. (2009): 
 
nmol CYP450/mL = (ΔA450 - ΔA490)/0.091 
(∆A420 - ∆A490) theoretical = nmol of P450/mL x (-0.041)  







 A typical CO differential spectrum was observed for RLM with the 
maximum absorbance occurring at 450 nm. On the contrary, a maximum absorbance 
was observed at 420 nm in all ZLM fractions (Figures 2.1.A and B). Male zebrafish 
hemoglobin subjected to the same CO differential scanning experiment showed a 
very high absorbance at 420 nm (Figure 2.1.C).  
  Concentrations of CYP450, CYP420 and their ratio ([CYP450]:[CYP420]) 
were determined and summarized in Table 2.1. MZLM with bile contamination 
resulted in a lower [CYP450]:[CYP420] ratio compared to MZLM without bile 
contamination. Similarly, unrinsed MZLM i.e. with hemoglobin contamination 
yielded a lower [CYP450]:[CYP420] ratio compared to rinsed MZLM. Although 
rinsed MZLM and MZLM without bile contamination fractions were similarly 
prepared, the concentration of CYP450 and [CYP450]:[CYP420] ratio were 
different.  
  
Table 2.1. Concentrations of CYP450 and CYP420 per milligram protein in the 








RLM  0.586 0.200 2.935 
MZLM with bile  0.013 0.997 0.013 
MZLM without bile  0.004 0.224 0.017 
Rinsed MZLM  0.062 0.260 0.240 
































































Figure 2.1. CO differential spectra of (A) RLM and MZLM with and without 









 Peak absorbance at 420 nm in a CO-differential scanning spectra of liver 
microsomes could be due to the presence of CYP420 which is the denatured form of 
CYP450, contaminating hemoglobin, methemoglobin or cytochrome b5 (Matsubara et 
al., 1976; Yamano and Ichikawa, 1978; Leitao et al., 2000; Klingenberg, 2003; 
Wilson et al., 2003). In this study, we investigated the effects of bile and hemoglobin 
contamination on the occurrence of the 420 nm peak in the CO-differential spectra of 
ZLM. Based on earlier experience, it was noted that the spleen, gall bladder and 
major blood vessels into and out of the liver had a high propensity to be accidentally 
ruptured during zebrafish liver isolation, owing to their small size and close proximity 
to the liver (Figure 2.2). As such, in the experiments presented in this work, special 
care was taken not to rupture the gall bladder when teasing the liver away from the 
intestine. Perfusion of the liver was not possible due to the limited size of the fish, 
hence rinsing the liver with homogenizing buffer was deemed the most practical way 






Figure 2.2. Dissected intestines, liver and gall bladder from zebrafish 
 
Our results confirmed zebrafish hemoglobin absorbed maximally at 420 nm 
(Figure 2.1.C) and rinsing the liver greatly reduced the peak at 420 nm (Figure 
2.1.B). Moreover, rinsed ZLM with deliberate bile contamination yielded a lower 
ratio of CYP450 to CYP420 content as compared to that without bile contamination 
(Table 2.1). This was observed previously in rabbit liver microsomes where 




CYP420 (Yamano and Ichikawa, 1978). Metabolically active ZLM was successfully 
isolated when both bile and hemoglobin contamination were circumvented. Results 
of the metabolic activity are presented in Chapter 3 in which the ZLM was utilized to 




 For the first time, a ZLM isolation protocol modified from typical RLM 
isolation protocols is presented in this study where bile and hemoglobin 
contamination was shown to be important considerations during liver dissection as 
they affect the CYP450 content of ZLM. Nevertheless, it is important to highlight that 
the current optimized ZLM isolation method lacks extraction efficiency and presents 
with batch-to-batch variation as observed with MZLM without bile and rinsed 
MZLM fractions. The concentration of CYP450 obtained was inherently low and the 
volume of the microsomal fraction obtained from fifty pooled zebrafish livers was 
approximately 300 µL, which could only be used to perform a limited number of 
assays. It is therefore important to recognize this technical limitation and reserve 
ZLM strategically for mechanistic drug metabolism studies. For high-throughput 








CHAPTER 3: EVALUATION OF THE CYP3A METABOLIC ACTIVITY 
AND BIOACTIVATION POTENTIAL IN ZEBRAFISH USING LIVER 




 Zebrafish (Danio rerio) larva has been explored in recent years as an 
alternative in vivo toxicity screening model for cardiotoxicity, neurotoxicity, 
teratogenesis, genotoxicity, gut and ocular toxicity in early drug discovery process 
(McGrath and Li, 2008; Eimon and Rubinstein, 2009). The advantages of using 
zebrafish larva for pharmaceutical applications were alluded in Chapter 1, Section 
1.6.1. Although zebrafish has been quite extensively experimented as a toxicology 
model, its role as a drug metabolism testing model is less established. Knowledge on 
xenobiotic metabolism in zebrafish is still scarce and the function of DMEs in 
zebrafish has not been investigated until recently (Jones et al., 2009; Yasuda et al., 
2009; Alderton et al., 2010; Jones et al., 2010; Thompson et al., 2010). Even so, in 
these studies, the DME functions of the zebrafish were not compared to human or rat, 
the common mammalian model used in preclinical studies. In addition, the ability of 
zebrafish to generate reactive metabolites is also unknown.  
 Interspecies differences in xenobiotic metabolism has far-reaching 
repercussions even if the animal model is not used for metabolism testing 
applications per se. Utility of animal models for toxicological testing is based on the 
assumption that the toxicological outcomes are predictive of human toxicities. 
However, the accuracy of this broad assumption depends on the nature and 
mechanism of toxicity, disposition (distribution, metabolism and excretion) profile of 
each compound within the biological system, and experimental design such as dose 
and duration of dosing. Non-concordance with any of these assumptions may lead to 
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poor prediction of human toxicities. With respect to metabolism, differences in the 
way a compound is metabolized or the ability or failure to generate reactive 
metabolites may impact greatly on the final observed toxicity outcomes in an animal 
model and hence, its predictivity of toxicity in human. An example to illustrate this is 
the drug efavirenz which causes renal toxicity in rats but not monkey and humans. 
This interspecies difference has been suggested to be likely due to differences in 
glutathione-S-transferase activity between the three species (Baillie and Rettie, 2011). 
In another example, different sites of organ toxicities are observed with 4-ipomeanol, 
which causes lung toxicity in animals but dose-limiting liver toxicity in humans. This 
has been attributed to differences in catalytic activity of CYP4B1 in human lungs, 
different bioactivating enzymes in the human liver or lack of detoxifying or 
conjugating enzymes in human liver (Baillie and Rettie, 2011).   
 Therefore, two research questions arose based on the current literature 
review. Since human CYP3A4 enzyme is the major CYP isozyme responsible for the 
metabolism of ~50% of marketed drugs (Guengerich, 2006), firstly, does zebrafish 
possess Cyp3a metabolic activity and if yes, what is the degree of concordance 
between zebrafish, human and rat? Two, can zebrafish generate reactive metabolites? 
To answer the first research question, this chapter aimed to perform metabolite 
profiling experiments on testosterone, a probe substrate of human CYP3A activity, in 
zebrafish and compare its metabolite profiles to human and rat. As acetaminophen 
(APAP) undergoes bioactivation in human to generate the toxic reactive metabolite, 
N-acetyl-p-benzoquinone imine (NAPQI) (Dahlin et al., 1984), the secondary aim 
was to establish the bioactivation potential of zebrafish using APAP as a probe 
substrate.  
 To address these questions, zebrafish liver microsomes (ZLM) were adopted 
as the primary testing system to ascertain the specific role of metabolism and 
eliminate confounding pharmacokinetic factors related to an in vivo model. 
Nonetheless, metabolism of testosterone was also investigated using zebrafish larvae 
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as it is the model adopted for high-throughput toxicity screening of candidate 
compounds. In this study, wild-type zebrafish was adopted to represent a 
heterogeneous and robust population of the model as it is commonly used for 
toxicological studies. In silico substrate-CYP docking was further performed to 
elucidate the possible zebrafish isozymes responsible for the activities observed in the 
functional enzymatic assays. The findings of this study would help gain a clearer 





3.2. Materials and methods 
 
3.2.1. Chemicals and reagents 
 
 Testosterone and formic acid were purchased from Merck (Darmstadt, 
Germany). The 6β-hydroxytestosterone metabolite standard was purchased from 
Cerilliant Corporation (Round Rock, TX, USA) while 2α-, 7α-, 15β-, 16α- and 16β-
hydroxytestosterone were purchased from Steraloids Inc. (Newport, RI, USA). 
Potassium phosphate monobasic (ACS grade) was purchased from Mallinckrodt 
Baker (Phillipsburg, NJ, USA). APAP, procainamide, potassium phosphate dibasic 
(ACS grade) and reduced glutathione (GSH) were purchased from Sigma–Aldrich 
(St. Louis, MO, USA). The NADPH regenerating system was purchased from BD 
Gentest (Woburn, MA, USA). Pooled human liver microsomes (HLM) from 20 
donors, with a protein concentration of 20 mg/mL and total CYP of 300 pmol/mg, 
and pooled male Sprague-Dawley rat liver microsomes (RLM) from 145 donors, with 
a protein concentration of 20 mg/mL and total CYP of 650 pmol/mg,  were obtained 
commercially from BD Biosciences (San Jose, CA, USA). HPLC-grade acetonitrile 
(ACN) and HPLC-grade methanol were purchased from Fisher Scientific 
(Leicestershire, UK) and Tedia Company Inc. (Fairfield, OH, USA), respectively. 
Water was purified using a Milli-Q water purification system (Millipore, Bedford, 






3.2.2. Animal husbandry 
 
 Adult wild-type zebrafish were purchased from Mainland Fish Farm, 
Singapore and acclimatized for a period of 2 to 5 days at the central aquarium at the 
Department of Biological Sciences (DBS), National University of Singapore (NUS) 
prior to liver dissection. Wild-type zebrafish embryo were collected from natural 
spawning at the central aquarium at the DBS, NUS and reared in E3M embryo 
medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2.2H2O, 0.33 mM MgSO4.7H2O, 
0.001 g/l methylene blue with pH adjusted to 7.2) (Cold Spring Harbor Protocols, 
2011) in an incubator at 28.5 ± 0.5°C. Dead larvae were removed and E3M medium 
changed daily until experimentation. All experiments were conducted in compliance 
with the guidelines of the Institutional Animal Care and Use Committee of NUS.   
 
3.2.3. Preparation of zebrafish liver microsomes (ZLM) 
 
 All procedures were conducted as described in Section 2.2.3 of Chapter 2. 
Female zebrafish liver microsomes (FZLM) were pooled from 24 female zebrafish 
where each liver was carefully isolated on ice without bile contamination, rinsed with 
60 µL of homogenizing buffer and dabbed dry with lint-free Kimwipes (Kimberly-
Clark Professional, Canada). Careful isolation without bile contamination and rinsing 
the livers were included based on the findings in Chapter 2 which evaluated the 





3.2.4. Protein and CYP quantification 
 
 Protein concentration of the FZLM was determined by the Bradford assay 
method using the Bio-rad protein assay kit from Bio-rad Laboratories (Hercules, CA, 
USA) with bovine serum albumin as standard. The FZLM was then subjected to CYP 
concentration determination at a standardized protein concentration of 0.194 mg/mL 
using the carbon monoxide (CO) differential scanning method adapted to a 96-well 





3.2.5. Investigation of Cyp3a metabolic activity of zebrafish using liver 
microsomes 
 
 To evaluate the Cyp3a activity of zebrafish in comparison with rat and 
human, testosterone metabolism assays were performed separately using FZLM, 
RLM and HLM.  Each reaction mixture, with a final volume of 250 μL, consisted of 
100 mM potassium phosphate buffer (pH 7.4), NADPH regenerating system 
(consisting of 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM magnesium 
chloride and 0.4 unit/ml glucose-6-phosphate dehydrogenase), and liver microsomes 
with a CYP concentration of 20 pmol/mL. The FZLM reaction mixture was pre-
incubated for 6-8 min at 28.5°C whereas RLM and HLM reaction mixtures were pre-
incubated at 37°C. The reaction was initiated by adding 1 μL of 25 mM testosterone 
dissolved in 100% methanol to give a final testosterone concentration of 100 μM and 
final organic concentration of 0.4%. The reaction mixtures were incubated at 28.5°C 
for FZLM and 37°C for RLM and HLM. At time points 0, 1 and 2 h, 70 µL of the 
incubation mixture was transferred to 70 µL ice-cold 0.5 µM prednisolone (internal 
standard, IS) in ACN. The mixtures were then centrifuged at 14,000 g for 15 min at 
4°C. Aliquots of supernatants were evaporated to dryness at 37°C for 2 h under a 
gentle flow of nitrogen gas using the Turbovap LV (Caliper Life Science, Hopkinton, 
MA, USA). Each sample was reconstituted with 20% ACN in water, vortexed and 2 
µL of the supernatant injected for ultra-high pressure liquid chromatography tandem 
mass spectrometry (UHPLC/MS/MS) analyses. Control incubations were performed 






3.2.6. Investigation of Cyp3a metabolic activity of zebrafish larvae 
 
 Zebrafish larvae at 5 days post fertilization (d.p.f.) were exposed to 
testosterone for 3 h at 28.5°C. Stock testosterone was dissolved in methanol and 
diluted in E3M medium to give a final working solution of 10 µM testosterone and 
final organic concentration of 0.1%. Experiments were carried out in triplicates in a 
12-well plate where each well (experimental replicate) contained 20 zebrafish larvae 
immersed in 1 mL of E3M medium (control) or 10 µM testosterone in E3M medium.  
At 3 h, 750 µL of medium was withdrawn for subsequent analysis while zebrafish 
larvae were anaesthetized with ice-cold medium.  The larvae were then rinsed twice 
with ice-cold phosphate buffered saline (PBS), suspended in 1 mL of PBS and 
transferred to a microfuge tube and centrifuged at 1,000 g for 1 min. The supernatant 
was removed and larvae macerated with a hand-held pellet pestle motor to form a 
homogenate. The medium and larvae homogenate samples were stored at -20°C until 
further sample preparation for analysis.  
 On the day of analysis, 400 µL of ice-cold water was added to the thawed 
larvae homogenate and further homogenized with two pulses of 25Hz x 10 sec with a 
mixer mill bead homogenizer, MM400 (Retsch, Haan, Germany). 100 µL of 0.5 µM 
prednisolone in ACN (IS) was added to 100 µL each of the medium and diluted 
larvae homogenate and centrifuged at 14,000 g for 10 min. 180 µL of the supernatant 
was evaporated to dryness at 37°C for 1 h under a gentle flow of nitrogen gas using 
the Turbovap LV (Caliper Life Science, Hopkinton, MA, USA) and reconstituted 
with 180 µL of 5% methanol in water. The reconstituted samples were subjected to 
solid phase extraction (SPE) using the Strata-X C18 polymeric reverse phase sorbent 
(Phenomenex, Torrance, CA, USA). SPE conditions were as follows: conditioning 
with 0.3 mL methanol, equilibration with 0.3 mL water, loading of 150 µL of the 
sample, washing with 0.3 mL 15% methanol and elution with 0.3 mL ACN. 280 µL 
of the eluate was dried under a gentle flow of nitrogen gas for 1 h. Each sample was 
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reconstituted with 20% ACN in water, vortexed and 2 µL of the supernatant injected 
for UHPLC/MS/MS analyses.  A stability test of testosterone in E3M incubated at 
28.5°C for 3 h was also performed. 
 
3.2.7. Investigation of reactive metabolite generating capability of zebrafish 
 
 To investigate the ability of ZLM to generate reactive metabolites, 
glutathione trapping assays of NAPQI (Hinson et al., 1977) were performed 
individually with FZLM, RLM and HLM. Incubation conditions were similar to the 
testosterone metabolism assay except that liver microsomes with a CYP 
concentration of 15 pmol/mL were used and 5 mM GSH was added. The FZLM 
reaction mixture was pre-incubated for 6-8 min at 28.5°C whereas RLM and HLM 
reaction mixtures were pre-incubated at 37°C. The reaction was initiated by adding 
25 μL of 10 mM APAP dissolved in water to give a final APAP concentration of 1 
mM. The reaction mixtures were incubated at 28.5°C for FZLM and 37°C for RLM 
and HLM. At 2 h, 250 µL of ice-cold 0.5 µM procainamide (IS) in ACN was added to 
the reaction mixture to quench the reaction. The mixtures were then centrifuged at 
14,000 g for 15 min at 4°C. Aliquots of supernatants were evaporated to dryness at 
37°C for 2 h under a gentle flow of nitrogen gas. Each sample was reconstituted with 
20 µL 0.1% formic acid in water and 2 µL and 3 µL injected for UHPLC/MS/MS and 
ultra performance liquid chromatography quadrupole, orthogonal acceleration time-
of-flight tandem mass spectrometer (UPLC/QTOF/MS/MS) analyses, respectively. 
Three control incubations were performed without GSH, NADPH or APAP for all 







3.2.8.1. UHPLC/MS/MS analyses of hydroxytestosterone and NAPQI-GSH 
adduct 
 
 The testosterone metabolism and APAP bioactivation samples were analyzed 
using an Agilent 1290 Infinity UHPLC interfaced with Agilent 6430 QQQ MS 
(Agilent Technologies, Santa Clara, CA, USA). The UHPLC and MS systems were 
both controlled by the Agilent MassHunter Workstation Software – LC/MS Data 
Acquisition for 6400 Series (Agilent Technologies). Chromatographic separations 
were performed on an ACQUITY UPLC BEH C18 1.7 μm 100 × 2.1 mm i.d. column 
(Waters, Milford, MA, USA) for the testosterone samples while APAP samples were 
separated using an ACQUITY UPLC BEH C18 1.7 μm 50 × 2.1 mm i.d. column 
(Waters). The column heater and autosampler were kept at 45 and 6 °C, respectively. 
The mobile phase consisted of solvent A (0.1% formic acid in water) and solvent B 
(0.1% formic acid in ACN). The flow rates were 0.45 mL/min and 0.6 mL/min for the 
testosterone and APAP experiments, respectively. 
The optimized elution conditions were as follows: (a) testosterone 
experiments: gradient of 30.0–90.0% solvent B (0–6.25 min), gradient of 90.0-95.0% 
solvent B (6.25-6.30 min), isocratic at 95.0% solvent B (6.30-7.05 min), gradient of 
95.0-30.0% solvent B (7.05-7.10min) and isocratic at 30.0% solvent B (7.10-
8.00 min) and (b) APAP experiments: gradient of 0.1–60.0% solvent B (0–1.40 min), 
gradient of 60.0-95.0% solvent B (1.40-1.41 min), isocratic at 95% solvent B (1.41–
1.90 min), gradient of 95.0-0.1% solvent B (1.90-1.95min) and isocratic at 0.1% 
solvent B (1.95–2.50 min). 
Multiple reaction monitoring (MRM) experiments and electrospray positive 
ionization mode (ESI +ve) were used for all analyses. The MS conditions for all the 
experiments are summarized in Table 3.1. 
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Table 3.1. Optimized MS conditions for the analyses of testosterone and APAP 
samples. 






(A) Testosterone 289  97 136 16 
OH-testosterone 305  269 136 8 
Prednisolone (IS) 361.5  343 104 4 
(B) Acetaminophen 152  110 104 12 
NAPQI-GSH 457.1  328.1 136 4 
Procainamide (IS) 236  163 104 12 
 
 
3.2.8.2. UPLC/QTOF/MS/MS analyses of NAPQI-GSH adduct 
 
 Accurate mass measurement methods were developed using an ACQUITY 
UPLC system interfaced with a QTOF/MS equipped with ESI source (Waters) for the 
analyses of APAP bioactivation samples. The UPLC/QTOF/MS system was 
controlled by MassLynx 4.1 software (Waters). Chromatographic separations were 
performed using the same column and elution conditions for APAP samples as 
described above. The QTOF/MS system was tuned for optimum sensitivity and 
resolution in ESI +ve mode using leucine enkephalin (200 pg/μL infused at 
10 μL/min). Prior to analysis, the system was calibrated in ESI +ve mode using 0.5 M 
sodium formate solution infused at a flow rate of 5 μL/min. All analyses were 
acquired using an independent reference spray via the LockSpray™ interface to 
ensure high mass accuracy and reproducibility. The [M+H]+ ion of leucine enkephalin 
(2 ng/µL infused at 8 μL/min) was used as the reference lock mass (m/z 556.2771) for 
the analysis of NAPQI-GSH. The LockSpray™ was operated at a reference scan 
frequency, reference cone voltage and collision energy of 5 s, 30 V and 5 V, 
respectively. The QTOF/MS/MS analyses were operated in “V” mode and the 
optimized MS conditions for the analyses of NAPQI-GSH adduct are summarized in 




Table 3.2. Optimized MS conditions for the accurate mass measurement of 
NAPQI-GSH using the QTOF/MS. 
 NAPQI-GSH 
Precursor mass (Da) 457.1 
Scan range (Da) 50-600 
Scan time (s) 0.2 
Interscan delay (s) 0.02 
Capillary voltage (V) 3400 
Sampling cone (V) 24 
Source temperature (°C) 100 
Desolvation temperature (°C) 350 
Cone gas flow (L/h) 0 
Desolvation gas flow (L/h) 500 
Collision energy (V) 12 
MCP detector voltage (V) 1800 
Pusher voltage (V) 915 
Pusher voltage offset (V) -0.70 






3.2.9. Docking studies (performed by collaborator, Asst Prof Yap Chun Wei)  
 
 Docking studies were used to determine the zebrafish cytochrome P450 
isozymes that could be responsible for the metabolism of testosterone and formation 
of NAPQI from APAP.  Studies have shown that human CYP3A4 and CYP2B6 
mediate the 6β-hydroxylation and 16β-hydroxylation of testosterone, respectively 
(Imaoka et al., 1996; Yamazaki and Shimada, 1997). To our knowledge, human 
CYP1A2 was found not to be involved in the metabolism of testosterone. 
Testosterone was docked into the binding site of human CYP3A4 (PDB ID: 3NXU), 
CYP2B6 (PDB ID: 3IBD) and CYP1A2 (PDB ID: 2HI4) using the software 
Molecular Operating Environment 2010.10 (MOE). The pose of testosterone in the 
binding site of CYP3A4 is likely to have the ketone group directed towards the heme 
group for 6β-hydroxylation, whereas for CYP2B6, the pose of testosterone is likely to 
have the hydroxyl group directed towards the heme group for 16β-hydroxylation. 
Since CYP1A2 is not involved in the metabolism of testosterone, the pose of 
testosterone in its binding site is likely to be different from those in CYP3A4 and 
CYP2B6. Hence, we hypothesized that it is possible to compare the pose of 
testosterone in the binding sites of zebrafish isozymes with the pose of testosterone in 
human CYP3A4 and CYP2B6 to determine the isozymes that may be responsible for 
the metabolism of testosterone in zebrafish. 
A study on the metabolism of APAP by human cytochrome P450 isozymes 
had shown that the formation of NAPQI is highest with CYP3A4, with CYP2E1 
having intermediate bioactivation capacity and CYP2C9 having the lowest capacity 
(Laine et al., 2009). APAP was docked into the binding site of human CYP3A4 (PDB 
ID: 3NXU), CYP2E1 (PDB ID: 3E6I) and CYP2C9 (PDB ID: 1R9O), using MOE. 
The chemical structure of APAP consists of a phenol group, an aromatic ring and an 
amide group. The formation of NAPQI involves N-hydroxylation. Thus the expected 
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pose of APAP in the binding site should have the amide group directed towards the 
heme group in CYP isozymes. In addition, the expected pose is likely to have 
hydrogen bonding interactions involving the phenol group and van der Waals 
interactions involving the aromatic ring. We hypothesized that differences in the 
expected pose of APAP in each isozyme may be useful to help explain the difference 
in bioactivation capacities. Since CYP3A4 has the highest bioactivation capacity, the 
expected pose of APAP in the binding site of CYP3A4 will be taken as the reference 
pose for APAP. Based on this hypothesis, the expected pose of human CYP2E1 will 
be more similar to the reference pose than the expected pose of human CYP2C9. 
Thus, by docking APAP to various zebrafish CYP isozymes and comparing the 
expected poses with the reference pose, it may be possible to determine the isozymes 
that are responsible for the formation of NAPQI from APAP in zebrafish. 
 Four zebrafish isozymes, Cyp3a65, Cyp3c1, Cyp1a and Cyp2y3, which have 
syntenic relationship to human CYP3A4, CYP1A2 and CYP2B6 (Goldstone et al., 
2010), were selected for the docking studies. The reasons for the selection of these 
isozymes for comparison are summarized in Table 3.3. 
 
Table 3.3. Syntenic zebrafish and human CYPs and the contributions of human 
CYPs to testosterone metabolism and APAP bioactivation to NAPQI. 
Zebrafish Human 
Isozyme  Isozyme Testosterone metabolism APAP bioactivation to 




CYP3A4 Responsible for formation of 
6β-hydroxytestosterone 
(Yamazaki and Shimada, 
1997) 
High level of bioactivation 
Cyp1a CYP1A2 Not involved Intermediate bioactivation 
Cyp2y3 CYP2B6 Responsible for formation of 
16β-hydroxytestosterone 







3.2.10. Homology modeling of zebrafish Cyps (performed by collaborator, Asst 
Prof Yap Chun Wei) 
 
 There are currently no 3D structures of zebrafish Cyp3a65, Cyp3c1, Cyp1a 
and Cyp2y3 available in the RCSB Protein Data Bank (PDB). Hence homology 
modeling was carried out to create 3D structures for the 4 zebrafish isozymes. The 
FASTA sequences of the 4 isozymes were obtained from UniProtKB 
(http://www.uniprot.org). Human CYP3A4 (PDB ID: 3NXU) was used as the 
template structure for zebrafish Cyp3a65 and Cyp3c1. Human CYP1A2 (PDB ID: 
2HI4) and CYP2B6 (PDB ID: 3IBD) were used as the template structure for zebrafish 
Cyp1a and Cyp2y3, respectively. The software MOE was then used to perform the 
homology modeling. The Protein Align module in MOE was used to align the 
zebrafish isozyme sequences with their respective template sequences. The 
BLOSUM62 matrix with a gap opening penalty of 7 and gap extension penalty of 1 
were used using the alignment process. The Homology Model module was then used 
to create the homology models. AMBER99 forcefield with calculation of implicit 
solvation energy using Generalized Born model was used for the modeling process. 
The resultant models were then energy minimized using the LigX module and 






3.3.1. Investigation of Cyp3a metabolic activity of zebrafish using liver 
microsomes 
 
 Multiple hydroxytestosterone metabolites were detected at different levels in 
the 1 and 2 h testosterone incubation samples of RLM, HLM, and FZLM. After 
eliminating false positive peaks by comparing the chromatogram of testosterone 
samples with the controls without liver microsomes, a total of seven putative 
hydroxylated metabolites of testosterone, M1-M7, were identified. The identity of 
three of the metabolites, M1, M5 and M6 were confirmed as 6β-, 16β- and 2α-
hydroxytestosterone, respectively using reference standards.  
The overlay extracted ion chromatograms of 2α-, 6β-, 7α-, 15β-, 16α- and 
16β-hydroxytestosterone reference standards and the extracted ion chromatograms of 
the putative hydroxylated metabolites of testosterone, M1-M7, in HLM, RLM and 
FZLM are shown in Figure 3.1. The response ratio of each metabolite was calculated 
by taking the area ratio of hydroxytestosterone to prednisolone (IS) and the profile of 
the metabolites formed at 2 h for each liver microsome fraction is shown in Figure 
3.2.A-C. The major metabolite formed by HLM, RLM and FZLM was 6β-
hydroxytestosterone (M1) observed at a retention time (Rt) of 1.332 min. The second 
most abundant metabolite formed by both HLM and FZLM was M7 (Rt = 2.004 
min) whereas it was 2α-hydroxytestosterone (M6, Rt = 1.962 min) for RLM. The 
third most abundant metabolite formed by FZLM was M3 (Rt = 1.667 min) which 
was unique to zebrafish as this metabolite was not observed in HLM and RLM. M2 
(Rt = 1.445 min) was only formed by FZLM and RLM while M4 was formed only 
by RLM and HLM. Even though the CYP concentration was standardized at 20 
pmol/mL, the levels of 6β-hydroxytestosterone (M1), marker of CYP3A activity, 
formed at 2 h were statistically different between all three groups when analyzed 
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using a one way-ANOVA followed by Tukey multiple comparison test (Figure 






Figure 3.1. Extracted ion chromatograms of hydroxytestosterone (m/z 305.2) in 
reference standards and liver microsome samples. (A) Hydroxytestosterone 
reference standards (overlay chromatograms); 2 hr testosterone samples of (B) HLM, 
(C) RLM, and (D) FZLM analyzed using the UHPLC/MS/MS. Putative hydroxylated 

























































































Counts vs. Acquisition Time (min)






















































































Figure 3.2. Individual profiles of hydroxytestosterone metabolites formed at 2-



























































Figure 3.2 (continued). (D) Combined profiles of hydroxytestosterone 
metabolites formed at 2-hour by FZLM, HLM, and RLM. One-way ANOVA 







3.3.2. Investigation of Cyp3a metabolic activity of zebrafish larvae 
 
 Two putative hydroxytestosterone metabolites were identified in zebrafish 
larvae homogenate and E3M medium samples after eliminating false positive peaks 
(Rt = 1.210 and 1.550 min) observed in control samples. The major metabolite, M8 
(Rt = 1.817 min), was unique and not found in the ZLM samples. The second 
metabolite was confirmed to be 6β-hydroxytestosterone (M1) using reference 
standards. The extracted ion chromatograms of the putative hydroxylated metabolites 




Figure 3.3. Extracted ion chromatograms of hydroxytestosterone (m/z 305.2) in 
the (A) zebrafish larvae homogenate and (B) E3M medium analyzed using the 
UHPLC/MS/MS. Putative hydroxylated metabolites of testosterone identified were 
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3.3.3. Investigation of reactive metabolite generating capability of zebrafish 
 
 The NAPQI-GSH adduct was detected in all microsomal samples. The 
response ratio was calculated as the area ratio of NAPQI-GSH to procainamide (IS) 
and compared among the three microsomal fractions. HLM formed the highest 
amount of NAPQI-GSH followed by RLM and FZLM (Figure 3.4). The difference 
between HLM and RLM was not statistically significant. Adducts formed in the 
controls without NADPH, GSH and APAP were negligible, confirming that NAPQI 
was generated from APAP in a metabolically competent system. 
 In addition, accurate mass measurement of the NAPQI-GSH adduct was 
performed using UPLC/QTOF/MS/MS to confirm its identity. The fragmentation 
patterns of NAPQI-GSH observed in all the samples were similar and typical of the 
CID fragmentation of GSH observed in other studies (Figure 3.5). The observed 
mass peaks corresponded to the hallmark loss of glycine (m/z 75) and pyroglutamic 























Figure 3.4. Response ratio of NAPQI-GSH in the three microsomal fractions 
enriched with APAP and GSH. One-way ANOVA followed by Tukey's multiple 



















Figure 3.5. Extracted ion spectra of NAPQI-GSH (m/z 457) in (A) HLM (B) 
RLM and (C) FZLM. The CID pathways of NAPQI–GSH and its respective 






















































3.3.4. Homology modeling of zebrafish Cyps 
 
 The Ramachandran Plot for zebrafish Cyp3a65, Cyp3c1, Cyp1a and Cyp2y3 
are shown in Figure 3.6. Cyp3a65, Cyp3c1, Cyp1a and Cyp2y3 has 2 (Val261, 
Thr281), 3 (Leu111, Val112, Lys163), 3 (Ser121, Cys294, Leu299) and 1 (Ser476) 
residues in disallowed regions, respectively. These are found in loop regions and 
away from the active site of the enzyme. Loop regions are known to be more flexible 
in conformation and hence more likely to deviate from the rigid orientation (Sánchez 























3.3.5. Docking studies 
 
 The poses of testosterone in human CYP3A4 (h3A4TES) and CYP2B6 
(h2B6TES) are given in Figure 3.7. h3A4TES interacted with 9 residues (Arg105, 
Phe108, Ser119, Ile120, Ile301, Phe304, Ala305, Ile369, Leu482) and had the ketone 
group directed towards the heme group. h2B6TES interacted with 15 residues (Ile114, 
Phe206, Ile209, Ser210, Phe297, Ala298, Glu301, Thr302, Leu362, Leu363, Val367, 
Val477, Gly478, Lys479, Ile480) and had the hydroxyl group directed towards the 
heme group. Testosterone did not have any poses that were similar to either h3A4TES 
or h2B6TES in human CYP1A2. This is consistent with the observation that human 
CYP1A2 has not been reported to be involved in the metabolism of testosterone.  
 Testosterone docking results for zebrafish Cyp3a65, Cyp3c1, Cyp1a and 
Cyp2y3 showed that for Cyp3a65 and Cyp3c1, testosterone was able to adopt poses 
that were similar to h3A4TES (Figure 3.8). Testosterone interacted with 8 and 7 out of 
9 residues in zebrafish Cyp3a65 and Cyp3c1, respectively. For Cyp1a, testosterone 
did not have any pose that was similar to either h3A4TES or h2B6TES. For Cyp2y3, 
testosterone was able to adopt a pose similar to h2B6TES but it interacted with only 7 
out of 15 residues. Hence, it is likely that metabolism of testosterone in zebrafish was 
mediated by Cyp3a65, Cyp3c1 but involvement of Cyp2y3 is inconclusive. The 2D 









Figure 3.7. Poses of testosterone in human CYP3A4 and CYP2B6. 
 
 







Two different poses of APAP fit the profile of the expected pose for human CYP3A4 
and is shown in Figure 3.9. The first pose (h3A4APAP1) interacted with 6 residues 
(Phe304, Ala305, Thr309, Ile369, Leu482, Leu483) with APAP. The second pose 
(h3A4APAP2) interacted with 5 residues (Arg105, Ser119, Ala370, Arg372, Leu373) 
with APAP. The 2D interaction map is provided in Appendix II: Supplementary 
section. These two poses were used as reference poses for APAP. Comparison of the 
poses of APAP in human CYP2E1 and CYP2C9 and the reference poses in human 
CYP3A4 showed that for CYP2E1, APAP was able to adopt a similar pose to 
h3A4APAP1. However, it only interacted with 4 of the 6 residues. For CYP2C9, APAP 
did not have any similar pose to both the reference poses. Thus, the results suggest 
that the degree of similarity between the expected pose and reference pose may be 
useful to determine bioactivation capacity for the isozymes.  
 APAP docking results for zebrafish Cyp3a65, Cyp3c1, Cyp1a and Cyp2y3 
showed that for both Cyp3a65 and Cyp3c1, APAP was able to adopt expected poses 
similar to both h3A4APAP1 and h3A4APAP2. For Cyp3a65, the binding interactions 
involved all the respective residues, whereas for Cyp3c1, the pose similar to 
h3A4APAP1 interacted with 4 out of the 6 residues while the pose similar to h3A4APAP2 
interacted with all 5 residues. APAP did not have any similar pose to both the 
reference poses for zebrafish Cyp1a and Cyp2y3. Hence, the results suggest that the 
formation of NAPQI from APAP in zebrafish could be attributed to Cyp3a65 and 















 An understanding of the disposition of drugs in zebrafish has been much 
neglected even though zebrafish is popularly pursued as an alternative 
pharmacological and toxicological screening model for early drug discovery 
applications. The current study evaluated the Cyp3a metabolic activity and reactive 
metabolite formation capability of zebrafish using testosterone and APAP, 
respectively, in comparison with human and rat.  
 
3.4.1. Testosterone metabolism 
 
 The 6β-hydroxylation of testosterone (Figure 3.10) is an indication of human 
CYP3A4/5 activity as it is mediated primarily by the CYP3A4 and CYP3A5 
isozymes when compared to other CYP isozymes (Waxman et al., 1991; Yamazaki 
and Shimada, 1997). Testosterone is thus one of the U.S. FDA-recommended 
substrate to evaluate in vitro CYP3A4/5 activity (FDA). Cyp3a activity was 
previously observed in other fish species such as scup, rainbow, Atlantic cod and 
medaka (Kleinow et al., 2008). However, to our knowledge, Cyp3a activity in 
zebrafish has not been demonstrated until recently where testosterone was found to be 
hydroxylated by zebrafish hepatocytes (Reschly et al., 2007) and zebrafish larvae 















Alderton et al. (2010) detected one hydroxylated metabolite in the zebrafish 
larvae whereas Reschly et. al. (2007) detected four hydroxylated metabolites, namely 
the 6β-, 15α-, 16α-, and 16β-hydroxytestosterone in zebrafish hepatocytes. In our 
study, we identified 2α-, 6β-, 16β-hydroxytestosterone and three unknown putative 
metabolites (M2, M3 and M7) in the ZLM and 6β-hydroxytestosterone and M8 in 
zebrafish larvae homogenate and medium (picture summary, Figure 3.11). The 
formation of 6β-hydroxytestosterone by zebrafish implies presence of Cyp3a 
activity. The zebrafish genome has five cyp3 genes but only cyp3a65 and cyp3c1 
have been cloned and shown to be heterogeneously expressed thus far (Tseng et al., 
2005; Corley-Smith et al., 2006). From our docking results, the good interaction 
observed between testosterone and Cyp3a65 and Cyp3c1 which was similar to 
testosterone interaction with human CYP3A4 indicates the likelihood of 
contributions of Cyp3a65 and Cyp3c1 to the metabolism of testosterone in zebrafish. 
Although CYP2B6 is responsible for the formation of 16β-hydroxytestosterone in 
humans (Imaoka et al., 1996), the involvement of zebrafish Cyp2y3 in the formation 
of 16β-hydroxytestosterone (M5) cannot be confirmed as the interaction between 
testosterone and Cyp2y3 was poor.  
The elution pattern of the six reference standards we procured match closely 
with previous literatures (Wood et al., 1983; Wang and Zhang, 2007). Based on the 
elution pattern from these literatures, it can be postulated that the identity of M7 in 
our study is likely to be 2β-hydroxytestosterone which elutes immediately after 2α-
hydroxytestosterone. Moreover, it has been reported that human forms 2β-
hydroxytestosterone but not 2α-hydroxytestosterone, unlike rat which forms both 2β-
hydroxytestosterone and 2α-hydroxytestosterone (Yamazaki and Shimada, 1997; 
Granhall et al., 2002; Langsch et al., 2009). The differential species metabolism 
between HLM and RLM in formation of 2α-hydroxytestosterone (M6) and M7 in our 
study further suggests that M7 is 2β-hydroxytestosterone. 
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Previous literature demonstrated species differential metabolism of 
testosterone by rat, human and porcine hepatocytes. It was observed that human 
hepatocytes formed fewer metabolites than rat hepatocytes and the various 
hydroxytestosterone metabolites were more equally distributed in rat compared to 
human (Langsch et al., 2009). In our study, the same profile was observed between 
HLM and RLM (Figure 3.2.A and B) and for the first time, a comparison was made 
with zebrafish. Although the main metabolite formed by zebrafish was still 6β-
hydroxytestosterone (M1), the profile of the hydroxytestosterone metabolites formed 
was distributed across more metabolites compared to RLM (Figure 3.2.B and C). 
Interestingly, the second most abundant metabolite formed by ZLM was M7, likely 
to be 2β-hydroxytestosterone, and this is more similar to human than rats. Despite 
the similarity, two unique metabolites, M3 in ZLM and M8 in zebrafish larvae, were 
observed specifically for zebrafish. The extent of formation of metabolites, taking 
6β-hydroxytestosterone formed at 2 h (Figure 3.2.D) and NAPQI (Figure 3.4) for 
comparison, appeared to be less for FZLM compared to HLM and RLM even though 
CYP concentrations were standardized across all microsomal fractions. However, 
this may have been confounded by the presence or absence of cytochrome b5 which 
was not determined for the isolated FZLM and standardized in the current assays. 
Cytochrome b5 had been found to play an important role in the metabolism of certain 
drugs in a CYP and substrate-dependent manner (Finn et al., 2008). The turnover rate 
of testosterone was seen to be increased with the presence of cytochrome b5 in an in 
vivo-like system consisting of human P450 reductase, CYP3A4, and cytochrome b5 
(Voice et al., 1999). Therefore, the extent of metabolite formation cannot be 
quantitatively compared at present until more definitive experiments are performed. 
Differences in biotransformation of testosterone between zebrafish larvae 
and ZLM isolated from adult zebrafish were also observed in our study. While the 
ZLM formed multiple hydroxytestosterone metabolites, the zebrafish larvae only 
produced two hydroxytestosterone metabolites. Formation of such few metabolites 
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by the larvae corroborates with the observation by Alderton et al. in which only one 
hydroxytestosterone metabolite was detected apart from a glucuronidated 
testosterone in 7 d.p.f. zebrafish larvae (Alderton et al., 2010). A recent study 
characterizing the developmental expression of cyp genes in zebrafish larvae 
revealed that 66 out of the 88 cyp genes examined demonstrated differential 
expression during development between 3 hours post-fertilization (h.p.f.) through 48 
h.p.f. (Goldstone et al., 2010). A bimodal expression pattern was observed with 
cyp3a65, the Cyp likely to be responsible for the metabolism of testosterone based 
on our docking studies. Even though the liver of the zebrafish larvae is fully 
developed by 5 d.p.f. (Chu and Sadler, 2009), the differences observed in our study 
suggest a difference either in the function or expression of the drug metabolizing 
enzymes between zebrafish larvae and adult zebrafish. 
 
Figure 3.11. Picture summary of the species differential metabolism of 





3.4.2. APAP bioactivation 
 
 Hepatotoxicity of APAP has been attributed to its reactive metabolite, 
NAPQI, formed from CYP-mediated metabolism of APAP. CYP3A4 was found to 
be one of the major CYP isozymes responsible for this bioactivation (Dahlin et al., 
1984; Albano et al., 1985; Laine et al., 2009). Recently, hepatotoxicity was observed 
in adult zebrafish exposed to APAP (North et al., 2010). Teratogenicity and 
nephrotoxicity in zebrafish due to APAP were also reported (David and Pancharatna, 
2009; Peng et al., 2010; Weigt et al., 2010). Although the formation of NAPQI has 
been demonstrated using human and animal liver microsomes such as that of rat, 
mouse, rabbit, pig and monkey, to our knowledge, the ability of zebrafish to generate 
the same reactive metabolite has not been evaluated. In this study, NAPQI which 
was adducted with GSH for detection was seen with ZLM albeit at lower levels than 
HLM and RLM. Differential APAP metabolism and APAP-induced cytotoxicity had 
been observed among species (Smolarek et al., 1990; Jemnitz et al., 2008). This 
reinforced the importance of selecting the relevant toxicological model to obtain 
reliable cross-species correlation especially when the toxicity is metabolism-related.  
The findings in this study suggest that formation of NAPQI could have played a role 
in the APAP-induced hepatotoxicity observed in the adult zebrafish by North et al. 






 This study demonstrated that zebrafish possess Cyp3a activity which is 
similar to the human model in the types of major hydroxytestosterone metabolites 
formed. However, it is more similar to the rat model in generating a variety of 
hydroxytestosterone metabolites, in which two were metabolites unique to zebrafish 
only. For the first time, we also demonstrated the potential of the zebrafish model in 
generating and trapping reactive metabolite of pharmaceutical drugs. The findings of 
this study not only reinforced interspecies differences in biotransformation but also 
differences in biotransformation over various developmental stages in the zebrafish 
model itself. It also underscores the importance of conducting a thorough 
characterization and interspecies comparison on the metabolic activities of new 
alternative models. Future work should include the investigation and comparison on 
the functional activities of the other DMEs and also the ability of zebrafish to 
generate toxic reactive metabolites via Phase I and/or Phase II metabolic pathways 
using other model drugs such as diclofenac or tienilic acid. Elucidation of the 
identities of the unique metabolites (M3 and M8) generated by zebrafish would also 




CHAPTER 4: ESTABLISHMENT AND EVALUATION OF A HIGH-




 Testosterone 6β-hydroxylation or midazolam 1-hydroxylation is the preferred 
in vitro marker of CYP3A4 activity recommended by the U.S. Food and Drug 
Administration (FDA) and these metabolites are typically detected via liquid 
chromatography tandem mass spectrometry (LC/MS/MS)-based methods. This 
method was adopted in Chapter 3 using zebrafish liver microsomes (ZLM) isolated 
from adult fish and five days post fertilization (d.p.f.) zebrafish larvae and established 
that both adult and larvae possess Cyp3a metabolic activity. Nevertheless, as alluded 
in the conclusion of Chapter 2, the extraction of ZLM is resource intensive and it was 
suggested that the use of ZLM would be better reserved for characterization and 
mechanistic studies rather than for metabolic screening testing in drug discovery. The 
use of the whole zebrafish larvae coupled to LC/MS/MS detection of metabolites in 
Chapter 3 was also not optimal as it required pooling of 20 zebrafish larvae per well 
in a 12-well plate. Even so, the signal of the 6β-hydroxytestosterone metabolite 
detected in the medium was not significantly high above baseline which means 
pooling of more zebrafish per replicate is necessary to increase sensitivity of this 
assay. As such, there is great impetus to innovate or improve the methods in Chapters 
2 and 3 so as to fully leverage on the strengths of zebrafish as an alternative in vivo 
model for high-throughput metabolic testing in drug discovery. 
 As zebrafish larva is small enough to fit into 96- or even 384-well plates, we 
coupled a high-throughput CYP3A4 assay kit together with zebrafish larvae in a 96-
well format and evaluated its potential for screening Cyp3a activity. The 
luminescence-based Promega P450-Glo™ CYP3A4 assay was chosen for this 
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purpose as it has been successfully applied to studying CYP3A4 induction and 
inhibition activities in human hepatocytes (Doshi and Li, 2011; Li and Doshi, 2011). 
Moreover, the simple 'add-mix-measure' methodology adds throughputness to the 
assay setup. As the P450-Glo™ CYP3A4 assays were developed for use with human 
liver microsomes and hepatocytes, a few research questions remain to be answered: 
1) Can zebrafish metabolize the luminogenic substrates? 2) If yes, what would be the 
optimum substrate concentration and conditions to be used to probe Cyp3a activity? 
This study hence aimed to establish and evaluate a high-throughput in vivo Cyp3a 
assay in zebrafish. Dose optimization assays were performed using two different 
luminogenic substrates, Luciferin-PFBE and Luciferin-IPA. A P-glycoprotein (P-gp) 
inhibition assay was also performed to seek understanding on the results obtained 





4.2. Materials and methods 
 
4.2.1. Chemicals and reagents 
 
 Magnesium sulphate heptahydrate, methylene blue, dimethyl sulfoxide 
(DMSO) and sodium bicarbonate were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Sodium chloride was purchased from Schedelco Pte. Ltd. (Singapore). 
Calcium chloride dihydrate and potassium chloride were purchased from Merck 
Millipore (Merck KGaA, Darmstadt, Germany). Disodium hydrogen phosphate, 
potassium phosphate monobasic and potassium phosphate dibasic were purchased 
from J.T. Baker (Phillipsburg, NJ, USA). Tariquidar, zosuquidar and elacridar were 
generously donated by Professor Paul Ho (Department of Pharmacy, National 
University of Singapore). Pooled human liver microsomes (HLM) from 20 donors, 
with a protein concentration of 20 mg/mL and total CYP of 300 pmol/mg were 
obtained commercially from BD Biosciences (San Jose, CA, USA). The NADPH 
regenerating system was purchased from BD Gentest (Woburn, MA, USA). P450-
Glo™ CYP3A4 Assay with Luciferin-IPA and P450-Glo™ CYP3A4 Assay with 
Luciferin-PFBE were purchased from Promega (Promega Corporation. Madison, 
USA). Methanol was purchased from Tedia Company Inc. (Fairfield, OH, USA). 
Water was purified using a Milli-Q water purification system (Millipore, Bedford, 




4.2.2. Animal Husbandry 
 
 Wild-type zebrafish embryos of natural spawning were collected at the 
aquarium of the Department of Biological Sciences (DBS), National University of 
Singapore (NUS) and reared in E3M embryo medium (5 mM NaCl, 0.17 mM KCl, 
0.33 mM CaCl2.2H2O, 0.33 mM MgSO4.7H2O, 0.001 g/L methylene blue with pH 
adjusted to 7.2) (Cold Spring Harbor Protocols, 2011) in an incubator at 28.5 ± 0.5 
°C. E3M medium was changed and health of zebrafish was visually observed and any 
dead larvae removed daily until 5 d.p.f. when experiments were performed as the 
liver is fully developed by then (Chu and Sadler, 2009). All experiments were 
conducted in compliance with the guidelines of the Institutional Animal Care and Use 
Committee of NUS (IACUC). 
 
4.2.3. Dose optimization of P450-Glo™ CYP3A4 Assay with Luciferin-PFBE in 5 
d.p.f. zebrafish larvae 
 
 Luciferin-PFBE was diluted in E3M medium to final working concentrations 
of 5, 25, 100, 200, 300 and 500 µM. D-luciferin standards ranging from 0.02 nM to 5 
nM were also prepared and diluted in E3M. Three 5 d.p.f. zebrafish per well in a clear 
96-well plate were immersed in 60 µL of the different concentrations of Luciferin-
PFBE prepared above at 28.5°C. Control incubations of each Luciferin-PFBE 
concentration without zebrafish and D-luciferin standards were performed in parallel. 
At 240 min, 50 µL of the treatment medium, controls and standards were transferred 
to an opaque white 96-well plate containing 50 µL luciferin detection reagent (LDR) 
and incubated for a further 20 min followed by measurement of luminescence signal 
using a Tecan-Infinite M200 plate reader (Tecan, Switzerland). Health of zebrafish 
was visually noted and any observed death recorded. The experiment was performed 




4.2.4. Dose optimization of P450-Glo™ CYP3A4 Assay with Luciferin-IPA in 5 
d.p.f. zebrafish larvae 
 
 Similarly, Luciferin-IPA was diluted in E3M to final working concentrations 
of 0.3, 3, 15 and 30 µM and solvent concentration of 1% v/v DMSO. D-luciferin 
standards ranging from 0.02 nM to 5 nM were also prepared and diluted in 1% v/v 
DMSO in E3M. Three 5 d.p.f. zebrafish per well in a clear 96-well plate were 
immersed in 60 µL of the different concentrations of Luciferin-IPA prepared above at 
28.5°C. Control incubations of each Luciferin-IPA concentration without zebrafish 
and D-luciferin standards were performed in parallel. After 60 min incubation, 50 µL 
of the treatment medium, controls and standards were transferred to an opaque white 
96-well plate containing 50 µL LDR and incubated for a further 20 min followed by 
measurement of luminescence signal.  
 The above Luciferin-IPA diluted in 1% v/v DMSO in E3M experiment was 
repeated to include more substrate concentrations, 5, 12.5, 20, 25 and 30 µM, and 
also with an increased in incubation duration to 120 min.  
 A third experiment variation was performed by changing the diluent to 10% 
Hanks Balanced Salt Solution (HBSS) (0.137 mM NaCl, 0.54 mM KCl, 25 μM 
Na2HPO4, 44 μM KH2PO4, 130 μM CaCl2.2H2O, 100 μM MgSO4.7H2O and 420 μM 
NaHCO3, 10 times diluted with Milli-Q water). Luciferin-IPA was diluted with 10% 
HBSS to final working concentrations of 3, 6, 12, 15 and 20 µM. The incubation 
duration was kept at 120 min.  
 Health of zebrafish was visually noted and any observed death recorded. The 
first experiment was performed in triplicates while the second and third experiments 




4.2.5. Km determination in HLM for P450-Glo™ CYP3A4 Assay with Luciferin-
IPA 
 
 Incubation conditions were performed according to manufacturer's protocol. 
In brief, each 60 µL reaction mixture consisting 3, 6, 12, 15 or 20 µM Luciferin-IPA 
diluted with 1% v/v DMSO in 100 mM KPO4, HLM with an equivalent of 1 µg CYP 
and NADPH regenerating system was incubated at 37°C. D-luciferin standards 
ranging from 1 nM to 100 nM were also prepared and diluted in 1% v/v DMSO in 
100 mM KPO4. Control incubations of each Luciferin-IPA concentration without 
NADPH B (a component of the NADPH regenerating system) and D-luciferin 
standards were performed in parallel. At 10 min, 50 µL of the reaction mixture, 
controls and standards were transferred to an opaque white 96-well plate containing 
50 µL LDR and incubated for a further 20 min followed by measurement of 
luminescence signal. All experiments were performed in triplicates. 
 
4.2.6. Effects of P-glycoprotein (P-gp) inhibitors on the metabolism of Luciferin-
IPA in 5 d.p.f. zebrafish larvae 
 
 Stock tariquidar, zosuquidar and elacridar were dissolved in 100% methanol. 
Each P-gp inhibitor was subsequently diluted with 10% HBSS to achieve final 
concentration levels of 0.1, 1 or 1 µM in a mixture also containing 15 µM Luciferin-
IPA. Final organic solvent compositions in the mixture were 0.5% DMSO and 0.1% 
methanol. Three 5 d.p.f. zebrafish per well in a clear 96-well plate were immersed in 
60 µL of the above mixtures containing the P-gp inhibitors and Luciferin-IPA at 
28.5°C. Control incubations without the P-gp inhibitors (only plain Luciferin-IPA) 
were performed in parallel. After 60 min incubation, 50 µL of the treatment medium, 
controls and standards were transferred to an opaque white 96-well plate containing 
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50 µL LDR and incubated for a further 20 min followed by measurement of 
luminescence signal. Experiments were performed in five replicates.   
 
4.2.7. Data analysis 
 
 The average background luminescence for each concentration of Luciferin-
PFBE and Luciferin-IPA was calculated using the respective control incubations 
without zebrafish or NADPH B (for the HLM experiment). The net luminescence due 
to Cyp3a activity in the zebrafish or CYP3A4 activity in HLM was calculated as 
follows: 
 
Net luminescence due to Cyp3a activity in zebrafish or CYP3A4 activity in HLM at 
X concentration =  
Luminescence signal of zebrafish or HLM treated with X concentration −  
Average luminescence of X concentration without zebrafish or NADPH B 
 
 The concentration of D-luciferin due to the net luminescence was then 
determined using the D-luciferin standard curve. Reaction velocity was calculated by 
dividing the D-luciferin concentration with incubation duration. The curves were 
plotted and analyzed using Graphpad Prism 5.03 (La Jolla, CA, USA).  
 In the P-gp experiments, net Cyp3a activity was expressed in percentage and 
calculated as follows: 
% net Cyp3a activity = 
Luminescence signal at X concentration of P-gp inhibitor
Luminescence signal of control without P-gp inhibitor







4.3.1. Dose optimization of P450-Glo™ CYP3A4 Assay with Luciferin-PFBE and 
Luciferin-IPA in 5 d.p.f. zebrafish larvae and Km determination of Luciferin-
IPA in HLM 
 
 Dose dependent increase in reaction velocity was observed with substrate 
inhibition above 100 µM for Luciferin-PFBE (Figure 4.1.A). This curve was fitted to 
a substrate inhibition model in Graphpad Prism and a value of Km = 31.02 µM and Ki 
= 725.7 µM with an R2 = 0.80 was obtained.  
 Substrate saturation was not observed for Luciferin-IPA in 5 d.p.f. zebrafish 
but instead, reaction velocity increased exponentially with increasing concentrations 
of Luciferin-IPA. This trend was reproducible in all three different variations of the 
experiment (Figure 4.1.B and C). The curves were fitted to the allosteric sigmoidal 
model, producing a K' = 2.12 x 105 µM (R2 = 0.94) for the 60 min incubation 
duration, K' = 7.45 x 1017 µM (R2 = 0.92) for the 120 min incubation duration and K' 
= 2.76 x 106 µM (R2 = 0.88) for the Luciferin-IPA diluted in 10% HBSS experiment. 
K' is related to Km but also contains terms related to the effect of substrate occupancy 
at one site on the substrate affinity of other sites (Copeland, 2000). It must be 
qualified that the software generated a remark of 'ambiguous' for the model fitting of 
both the Luciferin-IPA in E3M (60 and 120 min) curves. 
 As a positive control to validate the trend observed in zebrafish, the 
Luciferin-IPA assay was performed using HLM and a typical hyperbolic plot which 
fitted the Michaelis-Menten equation (Km = 81.1 µM, R2 = 0.97) was obtained. 
Maximal reaction velocity could not be determined due to experimental limitations of 
diluting the stock solution to a final tolerated organic concentration (1% v/v DMSO) 

































































































Figure 4.1. Reaction velocity against concentration of Luciferin substrates in 5 
d.p.f. zebrafish and HLM. (A) Luciferin-PFBE in E3M in 5 d.p.f. zebrafish (240 
min incubation) fitted to the substrate inhibition model: Km = 31.02 µM, Ki = 725.7 
µM, R2 = 0.80), (B) Luciferin-IPA in E3M (60 and 120 min incubation duration) in 5 
d.p.f. zebrafish fitted to the allosteric sigmoidal model, 60 min: K' = 2.12 x 105 µM, 
R2 = 0.94; 120 min: K' = 7.45 x 1017 µM, R2 = 0.92, (C) Luciferin-IPA in 10% HBSS 
(120 min incubation duration) in 5 d.p.f. zebrafish fitted to the allosteric sigmoidal 
model: K' = 2.76 x 106 µM, R2 = 0.88 and (D) Luciferin-IPA in KPO4 (10 min 
incubation) in HLM fitted to the Michaelis-Menten model: Km = 81.1 µM, R2 = 0.97. 
 denotes 5 d.p.f. zebrafish larvae;  denotes HLM. All zebrafish experiments were 
performed in five replicates except triplicates for the Luciferin-IPA in E3M (60 min 







 The signal-to-noise ratio was computed for each substrate by taking the ratio 
of the raw signal from wells with zebrafish to the average background signal from 
each corresponding concentration without zebrafish. The average signal-to-noise ratio 
± standard deviation (SD) from five replicates per concentration are presented in 
Tables 4.1 and 4.2. 
 
Table 4.1. Average signal-to-noise 
ratio ± standard deviation (SD) for 
Luciferin-PFBE in E3M in 5 d.p.f. 
zebrafish larvae.  
Table 4.2. Average signal-to-noise 
ratio ± SD for Luciferin-IPA in 10% 





noise ratio ± SD, 
(n=5) 
5 2.25 ± 0.16 
25 2.08 ± 0.28 
50 1.65 ± 0.19 
100 1.53 ± 0.08 
200 1.23 ± 0.06 
300 1.12 ± 0.06 




noise ratio ± SD, 
(n=5) 
3 2.61 ± 0.3 
6 14.23 ± 3.6 
12 27.01 ± 3.6 
15 100.45 ± 5.0 
20 196.35 ± 49.3 
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4.3.2. Effects of P-glycoprotein (P-gp) inhibitors on the metabolism of Luciferin-
IPA in 5 d.p.f. zebrafish larvae 
  
 All three P-gp inhibitors did not increase the luminescence signal but instead, 
caused mostly statistically significant suppression in signal with net Cyp3a activities 
at 78-94%, 69-88% and 71-78% for tariquidar, zosuquidar and elacridar, respectively, 
when compared to activity in the control arm without any P-gp inhibitor, set at 100% 































Figure 4.2. Effects of P-gp inhibitors on the metabolism of Luciferin-IPA in 5 
d.p.f. zebrafish. % net Cyp3a activity, calculated against control arm without P-gp 
inhibitor (0 µM), against three different P-gp inhibitors, dosed at 0.1, 1 and 1 µM. 
Unpaired t-test (2-sided) between treated and control group without P-gp inhibitor, 
*p<0.05, **p<0.01, (n=5). 
 





 As the aim of this study was to establish and evaluate a high-throughput in 
vivo Cyp3a assay in zebrafish, a novel combination of 5 d.p.f. larvae, which are small 
enough to fit in a 96-well plate, with the Promega P450-Glo™ CYP3A4 assay was 
employed. There are four available luciferin hCYP3A4 substrates by Promega, of 
which the first generation substrates which are less specific and has more cross-
reactivity with other CYP isozymes are Luciferin-BE, Luciferin-PFBE and Luciferin-
PPXE, while the fourth substrate which is more selective to hCYP3A4 is Luciferin-
IPA (Sobol et al., 2007; Cali et al., 2009). These P450-Glo™ CYP3A4 assays were 
developed for use with recombinant CYP enzymes, human liver microsomes or 
human hepatocytes. Since the substrates have never been tested with zebrafish 
previously, it was necessary to first establish if the zebrafish is able to metabolize 
these substrates. Any luminescence signal observed is then termed "Cyp3a metabolic 
activity" since it was not the aim of the study to identify the Cyp isozymes 
responsible for the metabolism of these substrates in the zebrafish. That said, based 
on the in silico modelling experiments in Chapter 3, it is postulated that any Cyp3a 
metabolic activity observed may likely be due to cyp3a65. 
 Instead of just testing with Luciferin-IPA which would seem the best choice 
of substrate given its selectivity, it was decided that metabolism of one of the first 
generation luciferin substrates should also be evaluated since there were qualititave 
differences in the metabolism pathways of testosterone between zebrafish and human 
(Chapter 3, Chng et al., 2012). Luciferin-PFBE was selected out of the three first 
generation substrates as it is recommended for cell-based assays, has less cross-
reactivity and is less sensitive to inhibition by DMSO (Promega, 2012). The 
treatment conditions were selected based on the protocols recommended for 
hepatocytes with a change in incubation temperature and medium to 28.5°C and 
E3M, respectively, as these are the ideal conditions for zebrafish growth, breeding 
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and development (Westerfield, 2000). The incubation duration of 240 min for 
Luciferin-PFBE was as recommended for hepatocytes. For Luciferin-IPA, the 
incubation duration was firstly tested at 60 min, as recommended. As Luciferin-IPA 
was supplied at 3 mM dissolved in 100% DMSO, a maximal tolerable DMSO 
concentration was set at 1% DMSO so that the concentration range for the dose 
determination experiment could be stretched as high as possible i.e. 30 µM. This 
maximal tolerable solvent concentration was decided based on a review on the 
conduct of in vitro metabolism studies where it was recommended to keep solvent 
concentrations to ≤1% (Riley and Grime, 2004). To date, little is known about the 
effects of solvents on Cyp activity in zebrafish except for one study on the effects of 
methanol and DMSO on Cyp1a activity in zebrafish larvae (David et al., 2012).  
 The 5 d.p.f. zebrafish larvae were able to metabolize both Luciferin-PFBE 
and Luciferin-IPA to generate luminescence signals well distinguished from 
background noise. However, background signal for Luciferin-PFBE was high for 
every concentration tested, yielding poor signal-to-noise ratios ranging from 1.1 - 2.3 
versus that of Luciferin-IPA which ranged from 2.6 - 196.4 (Tables 4.1 and 4.2). The 
signal-to-noise ratio for Luciferin-IPA was improved up to six fold higher when the 
Luciferin-IPA incubation duration was increased from 60 to 120 min.  
 Non-Michaelis-Menten kinetics was observed for the metabolism of both 
substrates with substrate inhibition occurring for Luciferin-PFBE and possibly 
homotropic co-operativity causing sigmoidal kinetics for Luciferin-IPA. The 
observed substrate inhibition for Luciferin-PFBE was consistent with the results 
obtained by Promega where substrate inhibition was also observed above 100 µM 
Luciferin-PFBE when incubated with recombinant CYP3A4 (Sobol et al., 2007). As 
for Luciferin-IPA, the exponential curve which fitted the allosteric sigmoidal model 
was a novel observation. This trend was reproducible for both the 60 and 120 min 
incubations (Figure 4.1.B).  
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 In recent years, it has become widely recognized that CYP enzymes do not 
necessarily always exhibit standard Michaelis-Menten kinetics. Non-Michaelis-
Menten kinetics, also known as atypical or allosteric kinetics, may be due to 
homotropic effects, where metabolism of the same substrate can yield velocity versus 
substrate concentration curves that are either sigmoidal (also called autoactivation), 
biphasic with continuously increasing velocity at high substrate concentration 
(implying a low-affinity second substrate site and referred to as biphasic), or concave 
downward with a decrease in velocity at high substrate concentration after an initial 
hyperbolic increase (substrate inhibition), or heterotropic effects, where activation or 
inhibition of product formation is due to a second compound (Atkins, 2005).  
 To investigate whether the observed sigmoidal trend for the metabolism of 
Luciferin-IPA was true or artefactual, any possible confounding factors that may have 
arisen due to differences between the protocol used in this study and manufacturer's 
recommendation were explored. The two differences were incubation temperature 
and the diluent, E3M medium, used to dilute the Luciferin-IPA. Buffers have been 
cited as a possible source of artefactual atypical kinetics previously (Houston and 
Kenworthy, 2000; Hutzler and Tracy, 2002). Nevertheless, the effects seen were 
inhibition of metabolic activity due to high salt concentrations up to 150 mM MgCl2 
or 30 mM CaCl2 whereas in the current study, these salts were in sub-mM 
concentrations and a converse enhanced metabolic activity was observed instead. 
Based on other literatures which found that Nile Red is an allosteric substrate as well 
as effector molecule (Lampe et al., 2008; Nath et al., 2008), it was hypothesized that 
methylene blue, a compound structurally similar to Nile Red, which was added in the 
E3M medium for its fungicidal properties for growing the zebrafish embryo, may 
have been an allosteric activator, potentiating the metabolism of Luciferin-IPA. In 
addition, the E3M medium also did not possess any buffering capacity. Based on 
previous literature where it was shown that luciferase activity is affected by pH (Law 
et al., 2006), it was also postulated that the lack of buffering capacity of E3M 
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medium could have an effect on the efficiency of the enzymes in LDR, likely 
luciferase, in converting luciferin to the luminescing compound in the last step of the 
experiment (Figure 4.3).  
  
Figure 4.3. Simplified schematic on the metabolism of Luciferin-IPA to luciferin. 
Luciferin Detection Reagent is required to convert luciferin to the light generating 
compound.  
 
 Therefore, 10% HBSS was tested as an alternative diluent as this medium 
was a buffer system which did not contain methylene blue, and has also been used by 
others in their zebrafish experiments (MacPhail et al., 2009; Irons et al., 2010; Ali et 
al., 2011; Wielhouwer et al., 2011). The sigmoidal trend remain unchanged after 
switching the medium to 10% HBSS, suggesting that the allosteric effects observed 
could truly be a homotropic effect and not due to methylene blue, as hypothesized. 
Moreover, the classical Michaelis-Menten plot obtained from the experiment with 
HLM further validated that the assay kit was working fine under our laboratory 
conditions. With this new buffered system, the luminescence signal also improved, 
yielding higher reaction velocities for every concentration level tested compared to 
the previous experiments in E3M medium (Figures 4.1.B and C). 
 Among other artefactual sources of atypical kinetics discussed by Hutzler and 
Tracy was the involvement of cellular active transporter systems (Hutzler and Tracy, 
2002). As it was postulated that the metabolism of Luciferin-IPA was likely due to 
zfcyp3a65 which is the homologue of hCYP3A4 sharing 54% sequence identity 
(Goldstone et al., 2010), a likely transporter to be involved in effluxing Luciferin-IPA 
and causing the artefactual trend could be P-gp, also known as multidrug resistant 
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protein 1 (MDR1). This is extrapolated from the fact that in humans, P-gp and 
hCYP3A4 share many common substrates and inhibitors (Kim et al., 1999; Wandel et 
al., 1999). The research area on drug transporters in zebrafish is still at its infancy. 
Forty-one ATP-binding cassette (ABC) transporters have been identified in the 
zebrafish genome (Dean and Annilo, 2005). The orthologue of ABCB1 coding for P-
gp in human is abcb4 in the zebrafish (EMBL-EBI) and the proteins share a sequence 
homology of 64% when aligned using BLASTP 2.2.8 (accession no.: 
NP_001108055.1 (danio rerio) and EAL24173.1 (homo sapiens)). P-gp has been 
shown to be expressed in adult zebrafish liver (Bresolin et al., 2005), whole 72 hours 
post fertilization (h.p.f.) zebrafish larvae (He et al., 2012), and blood-brain barrier of 
zebrafish as young as 2 d.p.f. (Umans and Taylor, 2012). To date, there are no 
literature reporting the effects of P-gp inhibitors in zebrafish with the exception of 
Scholz et al. who demonstrated that cyclosporine A could cause accumulation of 
rhodamine B in zebrafish (Scholz et al., 2008).  
 In the current study, the third generation P-gp inhibitors, tariquidar 
(XR9576), zosuquidar (LY335979) and elacridar (GF120918), which are more 
specific and have higher affinity to the transporter (Palmeira et al., 2012), were 
selected to evaluate their effects on the metabolism of Luciferin-IPA. If Luciferin-
IPA was truly a substrate of P-gp efflux pump where the effect of effluxing was 
saturable at higher concentration levels of Luciferin-IPA hence causing the observed 
sigmoidal trend, an increase in luminescence signal i.e. Cyp3a activity is expected 
when increasing concentrations of P-gp inhibitor is co-incubated with a fixed 
concentration of Luciferin-IPA. However, this was not observed but instead, a 
suppression of signals with all three different inhibitors (Figure 4.2) was seen. The 
following can therefore be inferred based on some assumptions:  
 
(1) Assuming the P-gp inhibitors are specific to zebrafish P-gp transporters as they are 
in mammalian models, Luciferin-IPA is not a substrate of P-gp transporters. 
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Caveat: This does not preclude possible involvement of other active transporters 
not evaluated in this study which may still be a source of artefact.  
(2) Assuming the metabolism of Luciferin-IPA was predominantly by cyp3a65 as 
postulated, the P-gp inhibitors used may have inhibited Cyp3a65 enzymatic 
activity causing a decrease in the net Cyp3a activity. This would not be surprising 
as some of these P-gp inhibitors such as zosuquidar have also been shown to 
inhibit hCYP3A4 (Dantzig et al., 1999). 
 
 The above inferences can only be confirmed with more experiments but as 
this was not the main aim of this study, further mechanistic investigation was not 
pursued. At present state, an attempt to eliminate the involvement of P-gp 
transporters as a possible cause of artefactual atypical kinetics was made but this 
could not be confirmed due to the lack of information and infancy in the area of drug 
transporter and inhibitor research in zebrafish. Nevertheless, with the current 
available information, it is postulated that Luciferin-IPA is possibly not a substrate 
for P-gp by comparing the sequence homology and drawing parallels from the cross-
reactivity of substrates in human CYP3A4 and P-gp transporters. It is likely that the 
allosteric sigmoidal kinetics is innate to the system used.  
 Atypical kinetics is commonly observed in vitro with purified recombinant 
systems (Atkins, 2004). Increasingly, atypical kinetics are also seen with multi-
enzyme systems such as liver microsomes and even hepatocytes, indicating that the 
kinetics observed is probably not an in vitro artefact but true interactions at the 
enzymatic level. Examples of these are summarized in Table 4.3. The activation 
effects observed in these multi-enzyme systems were isolated to be due to activation 
of CYP3A4 through chemical and immunoinhibitory assays and confirmation using 





Table 4.3. Examples of activation kinetics (positive heterotropic effects) reported 
in the literature in multi-enzyme systems. 
 


































CYP3A4‡ Ngui et al. 
(2001) 
 
*confirmed through use of CYP3A4 inhibitor, troleandomycin. 
†although phenacetin O-deethylation is a marker activity for CYP1A2, it is also 
mediated through CYP3A4 which is abundant in HLM and hence played a dominant 
role when activated in this experiment. This was confirmed through recombinant 
CYP3A4, immuno- and chemical inhibitory experiments. 
‡Confirmed through immunoinhibitory studies and recombinant CYP3A4 
experiments. 
 
 There are only a few examples of allosteric kinetics occurring in vivo thus 
far, of which all examples involved heterotropic effects (Tang et al., 1999; Hutzler et 
al., 2001; Egnell et al., 2003). In this study, the homotropic effects seen with substrate 
inhibition for Luciferin-PFBE and allosteric sigmoidal kinetics in Luciferin-IPA are 
noteworthy as these occurred in an intact in vivo organism. Being a whole biological 
system with multiple enzymes, it can be postulated that the metabolism of Luciferin-
PFBE and IPA was possibly mediated through a single, predominant Cyp enzyme, 
likely Cyp3a65, thus giving rise to a clear atypical kinetic profile which would have 
been masked if there were multiple enzymes involved in its metabolism. This being 
the case, the assay is selective and would be useful for experiments which aim to 
assess the effects of compounds on Cyp3a65 metabolic activity.    
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 As a recap, the main aim of this study was to establish and evaluate a high-
throughput Cyp3a assay in zebrafish. Based on the current findings, Luciferin-IPA is 
a better probe substrate than Luciferin-PFBE due to the good signal-to-noise ratio 
across all concentrations tested. For future applications such as assessing induction or 
inhibition of Cyp3a activities, a fixed concentration at 15 µM of Luciferin-IPA was 
selected as the treatment concentration to be used. This concentration was chosen as 
it is the intermediate concentration where the kinetics was not grossly activated, and 
the good signal-to-noise ratio renders the assay sensitive for detecting any remaining 






 In this study, a novel high-throughput in vivo assay with a short turnaround 
time of three hours was developed and evaluated for screening Cyp3a activity in 5 
d.p.f. zebrafish. Two different substrates were investigated, and for the first time, 
atypical kinetics involving homotropic effects were observed in an in vivo system. 
This indicated that the metabolism of the substrates was likely due to a single, 
predominant enzyme and hence, the assay is selective in assessing the effects of the 
enzyme, postulated to be Cyp3a65, which elicited the Cyp3a metabolic activity. 
Luciferin-IPA was the better substrate of the two, with a high signal-to-noise ratio. 
Two different incubation durations and diluents were tested, and the optimized 
experimental workflow is summarized in Figure 4.4. This assay is useful for early 
drug discovery applications as it marries the strengths of both in vitro and in vivo 
models. Future work in identifying the enzymes responsible for the metabolism of the 
luciferin substrates using methods such as gene knock-down or recombinant enzymes 
should be pursued to gain a mechanistic understanding on the metabolism of these 
substrates in zebrafish. This would then pave way for in-depth investigation of the 
atypical kinetics phenomenon observed.   
  
Figure 4.4. The experimental workflow of a high-throughput in vivo Cyp3a assay 





CHAPTER 5: EVALUATION OF THE INDUCIBILITY OF CYP3A 




 CYP induction is widely accepted as an important factor for consideration 
during drug discovery and development, as revealed by a survey on the current 
practices and recommendations on in vitro and in vivo induction of cytochrome P450 
(CYP) from the perspective of members of the Pharmaceutical Research and 
Manufacturers of America (PhRMA) (Chu et al., 2009). In this survey, it was 
gathered that many companies implement nuclear receptor assays, most notably 
Pregnane X Receptor (PXR), for early detection of potential for induction. It was 
found that 64% of those surveyed routinely use nuclear receptor transactivation 
assays to assess the potential of test compounds in inducing enzyme activities while 
binding assays are less popular (93% surveyed do not routinely use binding assays) 
due to the lack of strong correlation between receptor binding and transactivation. In 
the transactivation PXR assays, carcinoma cell lines such as HepG2 or HuH-7 
transiently or stably transfected with PXR expression and reporter constructs are 
typically used. These high-throughput reporter assays are useful tools adopted by 
pharmaceutical companies to guide their discovery programs. Primary human 
hepatocytes (PHH) on the other hand, are used by nearly all the companies surveyed 
to characterize enzyme induction potential of compounds in drug development, with a 
majority also using it during the drug discovery stage. Nevertheless, due to cost and 
availability limitations of PHH, PHH from only one donor is typically used in the 
drug discovery phase whereas biological replicates from at least three donors are 
reserved for assessing enzyme induction of compounds in the development stage.   
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 With the above survey findings, the zebrafish clearly has potential and a role 
to play in early drug discovery if it can be developed for screening of enzyme 
induction activity. Similar to the nuclear receptor transactivation assays, zebrafish is 
potentially amenable to high-throughput screening. Additionally, zebrafish has an 
added advantage over in vitro systems even though its absorption, distribution, 
metabolism and excretion (ADME) characteristics are not well elucidated yet as 
it embodies the in vivo complexities involved in producing a final drug 
interaction outcome. Furthermore, induction due to metabolites generated from 
metabolism of parent compound may be detectable in an in vivo zebrafish model, 
unlike the transactivation assays. Finally, cost and availability issues associated with 
use of PHH may be mitigated by using zebrafish.  
 Nevertheless, inducibility of Cyp3a activity in zebrafish remains unknown. 
Although hydroxylated testosterone metabolite were detected by Alderton et al., they 
did not further elucidate the inducibility of the Cyp function in zebrafish (Alderton et 
al., 2010). Thus far, Tseng et al. have evaluated the effects of dexamethasone and 
rifampicin on cyp3a65 gene expression in 96 hours post fertilization (h.p.f.) zebrafish 
larvae (Tseng et al., 2005) while Bresolin et al. tested the effects of nifedipine, 
clotrimazole, and pregnenolone 16α-carbonitrile (PCN) on the expression of cyp3a in 
the liver of adult zebrafish. A couple of zebrafish Pxr (zfPxr) transactivation assays 
have also been performed whereby the effects of several pharmaceutical drugs on 
zfPxr activation were evaluated (Moore et al., 2002; Ekins et al., 2008).     
 It has thus far been confirmed that zebrafish possess Cyp3a metabolic activity 
via testosterone-6β-hydroxylation (Chapter 3) and metabolism of Luciferin-IPA 
(Chapter 4). Using the high-throughput luminescence-based assay optimized in 
Chapter 4, this chapter aimed to explore the inducibility of Cyp3a activity in 5 d.p.f. 
zebrafish larvae using eight U.S. Food and Drug Administration (FDA)-listed 
hCYP3A4 inducers (FDA). In addition, the effects of the hCYP3A4 inducers on the 
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expression of cyp3a65 and nr1i2 (the Pxr gene) were investigated. Dexamethasone 
was used as the positive control as it has previously been shown to induce expression 
of cyp3a65 in zebrafish larvae (Tseng et al., 2005). Acetaminophen was chosen as the 
negative control as it did not activate zfPxr in a study which employed luciferase-
based reporter Pxr activation assay (Ekins et al., 2008). The absorption of hCYP3A4 
inducers which were detectable using the liquid chromatography tandem mass 





5.2. Materials and methods 
 
5.2.1. Chemicals and reagents 
 
 Debrisoquine sulfate (internal standard, IS), erythromycin (IS), rifampicin, 
carbamazepine, dexamethasone, acetaminophen, sulforaphane, magnesium sulphate 
heptahydrate, sodium bicarbonate, methylene blue and dimethyl sulfoxide (DMSO) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Nafcillin sodium, 
prednisone and rufinamide were purchased from Santa Cruz Biotechnologies, Inc. 
(California, USA). Efavirenz was purchased from Toronto Research Chemicals 
(Ontario, Canada). Sodium chloride was purchased from Schedelco Pte. Ltd. 
(Singapore). Calcium chloride dihydrate, potassium chloride and ethanol were 
purchased from Merck Millipore (Merck KGaA, Darmstadt, Germany). Disodium 
hydrogen phosphate and potassium dihydrogen phosphate were purchased from J.T. 
Baker (Phillipsburg, NJ, USA). Phosphate buffered saline (PBS) was purchased from 
Vivantis Technologies Sdn. Bhd (Selangor, Malaysia). Methanol (MeOH) and 
acetonitrile (ACN) were purchased from Tedia Company Inc (Fairfield, OH, USA). 
Methyl tert-butyl ether (MTBE) was purchased from Acros Organics (New Jersey, 
USA). Ethyl acetate (EA) was purchased from Fisher Scientific UK Ltd. Formic acid 
98/100% was purchased from AnalaR® VWH International Ltd (Poole, England). 
P450-Glo™ CYP3A4 Assay with Luciferin-IPA was purchased from Promega 
(Promega Corporation. Madison, USA). Water was purified using a Milli-Q water 





5.2.2. Animal Husbandry 
 
 Wild-type zebrafish embryos of natural spawning were collected at the 
aquarium of the Department of Biological Sciences (DBS), National University of 
Singapore (NUS). All maintenance procedures were as described in Chapter 4, 
Section 4.2.2 and experiments were conducted in compliance with the guidelines of 
the Institutional Animal Care and Use Committee of NUS. 
 
5.2.3. Functional induction of Cyp3a activity in zebrafish 
 
 Stock solutions of carbamazepine, efavirenz, nafcillin, phenytoin, 
pioglitazone, prednisone, rifampicin, dexamethasone and acetaminophen were 
dissolved in 100% v/v MeOH whereas rufinamide was dissolved in 100% v/v DMSO. 
Test compounds were diluted from stock solutions in 10% Hanks Balanced Salt 
Solution (HBSS) (0.137 mM NaCl, 0.54 mM KCl, 25 μM Na2HPO4, 44 μM KH2PO4, 
130 μM CaCl2.2H2O, 100 μM MgSO4.7H2O and 420 μM NaHCO3, 10 times diluted 
with Milli-Q water) to final working concentration levels with a solvent concentration 
of 1% v/v MeOH for all compounds except 0.33% v/v DMSO for rufinamide. 
Optimal incubation duration of inducers was determined using dexamethasone and 
rifampicin. Three 5 d.p.f. zebrafish per well in a clear 96-well plate were pre-treated 
with 200 µL of 50 µM dexamethasone or 75 µM rifampicin for 24 hr and 48 hr 
separately. At the end of pre-treatment period, the inducer medium was removed and 
replaced with 60 µL of 15 µM Luciferin-IPA. At 2 hr, 50 µL of the medium was 
transferred into an opaque white 96-well plate containing 50 µL luciferin detection 
reagent (LDR) in each well and incubated for a further 20 min followed by 
measurement of luminescence using a Tecan-Infinite M200 plate reader (Tecan, 
Switzerland). Using the optimized incubation duration of 48 hr, the experiment was 
repeated with all other inducers. In brief, three 5 d.p.f. zebrafish per well in a clear 
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96-well plate were pre-treated with 200 µL of hCYP3A4 inducers: rifampicin, 
phenytoin, carbamazepine, nafcillin, pioglitazone, prednisone and rufinamide at 0.1, 
1, 10, 50 or 100 µM and efavirenz at 0.1, 0.5, 1 or 10 µM for 48 hr. Additionally, 
experiments testing dexamethasone as positive control and acetaminophen as 
negative control at 0.1, 1, 10, 50 or 100 µM were also performed. The concentration 
range for efavirenz was chosen as zebrafish mortality was observed beyond 10 µM. 
Solvent control experiments were performed in parallel. At the end of 48 hr pre-
treatment period, the inducer medium was removed and replaced with 60 µL of 15 
µM Luciferin-IPA. All procedures thereafter is as described in the optimization 
experiment. Health of zebrafish was visually noted and any observed death recorded. 
Fold induction was calculated as follows, where 'corrected luminescence' was 
obtained by subtracting the raw signal from each well with the average background 
signal:  
 
Fold induction =  Corrected luminescence at X µM
Corrected luminescence of solvent control  
 
Unpaired t-test (2-sided) was performed at the different inducer concentration 
levels using Graphpad Prism 5.03 to test the difference in induction effects between 
the solvent control group and each treatment concentration. Statistical significance 





5.2.4. Effects of hCYP3A4 inducers on the expression of cyp3a65 and nr1i2 in 
zebrafish 
 
5.2.4.1. Treatment of fish 
Forty zebrafish larvae aged 5 d.p.f. placed in each well in a 6-well plate were 
treated with 4 mL of 10% HBSS containing hCYP3A4 inducers rifampicin, 
phenytoin, carbamazepine, nafcillin, pioglitazone, prednisone or rufinamide at 100 
µM, and efavirenz at 10 µM for 48 hr at 28.5 ± 0.5 °C. Experimental set up using 100 
µM dexamethasone as positive control and 100 µM acetaminophen as negative 
control were also performed in parallel with solvent controls which were 1% MeOH 
for all compounds and 0.33% DMSO for rufinamide. At 48 hr, each pool of zebrafish 
was transferred to a microfuge tube and surrounding medium removed using a plastic 
Pasteur pipette with an attached 10 µL tip. The sample was immediately snap frozen 
in liquid nitrogen. All samples were stored in -80°C until RNA isolation. Experiment 
was performed in triplicates. 
 
5.2.4.2. RNA isolation and cDNA synthesis 
 
 RNA isolation was performed using the RNeasy Mini Kit (Qiagen Inc. 
Valencia, CA, USA). A volume of 600 μL RLT buffer was added to the larvae and 
they were homogenized using plastic pestle homogenizer followed by centrifugation 
for 10 min at 8000 g. The supernatant was then transferred to a new microfuge tube 
and total RNA was isolated according to RNeasy Mini Kit protocol and finally eluted 
with 50 µL Ambion® DEPC-treated water (Life Technologies. Carlsbad, California). 
cDNA synthesis was performed according to manufacturer’s protocol by reverse 
transcribing 1 µg of total RNA to cDNA using iScript cDNA Synthesis Kit and Bio-




5.2.4.3. Quantitative real time-polymerase chain reaction (qRT-PCR)  
 
 Primers for the genes of interest (cyp3a65 and nr1i2) and reference genes 
(actb, gadph, tuba1b, rpl13, eef1a1|1 and b2m) listed in Table 5.1 were purchased 
from Integrated DNA Technology Pte Ltd (Singapore) and used for qRT-PCR. 
Reference genes selected were those that represent different biological pathways and 
have been shown to be stably expressed in zebrafish (Tang et al., 2007; Casadei et al., 
2011). The cDNA template was diluted 10-fold and 4 µL of it was added into a 20 µL 
reaction mixture containing 500 nM of forward and reverse primer each and 10 µL of 
SsoFastTM EvaGreen® Supermix (Bio-Rad Laboratories. CA, USA). Thermal cycling 
performed by Bio-Rad CFX 96TM Real-Time Detection System (Bio-Rad 
Laboratories, CA, USA) consisted of an enzyme activation step for 30 sec at 95°C 
followed by 40 cycles of denaturation (5 sec at 95°C) and annealing/extraction (5 sec 
at 60°C). Dissociation curve analysis was performed along with gel electrophoresis to 
check for primer specificity. As some variations in expression levels of the six 
reference genes tested were observed across all 12 groups including solvent controls, 
expression of target genes was normalized to all six reference genes using a free web-
based program, RT2 Profiler PCR Array Data Analysis version 3.5 (Qiagen, Venlo, 
Netherlands). The fold change in mRNA expression levels of cyp3a65 and nr1i2 in 













Gene ID (Product 
length, bp) 
Sequence (5’-3’) Reference  
Cytochrome P450 3a65 
(Cyp3a65) 
cyp3a65 NM001037438.1 (131) Forward CGGTGCGTACAGTATGGATG Tseng et al. 
(2005) 
Reverse AGAGAGGGTTCAGCAGGTCA 
Pregnane X receptor (Pxr) nr1i2 NM001098617.1 (81) Forward ATGAAGTGACGGGAATTTGGG (Lister et al., 
2009) Reverse GATGGTGCTGAAAACCAGCTC 
β-actin actb  NM181601 (322) Forward GCAGAAGGAGATCACATCCCTGGC Casadei et al. 
(2011) Reverse CATTGCCGTCACCTTCACCGTTC 
Glyceraldehyde-3-phophate 
dehydrogenase (Gapdh) 
gapdh NM213094 (84) Forward CGCTGGCATCTCCCTCAA Tang et al. 
(2007) Reverse TCAGCAACACGATGGCTGTAG 
Tubulin-α-1b tuba1b NM194388 (171) Forward TGGAGCCCACTGTCATTGATG Tang et al. 
(2007) Reverse CAGACAGTTTGCGAACCCTATCT 
Ribosomal protein L13-α rpl13 NM_198143.1 (148) Forward TCTGGAGGACTGTAAGAGGTATGC Tang et al. 
(2007) Reverse AGACGCACAATCTTGAGAGCAG 
Elongation factor-1-α eef1a1|1 
 
L23807.1 (87) Forward CTGGAGGCCAGCTCAAACAT Tang et al. 
(2007) 
Reverse ATCAAGAAGAGTAGTACCGC 
Beta-2-microglobulin b2m NM131163 (110) Forward AGGATTGTCTGCTTGGCTCTCT Tang et al. 
(2007) Reverse GGAGTGGAGACTTTCCCCTGTAC 
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5.2.5. Pxr inhibition assay 
 
 Stock solutions of carbamazepine, dexamethasone and sulforaphane were 
dissolved in 100% v/v MeOH and diluted with 10% HBSS to final working 
concentration levels with a final solvent concentration of 1% v/v MeOH. Three 
zebrafish larvae aged 5 d.p.f placed in each well in a clear 96-well plate were pre-
treated with 200 µL of the following medium for 48 hr: (1) treatment group - a 
mixture of 100 µM carbamazepine and 15 µM sulforaphane, (2) positive control 
group - a mixture of 100 µM dexamethasone and 15 µM sulforaphane, (3) control 
group -  100 µM carbamazepine , (4) control group - 100 µM dexamethasone, (5) 
control group - 15 µM sulforaphane and (6) solvent control group - 1% MeOH. At the 
end of 48 hr pre-treatment period, the medium was removed and replaced with 60 µL 
of 15 µM Luciferin-IPA. At 2 hr, 50 µL of the medium was transferred into an 
opaque white 96-well plate containing 50 µL LDR in each well and incubated for a 
further 20 min followed by measurement of luminescence using a Tecan-Infinite 
M200 plate reader (Tecan, Switzerland). All incubations were performed at 28.5 ± 0.5 
°C and in five replicates. Health of zebrafish was visually noted and any observed 





5.2.6. In vivo Systemic Absorption  
 
5.2.6.1. Treatment of zebrafish 
 
 Fifty zebrafish larvae aged 5 d.p.f. placed in each well were treated with 3 
mL each of 100 μM carbamazepine, pioglitazone or rifampicin in a 6-well plate for 1 
hr. 1% MeOH solvent controls were performed in parallel. At the end of 1 hr 
incubation, the zebrafish was transferred to a microfuge tube and surrounding 
medium was removed. The zebrafish was then quickly rinsed with 250 µL ice-cold 
PBS. The total wet weight of the zebrafish was noted down. Samples were stored at -
80 °C until future analysis. All drug treatment and control experiments were 
performed in triplicates.  
 
5.2.6.2. Sample Preparation 
 
 A volume of 8 μL of 10% HBSS was added to every 1 mg of zebrafish 
larvae. The mixture was homogenized with two 3 mm homogenizer beads using the 
Mixer Mill MM 400 (Retsch, Germany). Each sample was subjected to three cycles 
of homogenization at 25 Hz and 10 sec per cycle.  
  
5.2.6.3. Liquid–liquid extraction 
 
 100 µL of 1 M NaOH was added to 100 µL of homogenate before extracting 
with 900 μL of a mixture of MTBE:EA (1:1, v/v) containing 5 µM of IS 
(erythromycin for rifampicin; debrisoquine for carbamazepine; fluvoxamine for 
pioglitazone). The sample was then mixed using a large capacity mixer (Glas-Col®, 
Terre Haute, USA) for 15 min at 70 motor speed. Thereafter, it was centrifuged at 
18000 g, 4°C for 10 min using the Microfuge® 22R Centrifuge (Beckman CoulterTM, 
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Kraemer Blvd, Brea, CA, USA). 800 μL of the upper organic phase was separated 
and evaporated to dryness under a stream of nitrogen at 3 psi, 50°C using the 
TurboVap® LV (Caliper, Life Sciences, Hopkinton, MA, USA). The residue was 
reconstituted with 100 μL of initial LC mobile phase composition and filtered with a 
0.45 µm syringe filter (Millipore, Carrigtwohill, Co, Cork, Ireland) prior to liquid 
chromatography tandem mass spectromety (LC/MS/MS) analysis.  
 
5.2.6.4. LC/MS/MS Method  
 
 LC/MS/MS analysis was performed using the ACQUITY Ultra Performance 
Liquid Chromatography (UPLC) System (Waters, Milford, MA, USA) and a hybrid 
triple quadrupole-linear ion trap mass spectrometer equipped with a TurboIonSpray 
electrospray ionization (ESI) source (QTRAP 3200, Applied Biosystems, Foster City, 
CA, USA). Chromatographic separation was performed using a reverse phase 
column, Acquity UPLC® BEH C18, 1.7 µm, 2.1 × 50 mm, at a column temperature of 
45°C and autosampler temperature of 10°C. The mobile phase consisted of solvent A 
(0.1% formic acid in water) and solvent B (0.1% formic acid in ACN) at a constant 
flow rate of 0.6 mL/min. The mass spectrometer was operated in the positive ESI 
mode and the m/z transitions are summarized in Table 5.2. The optimized source 
dependent parameters were: curtain gas (nitrogen) at 15 psi, collision gas set to 
medium, turbo gas temperature of 550°C, ionspray voltage at +5,500 V, ion source 
gas 1 at 40 psi, ion source gas 2 at 45 psi, and the interface heater was on. The 
optimized elution conditions were as follows: gradient of 20–90% solvent B (0–
1.40 min), gradient of 90-95% solvent B (1.40-1.50 min), isocratic at 95% solvent B 
(1.50–1.90 min), gradient of 95-20% solvent B (1.90-1.95min) and isocratic at 20% 
solvent B (1.95–2.50 min). Data analysis was performed using the Analyst 1.4.2 
software (Applied Biosystems). The systemic absorption of drug compounds in 
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zebrafish was calculated in terms of number of grams of drug compound in 1,000,000 
grams of zebrafish (parts per million, ppm).  
 
 
Table 5.2. Mass spectrometry parameters of analytes and their respective IS. 
DP, declustering potential; EP, entrance potential; CE, collision energy; CXP, 























Carbamazepine + 237.1 194.2 0.96 42.05 9.52 26.54 2.66 
Debrisoquine (IS) + 176.0 134.1 0.53 38.95 9.87 24.55 1.72 
Pioglitazone + 357.1 134.1 0.695 52.56 9.89 38.79 1.81 
Fluvoxamine (IS) + 319.2 71.1 0.96 35.83 9.45 28.83 1.89 
Rifampicin + 823.5 399.3 1.25 46.78 9.62 34.73 3.67 





5.3.1. Functional induction of Cyp3a activity in zebrafish 
 
 The optimal incubation duration of inducers was determined to be 48 hr due 
to statistically significant fold induction with dexamethasone and higher fold 
induction with rifampicin at 48 hr compared to 24 hr (Figure 5.1).The inducibility of 
Cyp3a activity in 5 d.p.f. zebrafish was evaluated using eight FDA-listed hCYP3A4 
inducers  (FDA) with Luciferin-IPA as the probe substrate of Cyp3a activity at the 
end of 48 hr. Additionally, dexamethasone and acetaminophen were used as positive 
and negative control, respectively. Cyp3a activity was induced when treated with 
carbamazepine, phenytoin, prednisone, pioglitazone and nafcillin (Figure 5.2) while 
no induction was observed for rifampicin, rufinamide and efavirenz (Figure 5.3). 
Induction was observed in the positive control, dexamethasone (Figure 5.2.F) and 
none, in the negative control, acetaminophen (Figure 5.3.D). Concentration-
dependent induction was seen for carbamazepine, phenytoin and prednisone from 0 to 
100 μM (Figure 5.2.A-C) while a more variable trend was observed for pioglitazone 











































2.5 24 hr 50 µM dexamethasone
48 hr 50 µM dexamethasone
24 hr 75 µM rifampicin


















Figure 5.1. Optimization of incubation duration of hCYP3A4 inducers in 5 d.p.f. 
zebrafish. Fold induction of Cyp3a activity in 5 d.p.f. zebrafish treated for 24 or 48 
hr with 50 µM dexamethasone or 75 µM rifampicin followed by measurement of 
Cyp3a activity using Luciferin-IPA assay. Unpaired t-test (2-sided) between treated 
















































































































































































































Figure 5.2. hCYP3A4 inducers causing statistically significant positive fold 
induction of Cyp3a activity in 5 d.p.f. zebrafish compared to solvent control. 
Fold induction of Cyp3a activity against increasing concentrations of (A) 
carbamazepine, (B) phenytoin, (C) prednisone, (D) pioglitazone, (E) nafcillin, and (F) 
dexamethasone (positive control). Unpaired t-test (2-sided) between treated group 




























































































































Figure 5.3. hCYP3A4 inducers which did not induce Cyp3a activity in 5 d.p.f. 
zebrafish compared to solvent control. Fold induction of Cyp3a activity against 
increasing concentrations of (A) rifampicin, (B) rufinamide, (C) efavirenz, and (D) 

























5.3.2. Effects of hCYP3A4 inducers on the expression of cyp3a65 and nr1i2 in 
zebrafish 
 
 Expression of cyp3a65 was modestly induced by all hCYP3A4 inducers with 
fold induction ranging from 1.11 - 1.36 (Figure 5.4.A). The induction was statistically 
significant compared to control only for rifampicin (1.36-fold (1.01, 1.71)), 
prednisone (1.34-fold (1.10, 1.58)) and rufinamide (1.30-fold (1.17, 1.42)). A 
statistically significant suppression of cyp3a65 expression was seen in the 
dexamethasone control group. When grouped according to the clinical classification 
of strength of inducers by FDA, the potency of the inducers within each group of 
inducers yielded a very different profile when comparing the cyp3a65 expression 
against Cyp3a activity (Figure 5.4). The most notable disparity was seen with 
rifampicin and dexamethasone where expression of cyp3a65 was induced but not 
Cyp3a activity when treated with rifampicin while expression of cyp3a65 was 
markedly suppressed but Cyp3a activity strongly induced when treated with 









































































































































































Figure 5.4. Effects of hCYP3A4 inducers on the (A) expression of cyp3a65 and 
(B) Cyp3a activity in 5 d.p.f. zebrafish. All compounds were dosed at 100 µM 
except efavirenz which was dosed at 10 µM due to toxicity limitations. The inducers 
were grouped together as strong, moderate and weak according to the clinical 
classification by FDA where strong inducers: ≥ 80% decrease in area under curve 
(AUC), moderate inducers: 50-80% decrease in AUC, and weak inducers: 20-50% 
decrease in AUC (FDA). A decrease in area under the curve (AUC) refers to a 
decrease in exposure to the co-administered drug with the current inducer drug. 
Unpaired t-test (2-sided) between treated and solvent control group, *p <0.05, 
**p<0.01, ***p <0.001, ****p <0.0001, (n=3 for cyp3a65 gene induction 





 Scrutinizing the fold induction of the Cyp3a activity and cyp3a65 expression 
closely (Table 5.3), the five hCYP3A4 inducers (carbamazepine, phenytoin, 
prednisone,  pioglitazone and nafcillin) which caused induction in Cyp3a activity 
showed a higher fold induction in activity versus cyp3a65 expression (ratio>1.00) 
whereas the three hCYP3A4 inducers which did not induce Cyp3a activity 
(rifampicin, rufinamide and efavirenz) had lower fold induction activity versus 
cyp3a65 expression (ratio<1.00). This was an interesting observation which also held 
true for dexamethasone with acetaminophen as the only exception. 
 
Table 5.3. Summary of fold induction of Cyp3a activity, cyp3a65 and nr1i2 
mRNA expression and ratio of the fold induction of Cyp3a activity to cyp3a65 
expression in 5 d.p.f. zebrafish treated with hCYP3A4 inducers, dexamethasone 
(positive control) and acetaminophen (negative control).  
 
Compound 
Fold induction of 
Cyp3a activity 
Mean (95% C.I.) 
Fold induction of 
cyp3a65 
expression 
Mean (95% C.I.) 
Fold induction of 
nr1i2 expression 
Mean (95% C.I.) 






Carbamazepine 1.51 (0.88, 2.14)* 1.22 (0.80, 1.63) 1.05 (0.80, 1.30) 1.24 
Phenytoin 1.60 (1.19, 2.00)* 1.19 (1.00, 1.39) 0.97 (0.90, 1.03) 1.34 
Prednisone 2.02 (1.82, 2.21)**** 1.34 (1.10, 1.58)* 1.40 (1.09, 1.70)** 1.51 
Pioglitazone 1.47 (0.82, 2.10)* 1.21 (0.96, 1.46) 1.04 (0.92, 1.16) 1.21 
Nafcillin 1.75 (1.26, 2.25)* 1.11 (0.91, 1.30) 1.09 (1.00, 1.19) 1.58 
Rifampicin 0.93 (0.51, 1.34) 1.36 (1.01, 1.71)* 1.31 (1.13, 1.49)** 0.68 
Rufinamide 1.13 (0.90, 1.35) 1.30 (1.17, 1.42)** 1.28 (1.14, 1.42)** 0.87 
Efavirenz# 0.99 (0.43, 1.55) 1.20 (0.97, 1.44) 1.09 (1.00, 1.19) 0.83 
Dexamethasone 1.86 (1.61, 2.11)*** 0.55 (0.46, 0.63)** 1.74 (1.48, 2.01)**** 3.38 
Acetaminophen 1.28 (0.90, 1.66) 0.82 (0.62, 1.00) 0.98 (0.89, 1.08) 1.56 
C.I.: confidence interval. # dosed at 10 µM due to toxicity limitations. Unpaired t-test (2-
sided) between treated and solvent control group, *p <0.05, **p<0.01, ***p <0.001, ****p 






 A statistically significant induction of nr1i2 expression was observed in 
rifampicin, prednisone, rufinamide and dexamethasone-treated groups (Figure 5.5). 
All other compounds did not cause any induction of nr1i2 expression including the 


















































































Figure 5.5. Effects of hCYP3A4 inducers on the expression of nr1i2 in 5 d.p.f. 
zebrafish. All compounds were dosed at 100 µM except efavirenz which was dosed 
at 10 µM due to toxicity limitations. The inducers were grouped together as strong, 
moderate and weak according to the clinical classification by FDA where strong 
inducers: ≥ 80% decrease in area under curve (AUC), moderate inducers: 50-80% 
decrease in AUC, and weak inducers: 20-50% decrease in AUC (FDA). A decrease in 
area under the curve (AUC) refers to a decrease in exposure to the co-administered 
drug with the current inducer drug. Unpaired t-test (2-sided) between treated and 






5.3.3. Pxr inhibition assay 
 
 Plain sulforaphane did not affect basal Cyp3a activity. It however reversed 
the induction of Cyp3a activity by both carbamazepine and dexamethasone (positive 
control) in a statistically significant manner. The reversal however led to a 
statistically significant suppression of Cyp3a activity when compared to solvent and 
















































Figure 5.6. Effects of sulforaphane on carbamazepine- and dexamethasone-
induced Cyp3a activity in 5 d.p.f. zebrafish. Dexamethasone and carbamazepine 
were dosed at 100 µM while sulforaphane at 15 µM. Cyp3a activity was expressed as 
percentage of solvent control. Unpaired t-test (2-sided), *p <0.05, **p<0.01, ***p 




5.3.4. In vivo systemic absorption 
 
 The three inducers amenable to LC/MS/MS detection in our laboratory were 
detected in 5 d.p.f. zebrafish larval homogenate when treated at 100 µM for 1 hr. The 
drug concentration levels ranged from 11.29 to 119.57 ppm (Table 5.4). 
 
Table 5.4.  Concentrations of hCYP3A4 inducers detected in 5 d.p.f. zebrafish 









in zebrafish larvae 
(ppm ± S.D.), (n=3) 
Carbamazepine 2.45 100 11.29 ± 2.15 
Pioglitazone 2.30 100 119.57 ± 16.09 
Rifampicin 2.70 100 65.90 ± 9.18 






 The inducibility of Cyp3a activity was evaluated in this study using the high-
throughput luminescence-based assay developed and optimized in Chapter 4. In 
addition, the effects of the FDA-listed hCYP3A4 inducers on the expression of 
cyp3a65 and nr1i2 were also investigated. At 100 µM for all compounds and 10 µM 
for efavirenz, 5 out of the 8 inducers (62.5%) evaluated induced Cyp3a activity in 5 
d.p.f. zebrafish whereas cyp3a65 was upregulated by all compounds, albeit only 
statistically significant for rifampicin, rufinamide and prednisone (Figure 5.4). The 
expression of nr1i2 was also upregulated significantly for rifampicin, rufinamide and 
prednisone, in congruence with the upregulation of cyp3a65. 
 The 62.5% selectivity of the hCYP3A4 inducers was not totally unexpected 
as species differences in CYP3A induction by xenobiotics are well established. 
Classical examples include rifampicin which causes a strong induction of CYP3A 
activity in humans but not rodents while PCN and dexamethasone elicit the opposite 
strong induction in rodents but not humans (Moore and Kliewer, 2000; Lu and Li, 
2001; Nishimura et al., 2007). In this study, 5 d.p.f. zebrafish demonstrated an 
induction characteristic similar to rodents as rifampicin did not cause any induction 
while dexamethasone produced a strong induction in Cyp3a activity.  
 These species differences in sensitivity to different xenobiotics have been 
attributed to the differences in the ligand binding domain (LBD) of PXR, the nuclear 
receptor which plays a key role in the regulation of CYP3A genes in mammals 
(LeCluyse, 2001). Reschly et al. observed that classical PXR-mediated effects such 
as an increase in CYP3A-like activity, CYP2C-like activity and mRNA transcription 
of mdr1 were produced in adult zebrafish treated with phenobarbital or endogenous 
bile salts (Reschly et al., 2007). In another study, Bresolin et al. demonstrated the 
intrinsic association between nr1i2, cyp3a and mdr1 genes in adult zebrafish where 
these genes were all upregulated by 1.6-1.9-fold when treated with PCN (Bresolin et 
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al., 2005). Taken together, these studies suggested that the Cyp3a regulation pathway 
by Pxr is conserved between zebrafish and human. Indeed, this current study 
confirmed the association of cyp3a65 with nr1i2 as both genes were significantly 
upregulated by rifampicin, rufinamide and prednisone. Furthermore, the Pxr 
inhibition assay performed using sulforaphane revealed that the induction of Cyp3a 
activity by dexamethasone and carbamazepine was mediated through the Pxr  
pathway. Sulforaphane was selected as the antagonist of choice for PXR as it has 
been shown to inhibit PXR function in both the full-length PXR and plain LBD-
transfected vectors (Zhou et al., 2007). The concentration used in this study was 
based on literature where the IC50 of sulforaphane was reported as 12 µM and 
concentrations up to 25 µM SFN have been previously used in in vitro cell-based 
work (Zhou et al., 2007; Antolino-Lobo et al., 2011).  
  The above said, in a recent study where 165 compounds including steroids, 
bile salts and xenobiotics were screened using a luciferin-based reporter PXR 
activation assay in which zfPxr was transfected into HepG2 cells, only very few 
xenobiotics activated the zfPxr when compared to human PXR (hPXR) (Ekins et al., 
2008). Four compounds common to this study, carbamazepine, phenytoin, rifampicin 
and dexamethasone, did not activate the zfPxr in their study (Ekins et al., 2008). 
Similarly, in another study utilizing transactivation assay which screened 10 
xenobiotics, 11 natural and synthetic steroids, 9 bile acids, and 5 benzoates, only 8 
compounds, out of which, 3 xenobiotics, namely nifedipine, clotrimazole and 
phenobarbital, activated the zfPxr. Rifampicin and dexamethasone also did not 
activate zfPxr in their study (Moore et al., 2002). Compared to ligand binding assays, 
PXR transactivation assays are more popularly used by pharmaceutical companies to 
assess the potential of test compounds to cause enzyme induction (Chu et al., 2009) 
as transactivation assays have a better correlation with CYP3A4 induction activity 
with a good concordance of as high as 74% (Shukla et al., 2011). Assuming the 
results from the above two transactivation studies were accurate and not due to 
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chance errors, this suggest that the upregulation of cyp3a65 gene expression by 
carbamazepine, phenytoin, rifampicin and dexamethasone could be mediated through 
another pathway apart from Pxr. Interestingly, a very recent study discovered that 
cyp3a65 is also regulated through the aryl hydrocarbon receptor 2 (Ahr2) pathway 
(Chang et al., 2013). In their study, depletion of either nr1i2 or ahr2 eliminated 
cyp3a65 transcription completely, raising the possibility that interactions between 
these two nuclear factors are necessary for cyp3a65 expression. Therefore, although 
the current study showed that cyp3a65 is associated with the Pxr pathway through the 
chemical inhibition assay and congruent upregulation of both genes by several 
compounds, the discrepancy between the results from the literature cited-zfPxr 
transactivation assays and the cyp3a65 gene expression experiment presents with 
exciting opportunities for further investigation on the mechanism of cyp3a65 
regulation in zebrafish.  
 In this study, the expression of cyp3a65 was interestingly repressed when the 
zebrafish was treated with 100 µM dexamethasone. The present findings however 
corroborated with Tseng et al. who also observed a repression of cyp3a65 at 100 µM 
dexamethasone but upregulation at 10 µM dexamethasone in 84 hours post 
fertilization (h.p.f.) zebrafish using in situ hybridization techniques (Tseng et al., 
2005). In their study, upregulation of cyp3a65 was also observed in fish treated with 
10 and 100 µM rifampicin. The inverted U-shaped dose-response phenomenon 
associated with glucocorticoids on the regulation of CYPs has previously been 
observed with cyp2c11 in rat hepatocytes (Iber et al., 1997). Similarly,  the same 
trend on CYP3A4 expression has also been found in immortalized human hepatocytes 
treated with reserpine, rifabutin, rifapentine and ritonavir (Ripp et al., 2006), and 
human hepatocytes treated with omeprazole and clotrimazole (Raucy, 2003). These 
trends which used to be attributed to toxicity or solubility issues have more recently 
been agreed upon by pharmaceutical researchers to have an underlying pharmacology 
which is incompletely understood at this point in time (Chu et al., 2009). The 
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reproducibility of the repression of cyp3a65 by high dose dexamethasone in this 
study reaffirms that this is an inherent characteristic of the zebrafish and worthy for 
further investigation. 
 The increased expression of nr1i2 gene when treated with prednisone and 
dexamethasone was expected as glucocorticoids have been shown to induce NR1I2 
gene expression (Pascussi et al., 2000; Pascussi et al., 2003). However, the induction 
caused by rifampicin and rufinamide was an interesting finding. A literature search 
was performed and it was found that one study observed the induction of NR1I2 
expression by rifampicin in a human intestinal cell line (Haslam et al., 2008) and a 
short conference proceeding reported the same effect in HepG2 cell line (Kishimoto 
and Fukushima, 2011). These results suggest that rifampicin and rufinamide may 
have effects on other pathways such as the glucocorticoid pathway in zebrafish. 
However, this hypothesis warrants a thorough investigation as contradictory findings 
have been made where Calleja et al. (1998) showed that rifampicin was an activator 
of glucocorticoid receptors which was later refuted by Herr et al. (2000).    
 CYP3A4 mRNA is typically induced to a higher extent than CYP3A4 activity 
in human hepatocytes (Fahmi et al., 2010). This could be due to the test compound 
being both an inducer and inhibitor for the same enzyme whereby RNA expression is 
unaffected by the enzyme inhibitor properties which only affects enzyme activity 
assays. It could also be due to formation of non-functional proteins. This has led to a 
consensus recommendation by pharmaceutical researchers that for hepatocyte 
induction experiments, CYP3A4 positive controls should exhibit ≥2-fold vehicle 
control catalytic activity and ≥6-fold vehicle control mRNA level (Chu et al., 2009). 
However, in this study, the converse was seen for compounds which caused 
statistically significant induction in Cyp3a activity (Table 5.3). mRNA molecules in 
prokaryotes and eukaryotes are usually found in the form of polyribosomes where 
multiple initiations of protein translation take place on a single mRNA molecule 
(Alberts et al., 2008). One would then expect that when mRNA transcripts are 
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increased due to induction, the outcome would be a non-linear increase in proteins 
and ultimately protein function but this does not hold true all the time due to multiple 
factors such as mRNA stability, cellular conditions and post-translational protein 
modification. Therefore, it could be hypothesized that in the zebrafish, the higher 
ratio of Cyp3a enzymatic activity to cyp3a65 could be due to efficient protein 
translation machinery which produced functional Cyp proteins. Again, this hypothesis 
requires further investigation as the current study assumed Cyp3a65 to be the 
isozyme responsible in producing the observed Cyp3a activity.    
 Carbamazepine, rifampicin and pioglitazone were shown to be absorbed into 
the zebrafish. No direct correlation was seen between the absorption and the 
experimental Log P values or molecular weights of the compounds (Table 5.4). 
Among many other factors, drug-protein binding which was not determined in this 
study could have contributed to the differences in amounts absorbed between the 
different compounds. Nevertheless, the data confirms that the compounds were taken 
up by zebrafish and could account for the observed effects. An attempt to correlate 
the absorption data with the extent of induction was not made as it would not be 
accurate to do so. This is because due to the fish size limitation, the current study 
could only quantify the total drug concentration, and not the unbound drug fraction, 
from whole larvae. This would not be representative of the systemic circulation or 
concentration at the organ of interest, which was the liver. 
 Although it is tempting to apply the current high-throughput platform to 
assess future test compounds for their induction potential as it not only reduces the 
cost and amount of test materials required but also generates a large amount of 
quality in vivo data within a short period of time, the platform certainly requires 
further optimization, development and validation. A typical method for assessing 
induction potential of compounds is to use parameters such as EC50 or Emax to derive 
various indices for comparison (Fahmi and Ripp, 2010). However, in this study, a 
concentration-dependent induction trend was not obtained for all compounds and for 
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those which showed the trend, the curve could not be fitted into the sigmoidal Emax 
model. Therefore, comparison of the induction potential of compounds was set at a 
concentration of 100 µM but this concentration may not be representative of 
therapeutic drug concentrations. Also, the different observed degrees of fold 
induction were quite similar and they could not be further categorized as strong, 
moderate or weak inducers. A more suitable means for comparison definitely needs to 
be explored to derive a fair comparison so as to rank-order compounds in terms of 
their induction potential. Variability between experimental replicates was also often 
observed despite a constant attempt to randomly sample zebrafish through the course 
of the study. This variability is nevertheless characteristic of in vivo animal studies. A 
possible way to reduce the variation would be to use a genetically homogeneous 







 This study is significant as for the first time, the effects of eight FDA-listed 
hCYP3A4 inducers on Cyp3a activity and cyp3a65 expression in 5 d.p.f. zebrafish 
were evaluated and shown to be inducible by selected compounds to different extents. 
Compared to the human model, the functional assay achieved 62.5% specificity. The 
lack of induction by rifampicin versus strong induction by dexamethasone in the 
zebrafish was a characteristic which was similar to the rat model. It was also 
demonstrated that cyp3a65 is associated with nr1i2 whereby induction by 
carbamazepine and dexamethasone is mediated via this pathway. When compared to 
literature, the current results suggested that cyp3a65 may not be solely regulated 
through the Pxr pathway. Apart from further optimizing and developing this in vivo 
high-throughput assay for future use in drug discovery, future work can include 
mechanistic investigations such as using mifepristone to inhibit the glucocorticoid 
receptors when zebrafish is treated with dexamethasone or prednisone. This would 
enable one to discern the contribution of glucocorticoid and Pxr pathways to the 
observed induction of Cyp3a activity by these two compounds. Pxr inhibition assay 
with sulforaphane should also be extended to all other compounds to elucidate the 
role of Pxr in the observed induction. Ahr inhibition should also be explored to 
elucidate the involvement of the Ahr pathway in the induction caused by the 
compounds tested. The effects of hCYP3A4 inducers on the expression of cyp3c1, the 
other Cyp3 family enzyme in the zebrafish besides cyp3a65, should also be 
investigated as there may be cross-reactivity in the metabolism of Luciferin-IPA. In 
silico docking strategies could also be adopted to study the binding of the hCYP3A4 
inducers to hPXR and zfPxr to explain the findings of the current study. The research 
area on induction of xenobiotic metabolism in the zebrafish model presents with 
exciting opportunities for exploration and with more discoveries, the advantages of 
this in vivo model can be leveraged upon for future use in drug discovery.        
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CHAPTER 6: EVALUATION OF THE USE OF ZEBRAFISH AS A HIGH-
THROUGHPUT IN VIVO MODEL FOR ASSESSING INHIBITION OF 




 The characterization of enzyme inhibitory properties of new chemical entities 
(NCEs) in drug discovery and development is as important as evaluation on its 
enzyme induction potential. From the perspective of the Pharmaceutical Research and 
Manufacturers of America (PhRMA), the preferred test systems for reversible 
cytochrome P450 (CYP) inhibition elucidation are liver microsomes and recombinant 
CYPs (Bjornsson et al., 2003) whereas for time-dependent inhibition (TDI) testing, 
100% of those surveyed used pooled liver microsomes (Grimm et al., 2009). The U.S. 
Food and Drug Administration draft guidance on "Drug Interaction Studies - Study 
Design, Data Analysis, Implications for Dosing, and Labeling Recommendations" 
also recommends the characterization of CYP inhibition using liver microsomes. The 
zebrafish model can clearly play a role in CYP inhibition testing if found to be 
suitable since pharmacodynamic factors such as differential binding affinities and 
pharmacokinetic factors such as distribution of drugs which are critical in yielding 
drug-drug interaction (DDI) outcomes are present in this in vivo system and absent in 
the in vitro liver microsomes or recombinant enzyme system. 
 Jones et al. (2010) attempted to assess the inhibition effects of α-
naphthoflavone and SKF525A on Cyp activity in zebrafish larvae but saw induction 
effects instead. Smith et al. (2012) investigated the effects of fluoxetine, 
ciprofloxacin, gemfibrozil and erythromycin on expressed zebrafish Cyp1a proteins 
and observed strong inhibition with erythromycin and fluoxetine. The inhibitory 
effects on Cyp3a activity in zebrafish remain unevaluated. Since Luciferin-IPA has 
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been successfully used as a probe substrate to investigate both reversible inhibition 
and TDI in human hepatocytes (Doshi and Li, 2011; Li and Doshi, 2011), this chapter 
aimed to assess the effects of six U.S. Food and Drug Administration (FDA)-listed 
hCYP3A4 inhibitors (FDA) on Cyp3a activity in zebrafish using Luciferin-IPA as the 
probe substrate. The absorption of hCYP3A4 inhibitors which are detectable using 
the liquid chromatography tandem mass spectrometry (LC/MS/MS) setup in our 





6.2. Materials and methods 
 
6.2.1. Chemicals and reagents 
 
 Cimetidine, erythromycin, fluvoxamine maleate, isoniazid, ketoconazole, 
verapamil hydrochloride, magnesium sulphate heptahydrate, sodium bicarbonate, and 
dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Sodium chloride was purchased from Schedelco Pte. Ltd. (Singapore). 
Calcium chloride dihydrate, potassium chloride and ethanol were purchased from 
Merck Millipore (Merck KGaA, Darmstadt, Germany). Disodium hydrogen 
phosphate and potassium dihydrogen phosphate were purchased from J.T. Baker 
(Phillipsburg, NJ, USA). Phosphate buffered saline (PBS) was purchased from 
Vivantis Technologies Sdn. Bhd (Selangor, Malaysia). Methanol (MeOH) and 
acetonitrile (ACN) were purchased from Tedia Company Inc (Fairfield, OH, USA). 
Methyl tert-butyl ether (MTBE) was purchased from Acros Organics (New Jersey, 
USA). Ethyl acetate (EA) was purchased from Fisher Scientific UK Ltd. Formic acid 
98/100% was purchased from AnalaR® VWH International Ltd (Poole, England). 
P450-Glo™ CYP3A4 Assay with Luciferin-IPA was purchased from Promega 
(Promega Corporation. Madison, USA).Water was purified using a Milli-Q water 
purification system (Millipore, Bedford, MA, USA).  
 
6.2.2. Animal Husbandry 
  
 Wild-type zebrafish embryos of natural spawning were collected at the 
aquarium of the Department of Biological Sciences (DBS), National University of 
Singapore (NUS). All maintenance procedures are as described in Chapter 4, Section 
4.2.2 and experiments were conducted in compliance with the guidelines of the 
Institutional Animal Care and Use Committee of NUS. 
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6.2.3. Optimization of duration of incubation with hCYP3A4 inhibitors 
 
 Three zebrafish larvae aged 5 d.p.f  placed in each well were pre-treated for 
2, 6, 24 or 48 hr with 100 µL of 1 µM ketoconazole or 10 µM fluvoxamine diluted 
with 10% HBSS from stock solution to a final solvent composition comprising 0.5% 
v/v MeOH and 0.5% v/v DMSO. Solvent control experiments were performed in 
parallel. At the end of pre-treatment time points, the medium was removed and 
replaced with 60 µL of 15 µM Luciferin-IPA. At 1 hr, 50 µL of the medium was 
transferred into an opaque white 96-well plate containing 50 µL luciferin detection 
reagent (LDR) in each well and incubated for a further 20 min followed by 
measurement of luminescence using a Tecan-Infinite M200 plate reader (Tecan, 
Switzerland). In addition, a co-incubation arm was also performed where the 
zebrafish was treated with 60 µL of a mixture containing 1 µM ketoconazole and 15 
µM Luciferin-IPA or 10 µM fluvoxamine and 15 µM Luciferin-IPA for 1 hr. At 1 hr, 
50 µL of the medium was transferred into a white plate containing LDR and all 
procedures are as described above. All incubations were performed at 28.5 ± 0.5 °C 
and in five replicates. Health of zebrafish was visually noted and any observed death 
recorded. Percentage remaining Cyp3a activity was calculated as follows, where 
'corrected luminescence' was obtained by subtracting the raw signal from each well 
with the average background signal:   
 
% remaining Cyp3a activity =  Corrected luminescence at X µM





6.2.4. Effects of hCYP3A4 inhibitors on Cyp3a activity in zebrafish 
 
 Stock solutions of cimetidine, erythromycin, fluvoxamine, isoniazid, 
ketoconazole and verapamil were dissolved in a mixture containing 50% v/v DMSO 
and 50% v/v MeOH. Three 5 d.p.f. zebrafish per well were pre-treated for 24 hr with 
100 µL of hCYP3A4 inhibitors: ketoconazole at 0.1, 0.5, 1, 10 or 50 µM, verapamil 
or fluvoxamine at 1, 10, 25, 50 or 75 µM and isoniazid, erythromycin or cimetidine at 
5, 20, 50, 75 or 100 µM diluted with 10% HBSS from stock solutions to a final 
solvent composition comprising 0.5% v/v MeOH and 0.5% v/v DMSO. Solvent 
control experiments were performed in parallel. The concentration ranges were 
chosen as such based on preliminary investigation. At the end of 24 hr, the inhibitor 
medium was removed and replaced with 60 µL of 15 µM Luciferin-IPA. At 1 hr, 50 
µL of the medium was transferred into an opaque white 96-well plate containing 50 
µL LDR in each well and incubated for a further 20 min followed by measurement of 
luminescence using a Tecan-Infinite M200 plate reader. All incubations were 
performed at 28.5 ± 0.5 °C and in five replicates. Health of zebrafish was visually 
noted and any observed death recorded. Percentage remaining Cyp3a activity was 
calculated as described above.    
Using the FDA’s clinical categorization of inhibition strength as a guide, the 
strength of inhibitors in zebrafish in this study was classified as strong if there was 
>80% inhibition of Cyp3a activity, moderate for 50 to 80% inhibition and weak for 
<50% inhibition. Unpaired t-test (2-sided) was performed to test the difference 
between each inhibitor concentration and solvent control group using Graphpad 
Prism 5.03 (La Jolla, CA, USA). Statistical significance was set at p<0.05. In 
addition, an inhibition curve was plotted for ketoconazole using a non-linear 
regression equation of log (inhibitor) vs. response with the same software to 




6.2.5. In vivo Systemic Absorption  
 
6.2.5.1. Treatment of zebrafish 
 
 Fifty zebrafish aged 5 d.p.f. placed in each well were treated with 3 mL each 
of 100 μM cimetidine, erythromycin, fluvoxamine or verapamil in a 6-well plate for 1 
hr. Additionally, to evaluate the absorption kinetics of fluvoxamine to correlate with 
the optimization of incubation duration experiment (Section 6.2.3), fifty 5 d.p.f. 
zebrafish per well were treated with 3 mL of 10 μM fluvoxamine for 1, 2, 6 or 24 hr. 
Solvent controls performed in parallel comprised a mixture containing 0.5% MeOH 
and 0.5% DMSO. At the end of incubation, the zebrafish was transferred to a 
microfuge tube and surrounding medium was removed. The zebrafish was then 
quickly rinsed with 250 µL ice-cold PBS. The total wet weight of the zebrafish was 
noted down. Samples were stored at -80 °C until future analysis. All drug treatment 
and control experiments were performed in triplicates.  
 
6.2.5.2. Sample Preparation and liquid-liquid extraction 
 
 Sample preparation followed by liquid-liquid extraction were performed as 





6.2.5.3. LC/MS/MS Method  
 
 The liquid chromatograph tandem mass spectrometry setup and parameters 
were as described in Chapter 5, Section 5.2.6.4. The mass spectrometer was operated 
in the positive ESI mode and the m/z transitions are summarized in Table 6.1. The 
optimized elution conditions were as follows: gradient of 20–90% solvent B (0–
1.40 min) for erythromycin and fluvoxamine while gradient of 5-90% solvent B (0-
1.40 min) for verapamil and cimetidine, followed by gradient of 90-95% solvent B 
(1.40-1.50 min) and  isocratic at 95% solvent B (1.50–1.90 min) for all compounds, 
then gradient of 95-20% solvent B (1.90-1.95 min) and isocratic at 20% solvent B 
(1.95–2.50 min) for erythromycin and fluvoxamine while gradient of 95-5% solvent 
B (1.90-1.95 min) and isocratic at 5% solvent B (1.95-2.50 min) for verapamil and 
cimetidine. Data analysis was performed using the Analyst 1.4.2 software (Applied 
Biosystems). The systemic absorption of drug compounds in zebrafish was calculated 
in terms of number of grams of drug compound in 1,000,000 grams of zebrafish 
(parts per million, ppm).  
 
 Table 6.1. Mass spectrometry parameters of analytes and IS. 
 DP, declustering potential; EP, entrance potential; CE, collision energy; CXP, 
collision cell exit potential 























Cimetidine* + 253.1 95.2 0.64 27.48 831 35.5 1.72 
Verapamil* + 455 165.2 1.13 59.76 9.38 38.04 2.45 
Fluvoxamine + 319.2 71.1 0.96 35.83 9.45 28.83 1.89 
Pioglitazone (IS) + 357.1 134.1 0.695 52.56 9.89 38.79 1.81 
Erythromycin + 734.5 158.2 0.87 44.12 9.54 40.05 2.1 





6.3.1. Effects of varying incubation duration on the inhibition of Cyp3a activity 
by ketoconazole and fluvoxamine 
 
 Inhibition was not observed for both ketoconazole and fluvoxamine when co-
incubated with Luciferin-IPA for 1 hr (Figure 6.1). On the contrary, statistically 
significant activation occurred instead with the fluvoxamine co-incubation arm, 
yielding 153% remaining Cyp3a activity. Cyp3a activity was inhibited for all pre-
incubation experiments with ketoconazole and fluvoxamine except the 6 hr pre-
incubation time point for fluvoxamine where inhibition was not observed. Since the 
inhibitory activity was not reproducible at 6 hr for fluvoxamine, 24 hr was selected as 
the pre-incubation duration for subsequent experiments instead of 2 hr to allow 
accumulation of the inhibitors with a longer exposure time. Ketoconazole also 
exerted stronger inhibition action with 24 hr incubation. No fish survived at the end 
of 48 hr pre-incubation with the inhibitors due to evaporation of incubation medium.  






























Figure 6.1. Effects of varying incubation duration on the inhibition of Cyp3a 
activity by ketoconazole and fluvoxamine. Unpaired t-test (2-sided) between 
treated and solvent control group in each arm, *p<0.05, **p <0.01, (n=5).     
116 
 
6.3.2. Effects of hCYP3A4 inhibitors on Cyp3a activity in zebrafish 
 
 All test inhibitors showed concentration-dependent inhibition of Cyp3a 
activity in zebrafish except isoniazid (Figure 6.2). The health of zebrafish was 
comparable between treated and solvent control group where no mortality was 
observed. The concentration-dependent trend for ketoconazole fitted well to the log 
(regression) vs. response model and yielded an IC50 value of 1.198 μM (R2 = 0.91, 
95% C.I.: 0.61 – 2.35) (Figure 6.3). Figure 6.4 shows the different extent of inhibition 
of Cyp3a activity by the test inhibitors dosed at 50 μM. Strongest inhibitory activity 
was observed for ketoconazole (>80% inhibition), moderate inhibition for 
fluvoxamine, erythromycin and verapamil (50 - 80% inhibition) and weak inhibition 








































































































































































Figure 6.2. Percentage remaining Cyp3a activity in 6 d.p.f. zebrafish against 
different concentrations of hCYP3A4 inhibitors. (A) ketoconazole, (B) 
erythromycin, (C) verapamil, (D) fluvoxamine, (E) cimetidine and (F) isoniazid. 
Unpaired t-test (2-sided) between treated and solvent control group, *p<0.05, 





























Figure 6.3. Inhibition curve of ketoconazole on the metabolism of Luciferin-IPA 

























































Figure 6.4. Percentage remaining Cyp3a activity in 6 d.p.f. zebrafish against 
each of the hCYP3A4 inhibitors dosed at 50 μM. Unpaired t-test (2-sided) between 






6.3.3. In vivo systemic absorption 
 
 The four inhibitors amenable to LC/MS/MS detection in our laboratory were 
detected in 5 d.p.f. zebrafish larval homogenate when treated at 100 µM for 1 hr. The 
drug concentration levels ranged from 5.50 to  192.53 ppm (Table 6.2). 
 
Table 6.2.  Concentrations of hCYP3A4 inhibitors detected in 5 d.p.f. zebrafish 









in zebrafish larvae 
(ppm ± SD), (n=3) 
Cimetidine 0.40 100 5.50 ± 0.60 
Erythromycin 3.06 100 30.57 ± 7.73 
Fluvoxamine 3.20 100 192.53 ± 18.31 
Verapamil 3.79 100 62.59 ± 4.60 
 
 Absorption kinetics of 10 µM fluvoxamine in 5 d.p.f. zebrafish larvae is 
shown in Figure 6.5. Time-dependent increase in absorption of fluvoxamine was 
observed with a maximum of 127 ppm at 24 hr. 



























Figure 6.5. Concentration of fluvoxamine determined in 5 d.p.f. zebrafish after 





 The effect of FDA-listed hCYP3A4 inhibitors (FDA) on Cyp3a activity in 
zebrafish was evaluated in this study using the high-throughput luminescence-based 
assay optimized in Chapter 4. The strength of inhibition in zebrafish was compared to 
that of human hepatocytes and liver microsomes, and recombinant hCYP3A4 from 
literature which also used Luciferin-IPA as their probe substrate (Table 6.3). The 
relative inhibitory potencies were comparable between zebrafish and human.   
 
Table 6.3. Comparison between the strength of inhibition in zebrafish, human 
(clinical classification by FDA), human hepatocytes and human liver 
microsomes.  









IC50 value in 
hepatocytes 
(μM) (Doshi 
and Li, 2011)  









et al., 2011) 
Ketoconazole Strong (IC50 = 1.198 μM)  Strong
1  0.025 ± 0.002 0.07 0.04 
Verapamil Moderate Moderate2 0.62 ± 0.06 115 3.45 
Erythromycin Moderate Moderate 2.6 ± 0.3 ‘modest inhibition’ 7.33 
Fluvoxamine Moderate Weak3 N/A 46.94 N/A 
Cimetidine  Weak Weak N/A N/A N/A 
Isoniazid Weak Weak N/A N/A N/A 
N/A, not available. *Classified based on definition described in Section 6.2.4. 1≥5-fold 
increase in AUC or >80% decrease in CL, 2≥2 but <5-fold increase in AUC or 50-80% 






 The weak inhibition profile which was similar to humans could be due to 
absorption, distribution, metabolism and excretion (ADME) confounders such as poor 
absorption, high clearance or high protein binding, or it could be due to 
pharmacodynamic reasons where the compounds themselves may have poorer 
binding affinity at the active site versus the substrate and therefore exhibited weak 
inhibition. Nevertheless, it was confirmed that erythromycin, cimetidine, fluvoxamine 
and verapamil was systemically absorbed into the zebrafish within one hour. These 
findings were important because apart from performing negative controls in the 
inhibition experiments, detection of the presence of the inhibitors within the zebrafish 
reaffirms that the observed inhibitory effects on Cyp3a activity were associated with 
these compounds biologically and not due to analytical variation or chance 
correlation. Similar to the absorption of hCYP3A4 inducers in Chapter 5, no direct 
correlation was seen between the amount absorbed and experimental Log P values or 
molecular weights of the compounds tested (Table 6.2). An attempt to correlate the 
absorption data with the extent of inhibition was not made as it would not be accurate 
to do so. This is because due to the fish size limitation, the current study could only 
quantify the total drug concentration, and not the unbound drug fraction, from whole 
larvae. This would not be representative of the systemic circulation or concentration 
at the organ of interest, which was the liver. 
 Interspecies differences in inhibition of CYP activities are much less reported 
compared to CYP induction. One possible reason is that in vitro systems such as 
recombinant CYP enzymes and human liver microsomes are typically employed for 
CYP inhibition studies and the inhibitory parameters obtained such as Ki are useful 
for predicting clinical relevance (Bjornsson et al., 2003). Nevertheless, differences 
between species have been observed such as in the case of ketoconazole which 
showed inhibition of diclofenac 4′-hydroxylase activity in mouse, rat and monkey, 
but not in human and dog (Bogaards et al., 2000). Bogaards et al. characterized nine 
CYPs in seven species and provided a good summary on the differences and 
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similarities in their inhibition profile. In the current study, the inhibition potencies of 
the six inhibitors tested in zebrafish were encouragingly similar to human. 
 zfCyp3a65 and hCYP3A4 are 54% homologous and previous in silico 
docking study established that the interactions of testosterone and acetaminophen to 
the active site of zfCyp3a65 were similar to that of hCYP3A4 (Chapter 3, Chng et al., 
2012). The good concordance between the inhibition profile of zebrafish and human 
data which also used Luciferin-IPA as the probe substrate suggests that the 
competition and interaction between the hCYP3A4 inhibitors and Luciferin-IPA at 
the active site of zfCyp3a65 and hCYP3A4 are likely similar. As a pre-incubation 
protocol was used, it could not be concluded if the inhibition was due to the parent 
compound or metabolite i.e. the mechanism of inhibition such as competitive, non-
competitive or TDI could not be discerned.  
 A pre-incubation protocol was necessary as the co-incubation of the 
inhibitors and hCYP3A4 yielded an unexpected increase in Cyp3a activity as 
observed with fluvoxamine (Figure 6.1). This was also observed with several other 
inhibitors like erythromycin and verapamil during preliminary experiments. The 
activation of Cyp3a activity could be due to the atypical kinetics of the metabolism of 
Luciferin-IPA as discussed in Chapter 4 where these hCYP3A4 inhibitors could have 
caused heterotropic or allosteric activation when co-incubated with Luciferin IPA. 
The other plausible reason as hypothesized in Chapter 4 is that Luciferin-IPA is a 
substrate of the P-gp transporter, and these CYP inhibitors (fluvoxamine, 
erythromycin and verapamil) which are also P-gp inhibitors in human, could have 
resulted in the inhibition of P-gp pumps at the gut absorption site, resulting in a 
higher Luciferin-IPA concentration in the system. The inhibitors could have a higher 
potency towards P-gp compared to CYP and hence, the net effect observed was an 
increase in Cyp3a activity. Using a pre-incubation design, the inhibitors would be 
absent at the intestinal lumen and hence P-gp inhibition at the gut absorption site 
would be circumvented. The overall net effect of a decrease in luminescence signal 
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i.e. Cyp3a activity observed would hence be due to CYP inhibition and not 
confounded by P-gp inhibition. Nevertheless, this remains hypothetical as the 
distribution of P-gp in zebrafish is unclear at this moment. As the aim of this study 
was to evaluate the use of zebrafish to assess inhibitory potential of test compounds, 
the pre-incubation condition which produced inhibition was selected and further 
investigation on the apparent activation of Cyp3a activity due to the co-incubation 
experimental design was not pursued. The 24 hr pre-incubation experimental design 
not only produced results which showed 100% selectivity but also the same strength 
of inhibition potency as that in human. Maximal absorption of the candidate 
compound fluvoxamine at 24 hr in the absorption kinetics experiment further 
confirmed the advantage of this incubation duration. 
 Although five out of six of the inhibitors showed concentration dependent 
inhibition trends, only IC50 for ketoconazole could be determined. Again, the atypical 
kinetics of the metabolism of Luciferin-IPA could have complicated the net inhibition 
observed thus yielding a trend that could not fit the usual inhibition model due to the 
dynamic inhibition and metabolism occurring at the active site of the enzyme. 
Bearing in mind that this assay involves a whole organism, other pharmacokinetic 
parameters such as absorption, distribution, and clearance play a concerted role in the 
final observed inhibition profile. Fixing the concentration at 50 µM enabled us to 
capture a profile similar to human which also suggested that the effects of the 
dynamic pharmacokinetic processes which could cause variability in inhibition 
profile among the six different inhibitors were all balanced and negated at this 
concentration. Nevertheless, this observation should be further validated with more 
inhibitors to confirm the most optimum concentration to evaluate future test 
compounds. Apart from that, the inhibition profile should also be elucidated using 
different substrate concentrations to avoid misinterpretation of data since metabolism 
of the substrate follows atypical kinetics (Houston and Kenworthy, 2000). In view of 
the difficulty in obtaining Ki or IC50 for all compounds, the current assay is more 
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suitable for further development as a hazard detection assay to rank order compounds 
during early candidate profiling rather than for applications for prediction of 
inhibition potency in human through in vivo-in vivo scaling. The need for a pre-
incubation step may also pose a limitation for throughputness. Nevertheless, despite 
the limitations of the assay, the current study served as a proof-of-cocept that the 
inhibitory potential of compounds can be assessed in a high-throughput manner via 
an in vivo system in which the interplay of all pharmacokinetic and 




 In conclusion, the effects of hCYP3A4 inhibitors on Cyp3a activity in 5 d.p.f. 
zebrafish were evaluated in this chapter and a good concordance in terms of 
inhibition potency between zebrafish and human was observed. The results uncovered 
a great potential of using the zebrafish model coupled to a luminescence-based Cyp3a 
assay as a high-throughput in vivo platform for assessing inhibitory potential of 
compounds. For future work, apart from validating the model with more inhibitors 
and using different substrate concentrations, in silico docking studies of the 
hCYP3A4 inhibitors and Luciferin IPA into the active site of zfCyp3a65 could be 
performed and compared with hCYP3A4 to further understand the results observed in 
vivo in this study. As enzyme inhibition is a dynamic process, the inhibition profile at 
different time points for all the compounds should also be evaluated to derive an 
optimum experimental procedure that can be applied for testing future compounds.   
125 
 
CHAPTER 7: EVALUATION OF HEPATOCYTE-LIKE CELLS DERIVED 
FROM STEM CELLS AS AN ALTERNATIVE IN VITRO MODEL FOR 
DRUG METABOLISM TESTING 
7.1. Introduction 
 
 Primary human hepatocytes (PHH) remain the gold standard in vitro model 
for drug metabolism testing as it possess the complete ensemble of drug metabolizing 
enzymes, co-factors as well as the cell machinery which is amenable to induction by 
drugs. PHH are however not routinely used for screening assays in early drug 
discovery due to their limited supply and donor-to-donor variability. Therefore, 
scientists are on the constant search for an alternative source of hepatocytes which 
could provide unlimited cells with a stable and reproducible metabolic profile 
comparable to PHH.  
 The recent advances in stem cell technology have spurred the growth of 
knowledge and success in generating hepatocyte-like cells (HLCs) from different 
stem cell sources. Apart from classical sources such as embryonic stem cells, rapid 
development in this research area in the past decade has produced HLCs derived from 
new sources which present with less ethical concerns or tumorigenicity, such as the 
induced pluripotent stem cells (iPS) (Song et al., 2009; Si-Tayeb et al., 2010) 
mesenchymal stem cells (MSCs) from umbilical cord tissue (Zhang et al., 2009; 
Cheong et al., 2013) or MSCs from adipose tissue (Banas et al., 2009). Many of these 
works evaluated the hepatocytic characteristics of the HLCs in terms of expression of 
liver marker genes or proteins such as alfa fetoprotein (AFP) or hepatocyte nuclear 
factor 4α (HNF4a), albumin and urea secretion, indocyanine green uptake and 
clearance, and glycogen storage. While most of these works also evaluated the 
xenobiotic metabolic activities of the HLCs, only a few drug metabolizing enzymes 
(DMEs) were tested without characterization on the other plethora of Phase II 
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enzymes or transporters involved in drug disposition. Moreover, most of the works 
only compared metabolic activities or gene expression of selected DMEs or 
transporters between undifferentiated and differentiated cells without comparing to 
the gold standard PHH or current immortalized cell line models used for metabolism 
testing. As such, the potential of using these HLCs for application in drug metabolism 
testing in drug discovery remains unclear.   
 Understanding the metabolic maturity of HLCs is also of clinical significance 
as they have been explored in the development of bioartificial liver device or liver 
transplant. Since bioartificial liver devices are designed for extracorporeal dialysis, 
maintenance of metabolic function including drug detoxification is critical to its 
success. HLCs used for liver transplant should have an optimal metabolic capacity as 
many immunosuppressant drugs such as mycophenolate or cyclosporine administered 
post-transplant are extensively metabolized by the liver via Phase I and Phase II 
metabolism to active or inactive metabolites. Hence, the metabolic capability of the 
HLCs may have implications on the efficacy or toxicity of these drugs, which may 
inadvertently affect the outcome of the transplant surgery.   
 Thus, the aim of this study was to evaluate the drug metabolism profile of 
HLC derived from two stem cell sources, the human fetal liver multipotent progenitor 
cells (hFLMPC) and human amniotic epithelial cells (hAEC), in comparison with 
PHH and two immortalized hepatoma cell lines commonly used for drug metabolism 
studies, HuH-7 and HepaRG. The expression of 24 genes comprising Phase I and II 
DMEs, transporter and transcription factor genes involved in drug disposition was 
assessed using quantitative real time-polymerase chain reaction (qRT-PCR). The 







7.2. Materials and methods 
 
7.2.1. Chemicals and reagents 
 
 Rifampicin, salicylamide and dexamethasone were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Testosterone was purchased from Merck (Darmstadt, 
Germany) whereas 6β-hydroxytestostrone was purchased from Cerilliant Corporation 
(Round Rock, TX, USA). Phosphate buffered saline (PBS) was purchased from 
Vivantis Technologies Sdn. Bhd (Selangor, Malaysia). HPLC-grade acetonitrile 
(ACN) and HPLC-grade methanol were purchased from Fisher Scientific 
(Leicestershire, UK) and Tedia Company Inc. (Fairfield, OH, USA), respectively. 
Formic acid 98/100% was purchased from AnalaR® VWH International Ltd (Poole, 
England). P450-Glo™ CYP3A4 Assay with Luciferin-IPA and CellTiter-Glo® were 
purchased from Promega (Promega Corporation. Madison, USA). Water was purified 
using a Milli-Q water purification system (Millipore, Bedford, MA, USA).  
 
7.2.2. Cell culture 
 
 The human hepatoma HuH-7 cell line purchased from Health Science 
Research Resources Bank, Tokyo, Japan, was routinely cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) (Hyclone, Thermo Fisher Scientific, MA, US), 100 IU/mL penicillin and 100 
µg/mL streptomycin. Differentiated HepaRG and cryopreserved Caucasian PHH 
purchased from Life Technologies (California, US) were thawed and maintained as 
per manufacturer's protocol using the recommended kits and media. hFLMPC and 
hAEC were obtained from the National University Hospital of Singapore and KK 
Women’s and Children’s Hospital in accordance to protocols approved by the 
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Institutional Review Board. hFLMPC was maintained on collagen-coated tissue 
culture plates in human fetal hepatocyte medium (HFHM), as described (Lázaro et 
al., 2003). hAEC was maintained in a slightly modified culture medium from 
hFLMPC in which William’s E base medium was substituted with DMEM, 
dexamethasone and nicotinamide were omitted, and ITS Premix was used instead of 
ITS+ Premix (BD Biosciences, CA, USA). Culture medium was changed twice a 
week for all cultures. 
 
7.2.3. In vitro differentiation of hFLMPC and hAEC to HLC 
 
 The hFLMPC cultures were treated with HFHM supplemented with 20 
ng/mL of oncostatin M for 7 days to direct differentiation (Dan et al., 2006). The 
protocol used to direct differentiation of hAEC to HLC was modified from Banas et 
al. (2009). For the first three days, cells were treated with HFHM supplemented with 
20 ng/mL Activin A and 20 ng/mL fibroblast growth factor (FGF)-4. Thereafter, cells 
were cultured for 10 days in HFHM supplemented with 150 ng/mL hepatocyte 
growth factor, 100 ng/mL FGF1, 25 ng/mL FGF4, 30 ng/mL Oncostatin M and 0.1% 










 RNA isolation was performed using the RNeasy Mini Kit as per 
manufacturer’s instructions (Qiagen Inc. Valencia, CA, USA) for all cell types. For 
the Asian liver tissue which was frozen upon collection and obtained in accordance to 
protocols approved by the Institutional Review Board, the liver tissue was 
homogenized using an ultrasonicator at amplitude of 20% for 10 sec prior to RNA 
isolation. This was repeated twice and performed on ice. 1 µg of RNA was used for 
cDNA synthesis using iScript cDNA Synthesis Kit followed by qRT-PCR performed 
on the Bio-Rad CFX96™ Real-Time Detection System (Bio-Rad Laboratories, CA, 
USA). 4 µL of 10-fold diluted cDNA template was added in a 20 µL reaction mixture 
containing 500 nM of forward and reverse primer each and 10 µL of SsoFast™ 
EvaGreen® Supermix (Bio-Rad, CA, USA). Thermal cycling consisted of an enzyme 
activation step for 30 sec at 95°C followed by 40 cycles of denaturation (5 sec at 
95°C) and annealing/extension (5 sec at 60°C). Dissociation curve analysis and gel 
electrophoresis were performed to verify the specificity of the amplification. The 






Table 7.1. Primer sequences of target and reference genes.  




Gene ID Length 
(bp) 





Cytochrome P450 1A2 
(CYP1A2) 
CYP1A2 NM_000761.3 456 AAC AAG GGA CAC AAC 
GCT GAA T 
GGA AGA GAA ACA AGG 
GCT GAG T 
Cytochrome P450 2C9 
(CYP2C9) 
CYP2C9 NM_000771.3 137 CCT CTG GGG CAT TAT 
CCA TC 
ATA TTT GCA CAG TGA AAC 
ATA GGA 
Cytochrome P450 2C19 
(CYP2C19) 
CYP2C19 NM_000769.1 168 AAC CAA GGC TTC ACC 
CTG TGA TCC 
TGG ATC CAG GGG GTG CTT 
ACA A 
Cytochrome P450 2D6 
(CYP2D6) 
CYP2D6 NM_000106.5 222 GGT GTG ACC CAT ATG 
ACA TC 
CTC CCC GAG GCA TGC ACG 
Cytochrome P450 2E1 
(CYP2E1) 
CYP2E1 NM_000773.3 580 ACA GAG ACC ACC AGC 
ACA ACT 
ATG AGC GGG GAA TGA CAC 
AGA 
Cytochrome P450 3A4 
(CYP3A4) 
CYP3A4 NM_017460.5 324 CCA AGC TAT GCT CTT 
CAC CG 
TCA GGC TCC ACT TAC GGT 
GC 
Cytochrome P450 3A5 
(CYP3A5) 
CYP3A5 NM_000777.3 239 TGA CCC AAA GTA CTG 
GAC AG 
TGA AGA AGT CCT TGC GTG 
TC 
Cytochrome P450 3A7 
(CYP3A7) 
CYP3A7 NM_000765.3 183 ATT ACG CTT TGG AGG 
ACT TCT TCT 











Albumin ALB NM_000477.5 199 GAG CTT TTT GAG CAG 
CTT GG 
GGT TCA GGA CCA CGG ATA 
GA 
Alpha-fetoprotein (AFP) AFP NM_001134.1 182 AGC TTG GTG GTG GAT 
GAA AC 
TCT GCA ATG ACA GCC TCA 
AG 
Hepatocyte nuclear factor 4, 
alpha (HNF4a) 
HNF4A NM_178849.2 371 CTG CTC GGA GCC ACC 
AAG AGA TCC ATG 
ATC ATC TGC CAG GTG ATG 











Gene ID Length 
(bp) 








SULT1A1 NM_001055.3 91 ACA ACC CTG CAT TCC 
CCA CAC A 




UGT1A1 NM_000463.2 129 GGC CTC TCT CCT CTC ATT 
CA 




UGT2B7 NM_001074.2 82 CTG GGG TCA ATG GTC 
AGT AA 




NAT1 NM_001160170.1 297 GGA TGC CAT GGA CTT 
AGG C 




NAT2 NM_000015.2 151 TTG GAA GCA AGA GGA 
TTG CAT 
GAT CTG GTG CTC AAG AAT 
GTC AGT 
Glutathione S-transferase 
alpha 1 (GSTA1) 
GSTA1 NM_145740.3 80 CAG CAA GTG CCA ATG 
GTT GA 
TAT TTG CTG GCA ATG TAG 
TTG AGA A 
Glutathione S-transferase mu 
1 (GSTM1) 
GSTM1 NM_000561.3 70 TGA GCC CAA GTG CTT 
GGA CGC 













Aryl hydrocarboon receptor 
(AhR) 
AHR NM_001621.4 101 ACA TCA CCT ACG CCA 
GTC GC 




NR1I3 NM_001077482.2 121 AGT GCT TAG ATG CTG 
GCA TGA GGA 
TGC TCC TTA CTC AGT TGC 
ACA GGT 
Pregnane X receptor (PXR) NR1I2 NM_003889.3 442 CAA GCG GAA GAA AAG 
TGA ACG 





Table 7.1 (continued). Primer sequences of target and reference genes.  
  Protein name (abbreviation) Gene 
symbol 
Gene ID Length 
(bp) 








Breast cancer resistance protein 
(BCRP) 
ABCG2 AF098951.2 243 TTA TCC GTG GTG TGT 
CTG GA 
TTC CTG AGG CCA ATA AGG 
TG 
Multidrug resistance-associated 
protein 2 (MRP2) 
ABCC2 NM_000392.3 78 TGA GCA AGT TTG AAA 
CGC ACA T 
AGC TCT TCT CCT GCC GTC 
TCT 
P-glycoprotein (P-gp) ABCB1 NM_000927.4 102 GCC AAA GCC AAA ATA 
TCA GC 
TTC CAA TGT GTT CGG CAT 
TA 
Bile salt export pump (BSEP) ABCB11 AF091582.1 132 CAT AGT CCA AGC TGC 
CAA GGA G 
CTG GCG ATA GCT ACC CTT 
TGT T 
Organic anion-transporting 
polypeptide 1B1 (OATP1B1) 
SLCO1B1 NM_006446.4 77 ACA GCA GAG GCA CAA 
CCT TCA GA 
GAC AGA GCT GCC AAG AAC 
ATC TTC A 
Organic anion-transporting 
polypeptide 1B3 (OATP1B3) 
SLCO1B3 NM_019844.2 168 GGG TGA ATG CCC AAG 
AGA TA 













GAPDH NM_002046.3 144 ATG TTC GTC ATG GGT 
GTG AA 
TGT GGT CAT GAG TCC TTC 
CA 
TATA box binding protein (TBP) TBP NM_003194.4 143 GAG AGT TCT GGG ATT 
GTA CCG 
ATC CTC ATG ATT ACC GCA 
GC 
18S ribosomal RNA (18S) 18S NR_003286.2 169 CGG CTT AAT TTG ACT 
CAA CAC G 
TTA GCA TGC CAG AGT CTC 
GTT C 
Beta-actin (B-actin) ACTB NM_001101.3 70 AGC ACA GAG CCT CGC 
CTT TGC C 
ATC ATC ATC CAT GGT GAG 
CTG GCG 
Ubiquitin C (UBC) UBC NM_021009.5 74 GCC TTA GAA CCC CAG 
TAT CAG 
AAG AAA ACC AGT GCC CTA 
GAG 
Succinate dehydrogenase 
complex, subunit A, flavoprotein 
(SDHA) 
SDHA NM_004168.2 85 TGG TTG TCT TTG GTC 
GGG 




7.2.4.2. Data normalization and analysis 
 
 Six reference genes were validated across four cell types and the best pair of 
stably expressed genes were selected based on the criteria for heterogeneous sample 
set at M<1.0 (Vandesompele et al., 2002), analyzed using CFX Manager 2.0 software 
(Bio-Rad Laboratories). To obtain the relative gene expression profile of the target 
genes, the fold change in mRNA expression level of each target gene was compared 
against the average ∆Cq value of three Caucasian PHH using the ∆∆Cq method. The 
geometric mean values of the Cq of GAPDH and TBP were used for normalization. 
The data was further analysed using statistical methods such as hierarchical clustering 
and correlation analysis. The resultant data is visualized in the form of heat maps and 
the correlation between the samples were computed using Spearman method. All 
statistical analyses were performed using commands and packages built in R (Team). 
Principal component analysis (PCA) and partial least square discriminant analysis 






7.2.5. High-throughput functional metabolism screening assay – CYP3A4 (P450-
Glo Luciferin-IPA)/CYP1A (EROD)/Viability (CellTiter-Glo®) triplex assay  
 
 P450-Glo Luciferin-IPA and CellTiter-Glo® were purchased from Promega 
(Madison, USA) while ethoxyresorufin (EROD) was purchased from AnaSpec (CA, 
USA). Cells were seeded on a collagen-coated 96-black-walled, clear bottom plate 
according to cell densities which were either optimized in-house or recommended by 
manufacturer as summarized in Table 7.2. The cells were cultured overnight in their 
respective maintenance medium in a cell culture incubator maintained at 37°C and 
5% CO2 before performing the triplex assay in the order of evaluation of CYP3A4 
activity using Luciferin-IPA substrate, evaluation of CYP1A activity using EROD 
and cell viability determination using CellTiter-Glo® reagent.  
 On day of experiment, previous culture medium was removed and replaced 
with 60 µL of 3 µM Luciferin-IPA dissolved in 0.1% DMSO in culture medium. The 
plate was incubated for 1 h in a 37°C/5% CO2 incubator. Thereafter, 50 µL each of 
the medium was transferred to a white opaque polystyrene plate containing 50 µL of 
Luminescence Detection Reagent (LDR) (Promega) in each well. The white plate was 
incubated for 20 min at room temperature (25±2°C) and luminescence was read using 
a Tecan Infinite M200 plate reader (Tecan, Switzerland). The remaining medium 
from the original plate was removed and cells rinsed with Krebs Heinseleit Buffer 
(KHB) containing 3 mM salicylamide. 100 µL of 2 µM EROD dissolved in 1% 
methanol in KHB containing 3 mM salicylamide was added to the cells and the plate 
was incubated for 40 min in a 37°C/5% CO2 incubator. Subsequently, fluorescence 
was read (Ex 550/Em 592) using the Tecan Infinite M200 plate reader. In the final 
assay, the medium was removed and cells were rinsed with KHB. 100 µL KHB was 
added to all wells and equilibrated at 37°C for approximately 30 min. 100 µL of 
CellTiter-Glo® Reagent was then added and mixed for 3 min on an orbital shaker to 
induce cell lysis. The plate was incubated at room temperature for 10 min and 
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luminescence was recorded. Control group without cells were performed in parallel. 
All groups were performed in six replicates. 
 The net luminescence and fluorescence signal due to CYP3A4 or CYP1A 
activity was calculated by subtracting the respective signal from control wells without 
cells from the signal generated from wells with cells. The net 
luminescence/fluorescence signal was then normalized against luminescence signal 
from the cell viability assay. 
 
Table 7.2. Cell seeding densities for the various cell types for CYP3A4 (P450-Glo 
Luciferin-IPA)/CYP1A (EROD)/Viability (CellTiter-Glo®) triplex assay. 
  Caucasian 
PHH 






62,500 100,000 62,500 62,500 62,500 
Seeding 
volume 
125 uL 125 uL 125 uL 125 uL 125 uL 
Seeding 
density 
0.5 x 106 
cells/mL 
0.8 x 106 
cells/mL 
0.5 x 106 
cells/mL 
0.5 x 106 
cells/mL 




 CHRM1   GPWM1  DMEM + 
10% FBS 
-  - 
Seeding 
medium 
PM1 GPWM DMEM + 
10% FBS 
 -  - 
Experimental 
medium 
MM1 MWM1 Plain 
DMEM 
HFHM HFHM 
CHRM: Cryopreserved hepatocyte recovery medium, PM: Plating medium, MM: 
Maintenance medium, GPWM: General purpose working medium, MWM: 
Metabolism working medium, DMEM: Dulbecco’s modified Eagle’s medium, FBS: 
fetal bovine serum, HFHM: human fetal hepatocyte medium. 1Purchased and 





7.2.6. Induction of CYP3A4 
 
 Cells were seeded on a collagen-coated clear 96-well plate according to cell 
densities which were either optimized in-house or recommended by manufacturer as 
summarized in Table 7.3.  After culturing overnight, the medium was changed to 
fresh culture medium containing 10 or 50 µM rifampicin, 3.3 or 6.7 µM 
dexamethasone, or solvent control 0.1% v/v DMSO (125 µL/well). Inducer medium 
was refreshed at 24 hr. At 48 hr, inducer and solvent control medium was removed 
and cells were rinsed with 100 µL warm PBS followed by incubation with 60 µL of 
culture medium containing 3 µM Luciferin-IPA. Control without cells was also 
performed for background luminescence correction. At 2 hr, 50 µL of the medium 
was transferred to a white opaque polystyrene plate containing 50 µL LDR  in each 
well. The white plate was incubated for 20 min at room temperature (25±2°C) and 
luminescence was read using a Tecan Infinite M200 plate reader. To the original plate 
seeded with cells, 90 µL culture medium was added to each well to make up to 100 
µL total medium volume. 100 µL of CellTiter-Glo® Reagent was then added and 
mixed for 3 min on an orbital shaker to induce cell lysis. The plate was incubated at 
room temperature for 10 min and luminescence was recorded. The net luminescence 
due to CYP3A4 activity was calculated by subtracting the signal from control wells 
without cells from the signal generated from wells with cells. The net luminescence 
was then normalized against luminescence signal from the cell viability assay. Fold 
induction of CYP3A4 activity was determined by dividing normalized net 
luminescence of treated groups with that of solvent control. Experiment was 
performed in six replicates. 




Table 7.3. Cell seeding densities for the various cell types for CYP3A4 induction 
assay. 
  Caucasian 
PHH 




62,500 100,000 25,000 62,500 
Seeding 
volume 
125 uL 125 uL 125 uL 125 uL 
Seeding 
density 
0.5 x 106 
cells/mL 
0.8 x 106 
cells/mL 
0.2 x 106 
cells/mL 














MM1 IWM1 DMEM + 
10% FBS 
HFHM 
CHRM: Cryopreserved hepatocyte recovery medium, PM: Plating medium, MM: 
Maintenance medium, GPWM: General purpose working medium, IWM: Induction 
working medium, DMEM: Dulbecco’s modified Eagle’s medium, FBS: fetal bovine 
serum, HFHM: human fetal hepatocyte medium. 1Purchased and prepared according 









7.2.7. Testosterone metabolism  
 
7.2.7.1. Treatment of cells 
  
 Cells were seeded on a collagen-coated clear 24-well plate according to cell 
densities which were either optimized in-house or recommended by manufacturer as 
summarized in Table 7.4. After culturing overnight, the medium was changed to fresh 
culture medium containing 250 µM testosterone or solvent control of 0.5% MeOH 
(500 µL/well). At 4 hr, 450 µL of the medium was withdrawn and transferred to a 
new microfuge tube. 450 µL of ice-cold ACN was added and the mixture was 
centrifuged at 15,000 g for 15 min. 850 µL of the supernatant was withdrawn and 
stored at -80°C until sample analyses.   
 
Table 7.4. Cell seeding densities for HepaRG and HLC (hFLMPC) for 
testosterone metabolism assay. 
  HepaRG HLC (hFLMPC) 
No. of cells/well 600,000 350,000 
Seeding volume 500 uL 500 uL 
Seeding density 1.2 x 106 cells/mL 0.7 x 106 cells/mL 
Thawing medium GPWM1 - 
Seeding medium GPWM - 
Experimental medium MWM1 HFHM 
GPWM: General purpose working medium, MWM: Metabolism working medium, 
HFHM: human fetal hepatocyte medium. 1Purchased and prepared according to 





7.2.7.2. Sample preparation and liquid chromatography tandem mass 
spectrometry (LC/MS/MS) analysis  
  
 A volume of 150 µL of 0.5 µM prednisolone in ACN (IS) was added to 150 
µL of the thawed sample and centrifuged at 14,000 g for 10 min. 280 µL of the 
supernatant was evaporated to dryness at 37°C for 1 h under a gentle flow of nitrogen 
gas using the Turbovap LV (Caliper Life Science, Hopkinton, MA, USA) and 
reconstituted with 310 µL of 15% methanol in water. The reconstituted samples were 
subjected to solid phase extraction (SPE) using the Strata-X C18 polymeric reverse 
phase sorbent (Phenomenex, Torrance, CA, USA). SPE conditions were as follows: 
conditioning with 0.3 mL methanol, equilibration with 0.3 mL water, loading of 300 
µL of the sample, washing with 0.3 mL 15% methanol and elution with 0.3 mL ACN. 
280 µL of the eluate was dried under a gentle flow of nitrogen gas for 1 h. Each 
sample was reconstituted with 28 µL of 30% ACN in water, vortexed and 2 µL of the 







7.3.1. Reference gene optimization  
 
 The most stably expressed pair of reference genes were first evaluated and 
optimized using the 11 available samples from four cell types at the start of this 
project, namely Caucasian PHH (n=3), Asian liver cells (n=2), HuH-7 (n=3) and 
HLC (hFLMPC) (n=3). Six reference genes (GAPDH, TBP, SDHA, ACTB, UBC and 
18S) were evaluated in all 11 samples and pairwise comparisons were made within 
each cell type and across all four cell types. The most stably expressed genes were 
chosen based on the following criteria: homogeneous sample: M<0.5, heterogeneous 
sample: M<1.0 (Vandesompele et al., 2002). GAPDH and TBP satisfied the criteria 
and the geometric mean of the Cq values from these two genes were used for 
normalization in subsequent gene expression studies. Table 7.5 shows the M-value 
and coefficient of variation for GAPDH and TBP in each cell type and across all 11 
samples in a gene study. 
 
Table 7.5. Pairwise comparison of GAPDH and TBP [M-values and coefficient of 
variation (CV)] in each cell type and combined gene study of all 11 samples.  
 
 GAPDH TBP 
M-value  CV M-value  CV 
HLC (hFLMPC) 0.5326 0.1798 0.5326 0.1877 
Caucasian PHH 0.5372 0.1768 0.5372 0.1936 
Asian liver cells  0.0107 0.0037 0.0107 0.0037 
HuH-7 0.0342 0.0118 0.0342 0.0118 





7.3.2. Characterization of the drug disposition transcript profile of HLC derived 
from hFLMPC and hAEC 
 
 The relative gene expression (2-∆∆Cq) analysis of the 24 DME, transporter and 
transcription factor genes and three liver marker genes of each individual sample 
from HLC derived from hFLMPC and hAEC, Asian liver, HuH-7 and HepaRG cells 
compared against the average Cq from the three Caucasian PHH samples are shown in 
Table 7.6. An expression of 0.1-1-fold, comparable to Asian liver cells, Caucasian 
PHH and HepaRG, was observed for more than half of the genes evaluated in HLC 
(hFLMPC), many of which belonged to the Phase II DME or drug transporter genes. 







Table 7.6. Relative gene expression (2-∆∆Cq) analysis of the 24 target genes and three liver marker genes in the individual HLC (hFLMPC) and HLC 
(hAEC), Asian liver cells, HuH-7 and HepaRG samples. The expression of each gene is normalized against the geometric mean of GAPDH and TBP in 
each sample, and fold change compared against the average Cq from 3 Caucasian PHH samples. ND: not detected.   
 
  Hepatocyte-like cells derived from Asian liver cells Hepatocarcinoma cells 
  hFLMPC hAEC HuH-7 HepaRG 












CYP1A2                 CYP2C19                 
CYP2C9                 CYP2D6                 
CYP2E1                 CYP3A4                 
CYP3A5                 CYP3A7                 
Phase II 
SULT1A1                 
UGT1A1                 
UGT2B7                 
GSTA1                 NAT1                 
NAT2                 GSTM1                 
Phase III 
(Transporters) 
BCRP                 BSEP                 
MRP2                 OATP1B1                 
OATP1B3                 P-gp                 
Transcription 
factors 
AhR                 CAR                 
PXR                 
Liver markers 
AFP                 Albumin                 
HNF4a                  
ND <0.0001 0.0001-0.001 0.001-0.1 0.01-0.1 0.1-1 1-10 10-100 100-1000 >1000 
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 Hierarchical clustering showed clear separation between two big clusters of 
samples: one cluster consisting of the adult Caucasian PHH, Asian liver cells, and 
HepaRG, and the other cluster comprising HLC (hFLMPC), HLC (hAEC) and HuH-7 
(Figure 7.1). Each cell type clustered tightly within biological replicates except HLC 
(hFLMPC) which had one deviation. 
 
Figure 7.1. Hierarchical clustering analysis of gene expression for the 19 samples 
from six cell types . The clustering was based on the normalized ΔCq values of 
the selected 24 DME, transporter and transcription factor genes. Yellow denotes 
genes which were not detected. Sample coding: HLC-: HLC derived from hFLMPC, 





 The PCA revealed a distinct clustering of each cell type that was 
characteristic due to their unique gene expression profile (Figure 7.2). PLS-DA 
further revealed the following genes which contributed to class differentiation (Table 
7.7 and Figure 7.3). HLC (hFLMPC) was differentiated from HLC (hAEC) by 
ABCG2 (BCRP), CYP2D6, AHR, CYP3A5 and ABCC2 (MRP2) (VIP>1.10). 
 
Table 7.7. Genes contributing to class differentiation determined through partial 
least square discriminant analysis (VIP>1.20). Note: Abbreviated protein names 
are used in this table. 
 HLC (hFLMPC) HLC (hAEC) 
Caucasian PHH  CAR, CYP3A5, BCRP, 
NAT2 
CYP3A7, CYP3A5, CAR, 
UGT2B7, CYP2D6, AhR, 
MRP2 




CYP3A5, MRP2, CAR 
HepaRG PXR, GSTM1, SULT1A1, 
BCRP 
GSTM1, UGT1A1, 
SULT1A1, AhR, MRP2 










Figure 7.2. PCA scores plot of gene expression profiles generated from the 19 samples from six cell types. For the 24 DME, transporter and 















       
  
       
                            












       
Figure 7.3. Variable importance plots from PLS-DA between Caucasian PHH and (A) HLC (hFLMPC) and (B)HLC (hAEC), Asian liver cells and 





















































































































       
 
























































































































       
 


















































































































       
 

























































































































    
 







Figure 7.3 (continued). Variable importance plots from PLS-DA between HepaRG and (E) HLC (hFLMPC) and (F)HLC (hAEC), HuH-7 and (G) 
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 Finally, Spearman's correlation analysis showed that HLC (hFLMPC) 
correlated well with HuH-7, followed by Asian liver cells, HepaRG and Caucasian 
PHH, then HLC (hAEC), with the ranges of rs values as follows (Table 7.8): 
  
HLC (hFLMPC)/HuH-7: 0.46 – 0.60 
HLC (hFLMPC)/Asian liver cells: 0.29 – 0.69 
HLC (hFLMPC)/HepaRG: 0.19 – 0.60  
HLC (hFLMPC)/Caucasian PHH: 0.25 – 0.59  







Table 7.8. Spearman correlation matrix of the six different cell types. The correlation matrix was calculated based on the normalized ΔCq values of the 24 
DME, transporter and transcription factor genes. The numbers represent the pairwise Spearman's correlation coefficient, rs value. Undetected genes were 
assigned as '0' in the algorithm.  
 HLC from hFLMPC HLC from hAEC Caucasian PHH Asian liver HuH-7 HepaRG 
 HLC1 HLC2 HLC3 AEC1 AEC2 AEC3 Hu1008 Hu4224 Hu4169 AL1 AL2 AL3 AL4 HuH-7 P7 HuH-7 P8 HuH-7 P9 HepaRG1 HepaRG2 HepaRG3 
HLC1 1 0.6861 0.7000 0.0550 -0.1697 -0.0061 0.2713 0.3122 0.3652 0.4530 0.2870 0.3130 0.5017 0.4774 0.4670 0.5052 0.1930 0.2417 0.2643 
HLC2 
 
1 0.9035 0.1022 -0.4037 0.1266 0.2452 0.4374 0.5896 0.5174 0.4861 0.5539 0.6904 0.5974 0.5670 0.5809 0.4757 0.5635 0.5948 
HLC3 
 
1 0.0585 -0.4484 0.0681 0.2652 0.5043 0.5487 0.4757 0.5357 0.6000 0.6739 0.5704 0.5383 0.5974 0.4843 0.5670 0.5713 
AEC1 
 
1 -0.0413 -0.0395 -0.2114 -0.2419 -0.1162 -0.0681 -0.1188 -0.2655 -0.1939 0.2900 0.3179 0.2987 0.0323 -0.0664 -0.0410 
AEC2 
 
1 0.2916 -0.0250 -0.1384 -0.5252 -0.2492 -0.1518 -0.3591 -0.5645 -0.4859 -0.4716 -0.4743 -0.5082 -0.4600 -0.4457 
AEC3  1 0.0838 0.0419 -0.1135 0.0961 0.2804 0.0419 -0.0629 0.1109 0.1144 0.1223 -0.0017 -0.0122 0.0175 
Hu1008 
 
1 0.8791 0.5626 0.6809 0.7417 0.7104 0.5374 -0.2035 -0.2017 -0.1617 0.3670 0.5026 0.5078 
Hu4224 
 
1 0.6009 0.6287 0.8261 0.8539 0.5913 -0.1078 -0.1374 -0.0774 0.4365 0.5922 0.5904 
Hu4169 
 
1 0.7991 0.6148 0.7861 0.9417 0.3383 0.3174 0.3061 0.6217 0.6513 0.6452 
AL1 
 
1 0.8113 0.8026 0.8061 0.1800 0.1713 0.1878 0.4261 0.4739 0.4730 
AL2 
 
1 0.8722 0.6000 -0.0217 -0.0496 0.0113 0.3513 0.5096 0.5035 
AL3 
 
1 0.8052 0.1278 0.0957 0.1391 0.5965 0.7209 0.7043 
AL4 
 
1 0.4096 0.3843 0.3957 0.6226 0.6800 0.6809 
HuH-7 P7 
 
1 0.9870 0.9870 0.4887 0.3452 0.3583 
HuH-7 P8 
 
1 0.9678 0.4913 0.3200 0.3322 
HuH-7 P9  1 0.4687 0.3443 0.3539 
HepaRG1 
 




HepaRG3  1 
 
<0 0-0.25 0.25-0.50 0.50-0.75 0.75-0.99 1 
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7.3.3. High-throughput functional metabolism screening assay – CYP3A4 (P450-
Glo Luciferin-IPA)/CYP1A (EROD)/Viability (CellTiter-Glo®) triplex assay  
 
 HLC (hFLMPC) possess much lower CYP3A4 activity as compared to 
Caucasian PHH (Hu1008) and HepaRG but slightly better activity than HuH-7, albeit 
not statistically significant (Figure 7.4A). Contrary to the gene expression results, the 
CYP1A activity of HuH-7 was higher than PHH and HepaRG but the differences 
between all groups were not statistically significant except when compared to HLC 
(hAEC) which did not possess any CYP1A activity (Figure 7.4B). No functional 














































































Figure 7.4. (A) CYP3A4 and (B) CYP1A activity corrected against cell viability 
of HLC derived from hFLMPC and hAEC compared to Caucasian PHH 
(Hu1008), HepaRG and HuH-7. One-way ANOVA followed by Tukey's multiple 




7.3.4. Induction of CYP3A4 
 
 In the rifampicin-treated experiment, HLC (hFLMPC) was induced to a 
similar extent as HuH-7 (1.5-fold change) with the effects of a higher concentration 
of inducer being more pronounced in the HLC, albeit not statistically significantly 
different from HuH-7 (Figure 7.5). On the other hand, PHH (Hu4224) and HepaRG 
cells were highly induced with 15- and 20-fold change in CYP3A4 activity, 
respectively. In the dexamethasone-treated experiment, HuH-7, HepaRG and PHH 
were induced similarly with minimal increase when concentration of dexamethasone 
was doubled. CYP3A4 activity in HLC (hFLMPC) was greatly increased by the 
increase in concentration of dexamethasone and the fold induction between HLC 
(hFLMPC) and all 3 other cell types were statisticaly significantly different. 
Nevertheless, the large variability was to be noted. Due to unavailability of cells, the 













































































Figure 7.5. Fold change induction of CYP3A4 activity determined using 
Luciferin-IPA as a probe substrate compared against solvent control in HLC 
derived from hFLMPC compared to Caucasian PHH (Hu4224), HepaRG and 
HuH-7 treated with (A) rifampicin and (B) dexamethasone for 48 h. *p<0.05, 
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7.4.5. Testosterone metabolism 
 
 6β-hydroxytestosterone, the marker metabolite for CYP3A4 metabolic 
activity was not detected in the HLC (hFLMPC) sample as peaks observed in the 
chromatogram were background artefacts also seen in the control arm without cells 
(Figure 7.6). The marker metabolite was detected in HepaRG samples at 1.363 min 
(confirmed with standard), indicating CYP3A4 metabolic activity (Figure 7.7). 




Figure 7.6. Extracted ion chromatograms of hydroxytestosterone (m/z 305.2) in 
the 4h medium withdrawn from (A) plain 250 µM testosterone and (B) HLC 
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Figure 7.7.  Extracted ion chromatograms of hydroxytestosterone (m/z 305.2) in 
the 4h medium withdrawn from (A) plain 250 µM testosterone and (B) HepaRG 










 The potential of HLC derived from stem cells as an alternative in vitro model 
for drug metabolism testing was evaluated in this study. Two different sources of 
stem cells were evaluated, one of which was from committed liver progenitor cells, 
the hFLMPC (Haruna et al., 1996; Dan et al., 2006) isolated from the liver of aborted 
fetuses of 17-22 gestational week old, while the other, from a newer source of stem 
cell with less ethical concerns, hAEC (Miki et al., 2005; Miki, 2011). The HLC 
(hFLMPC) were differentiated using a previously published protocol (Dan et al., 
2006) while HLC (hAEC) was differentiated using a modified protocol used to 
differentiate adipose-derived stem cells (Banas et al., 2009). Both the HLC 
(hFLMPC) and HLC (hAEC) possess hepatocytic functions such as secretion of 
albumin, production of AFP and storage of glycogen (Dan et al., 2006; Lin et al., 
2011).  Nevertheless, the xenobiotic metabolism characteristics of these HLCs were 
not investigated in detail in the previous studies and hence, the current study set out 
to characterize the drug disposition transcript expression profile and functional 
CYP3A4 activity and inducibility of these HLCs.  
 In the drug disposition transcript profiling experiment, the expression profile 
of HLCs was compared to two adult PHH, one of which was the commercially 
obtained cryopreserved PHH from Caucasian female donors with an age range 
between 39-45 years old, while the other was liver tissue from Asian male donors 
between 20-30 years old. The Asian liver tissue samples were previously frozen, and 
for this study, thawed and homogenized as a whole before total RNA isolation, and as 
such, was termed 'Asian liver cells' in as it consisted of a mixture of parenchymal and 
non-parenchymal cells. This, however, does not affect the results as the expression of 
target genes were normalized against the pair of most stably expressed reference 
genes across all cell types. The HLCs were also compared to two hepatoma cell lines 
which have been found to be most suitable for use in drug metabolism testing, the 
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HuH-7 and HepaRG. In a study comparing four commonly used hepatoma cell lines 
and one transfected human liver epithelial cell line with PHH, the expression of DME 
genes in HuH-7 was found to correlate best with the pooled PHH in the Pearson's 
correlation analysis (Guo et al., 2011). In yet another study comparing the Phase I and 
II enzyme activities in five hepatic cell lines and PHH, the metabolic profile of HuH-
7 was also most comparable to PHH (Lin et al., 2012). More recently, the HepaRG 
cell line has been established, undergone thorough characterizations and been shown 
to possess comparable metabolic profiles to PHH (Aninat et al., 2006; Turpeinen et 
al., 2009; Lubberstedt et al., 2011; Andersson et al., 2012).  
 The 24 DME, transporter and transcription factor genes evaluated were 
clinically relevant genes which contribute significantly to metabolism of clinically 
administered drugs, or have been found to play a role in drug-drug interactions. A 
summary of the justification of the choice of genes studied is provided in the 





Table 7.9. Justification of the selection of drug disposition-related genes characterized in this study.  
Protein Remarks 
Phase I enzymes: Cytochrome P450s (CYP) 
CYP1A2 Represents approximately 15% of the total CYPs in the liver. Many carcinogens such as aromatic or heterocyclic amines and 
polycyclic hydrocarbons are substrates of CYP1A2. (Guengerich, 2005; Montellano, 2009). 
CYP2C9 Represents approximately 20% of the total CYPs in the liver (Guengerich, 2005). CYP2C9 is involved in metabolism of many 
clinical drugs including diclofenac, phenytoin, tolbutamide, ibuprofen and S-warfarin (Henne et al., 2009). Polymorphism of this 
gene affects patient response to warfarin (Jorgensen et al., 2012). 
CYP2C19 Represents approximately 5% of the total CYPs in the liver (Guengerich, 2005). CYP2C19 is responsible for the metabolism of a 
large number of clinically relevant drugs, including the anticonvulsant phenytoin, anti-ulcer drugs such as omeprazole, certain 
antidepressants, and the antimalarial drug proguanil. Patients can be categorized as extensive or poor metabolizer and the occurrence 
of this is different across ethnics. Polymorphism within the class of metabolizers also exists (Desta et al., 2002). 
CYP2D6 Represents approximately 5% of the total CYPs in the liver but responsible for metabolism of ~25% therapeutic drugs (Guengerich, 
2005; Montellano, 2009). Although this gene is not inducible, drug-drug interactions occur due to polymorphisms which has large 
interethnic differences (Teh and Bertilsson, 2012). The polymorphism impacts the dosing of tamoxifen, an anticancer drug used in 
breast cancer (Walko and McLeod, 2012).  
CYP2E1 Represents approximately 10% of the total CYPs in the liver (Guengerich, 2005; Montellano, 2009). CYP2E1 is responsible for the 
metabolism of smaller weight molecules including ethanol. Hepatotoxicity due to acetaminophen overdose has been attributed to 
generation of the reactive metabolite, N-acetyl-p-benzoquinone imine, by CYP2E1 (Raucy et al., 1989; Manyike et al., 2000). 
CYP3A4 This is the most abundant CYP isoform, representing approximately 30% of the total CYPs in the liver. More importantly, it is 
responsible for the metabolism of approximately 50% of the therapeutic drugs in the market (Guengerich, 2005; Montellano, 2009). 
Drug-drug, drug-food and drug-herb interactions due to enzyme inhibition or induction is common with this enzyme. Its expression 
in the fetal liver is very low and increases rapidly after birth, reaching 50% adult levels between 6-12 months of age.  
CYP3A5 Although it is generally accepted that CYP3A5, which shares 85% sequence identity with CYP3A4, is less important than CYP3A4, 
it is of clinical relevance due to its polymorphism which has large interethnic differences e.g. only 25% of Caucasians express 
CYP3A5, and if present, is usually less than CYP3A4 (Guengerich, 2005). This polymorphism plays a role in affecting the 
pharmacokinetics of tacrolimus and success rates of transplants (Op den Buijsch et al., 2007; Staatz et al., 2010; Ro et al., 2012). It 
also affects the efficacy and safety of statins (Willrich et al., 2009). Contrary to CYP3A4, CYP3A5 is expressed in fetal liver.  
CYP3A7 This is the major CYP3A isoform in fetal liver which decreases rapidly during the first week of life. It has similar catalytic activity 
to CYP3A4 and 3A5 and makes a major contribution to drug metabolism in the fetus. Therefore, considerations regarding drug 





Table 7.9 (continued). Justification of the selection of drug disposition-related genes characterized in this study.  
Protein Remarks 
Phase II Enzymes: Sulfotransferase (SULT) 
SULT1A1 Sulfotransferase enzymes catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds 
which include acetaminophen. SULT1A1 is the major form of SULT in the liver (Hempel et al., 2007). 
Phase II Enzymes: UDP-glucuronosyltransferase (UGT) 
UGT1A1 The UGTs conjugate approximately 40-70% of all clinical drugs (Wells et al., 2004; Jancova et al., 2010). UGT1A1 is the principal 
isoform responsible for glucuronidation of bilirubin. It also conjugates a wide selection of drugs including acetaminophen (Kiang et 
al., 2005). UGT1A1*28 has been associated with irinotecan toxicity (Ando et al., 1998) and also azatanavir-induced 
hyperbilirubinemia (Culley et al., 2013).  
UGT2B7 Involved in the conjugation of a wide array of drugs including opioids and NSAIDs such as morphine, codeine, diclofenac and 
ibuprofen. Although the magnitude of UGT-based drug interaction is less than CYP-based interactions (Williams et al., 2004), the 
clinical relevance of UGT-based interactions cannot be ignored as some drug-drug interactions have been observed in clinical trials 
(Kiang et al., 2005; Remmel and Zhu, 2009). 
Phase II Enzymes: N-Acetyltransferase (NAT) 
NAT1 Involved in the metabolism of p-aminobenzoic acid, p-aminosalicylic acid and p-aminobenzylglutamate (Jancova et al., 2010). 
There is genetic polymorphism with large interethnic variability with the NAT1 gene (Walker et al., 2009).  
NAT2 Involved in the detoxification of drugs such as isoniazid, hydralazine and sulphonamides (Jancova et al., 2010). Polymorphisms in 
NAT2 (rapid, intermediate and slow acetylator phenotypes) are associated with drug-induced liver injuries (Makarova, 2008). 
Population distribution of NAT2 polymorphism is largely varied (Walker et al., 2009). 
Phase II Enzymes: Glutathione S-transferase (GST) 
GST A1 GSTs detoxify reactive electrophiles by catalyzing their reactions with glutathione, thereby reducing the likelihood of deleterious 
interactions between such reactive species and essential cellular components, especially proteins and nucleic acids. Exogenous 
substrates include drugs, industrial intermediates, pesticides, herbicides, environmental pollutants, and carcinogens. They detoxify 
many cancer chemotherapeutic agents such as adriamycin, busulfan, carmustine, chlorambucil, cis-platin, cyclophosphamide, 






Table 7.9 (continued). Justification of the selection of drug disposition-related genes characterized in this study.  
Protein Remarks 
Transcription factors 
CAR Xenobiotic sensor involved in rapid-response regulation of a variety of DMEs and transporters such as CYP1A1, CYP1A2 and 
OATP1B3. Also regulates many overlapping genes with PXR such as CYP2B6, 2C9, 2C19, 3A4, 3A5, UGT1A1, GSTM1, MDR1 
and MRP2 (Wang et al., 2012).  
AhR CYP1A1, 1B1, 1A2 and 2S1 are regulated by the AhR (Ramadoss et al., 2005). Environmental contaminants, such as the 
halogenated aromatic hydrocarbons and nonhalogenated polycyclic aromatic hydrocarbons, represent the most extensively 
characterized classes of AhR ligands (Denison and Nagy, 2003). 
PXR PXR regulates many overlapping genes with CAR such as CYP3B6, 2C9, 2C19, 3A4, 3A5, UGT1A1, GSTM1, MDR1 and MRP2 
apart from other unique genes such as CYP7A1, UGT1A6 and OATP1A2 (Wang et al., 2012). It is activated by a large number of 
endogenous and exogenous chemicals including steroids, antibiotics, antimycotics, bile acids, and the herbal antidepressant St. 
John’s wort (Kliewer et al., 2002). 
Transporters 
OATP1B1  Both OATP1B1 and OATP1B3 are primarily expressed in the liver (Giacomini et al., 2010). OATPs facilitate the sodium- 
independent transmembrane transport of various endo- and xenobiotics (bile acids, bilirubin, steroid hormone conjugates, thyroid 
hormones, prostaglandins, clinically used drugs, and toxins (Svoboda et al., 2011). Many drugs are substrates or inhibitors of 
OATPs, and hence causing plausible drug-drug interactions (Clarke and Cherrington, 2012). Clinical interactions of cyclosporin A 
affecting disposition of pravastatin in transplant patients due to inhibition of OATP1B1 have been observed (Regazzi et al., 1993).  
OATP1B3 
BCRP BCRP actively extrudes endogenous and exogenous substrates across membranes. Clinical studies have demonstrated that subjects 
with reduced BCRP expression levels correlating with the Q141K variant are at increased risk of gefitinib-induced diarrhoea, and 
altered pharmacokinetics of several other drugs including irinotecan and rosuvastatin (Giacomini et al., 2010).  
MRP2 MRP2 is an efflux transporter of a diverse range of substrates including glutathione, glucuronide, and sulfate conjugates of many 
endo- and xenobiotics. It transports cancer chemotherapeutics, uricosurics, antibiotics, leukotrienes, toxins, and heavy metals (Gerk 
and Vore, 2002). It has clinically relevant genetic polymorphisms and plays a role in drug-drug interactions (Endres et al., 2006). 
P-gp P-gp is an efflux pump belonging to the ATP-binding cassette transporter super-family. The striking feature of this pump is that it 
has a broad substrate specificity which includes drugs from diverse therapeutic categories and hence is very susceptible to drug-drug 
interaction issues if the pump is inhibited or induced (Endres et al., 2006). Clinical interactions have been observed with various co-
administered drugs such as digoxin with quinidine, verapamil and erythromycin, among many others (Marchetti et al., 2007).   
BSEP Important for the biliary excretion of bile acids. BSEP is susceptible to inhibition by drugs. Known adverse reaction have been 





 The various analyses of the qRT-PCR data enabled different visualization of 
the complex data and revealed subtly different findings. The relative gene expression 
analyses provided detailed expression range for each of the 27 genes analyzed in each 
sample, benchmarked against Caucasian PHH, and is good for scrutinizing and 
comparing expression of individual genes between samples (Table 7.6). Based on this 
analysis, HLC (hFLMPC) expressed a fair number of drug disposition-related genes 
but the overall gene expression profile was poorer than HepaRG but better than HuH-
7, which expressed low levels for most genes except BCRP, P-gp, GSTM1 and AhR, 
possibly attributed to its cancerous origin. The expression of most of the CYP genes 
in HLC (hFLMPCs) was in the range of 0.001 - 0.1 compared to adult Caucasian 
PHH but it was encouraging to note that it expressed comparable levels (0.1 - 1.0) for 
the majority of Phase II and transporter genes. The hierarchical clustering analysis 
allowed one to discern which cell types were more similar to the other. In this 
analysis, it was seen that HepaRG clustered with the primary hepatocytes while HLC 
(hFLMPC) clustered with the HuH-7 and HLC (hAEC). Spearman's correlation 
analysis, reduced the rich information to a correlation coefficient, rs. This data output 
provided a quantitative comparison to appreciate the correlation between samples. 
The PCA scores plot condensed the information of each sample to a single data point 
and allowed visualization of clustering patterns on a two-dimensional graph. The 
relative distances between data points added another perspective for data 
interpretation, an aspect which cannot be derived from the dendogram in the 
hierarchical clustering analysis. In the PCA scores plot, HLC (hFLMPC) clustered 
nearer HuH-7, followed by HepaRG and Asian liver cells.  
 Although HLC (hAEC) produces albumin and AFP (Lin et al., 2011), when 
compared to adult PHH, the expression levels of the genes were low, indicating that it 
is not differentiated to the extent of a mature adult hepatocyte, and hence, possibly 
accounting for the poor expression of the DME genes as well. On the other hand, 
HLC (hFLMPC) expressed ALB and HNF4A genes in levels comparable to fully 
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differentiated hepatocytes. However, the high expression of the AFP gene and 
relative distribution of CYP3A genes i.e. high CYP3A7 and low CYP3A4, indicated 
that its fetal characteristics were still present. This suggests that there is still room for 
improvement in terms of differentiation to a more mature state, which could possibly 
improve the expression profile of the drug disposition transcripts as well. It should be 
noted that the HLC (hFLMPC) expressed CYP3A5 genes at levels comparable to 
adult Caucasian PHH and this is clinically significant if the cells were to be used for 
transplants since polymorphism of this gene affects the pharmacokinetics of 
immunosuppressants and success rates of transplants (refer description on CYP3A5 
in Table 7.9). 
 In the PCA scores plot (Figure 7.2), it could be seen that although the HLC 
(hFLMPC) samples were derived from three different fetal sources, they were 
clustered together. This suggests a greater degree of homogeneity in terms of their 
drug disposition transcript profile as compared to adult PHH and HepaRG. On the 
other hand, the greater spread of observations observed among both Caucasian PHH 
and Asian liver cells was not unexpected as large inter-individual variability in DME 
profiles is a known characteristic of adult PHH (Nakajima et al., 2002a; Nakajima et 
al., 2002b; Guengerich, 2006; Guo et al., 2011). Therefore, it is very encouraging that 
HLC (hFLMPC) has less inter-individual variability, making it a more viable model 
for routine screening applications during drug discovery. 
 The relative differences between the CYP3A4 functional activity in the five 
cell types correlated well with the gene expression analyses. HepaRG cells exhibited 
good CYP3A4 activity which was close to PHH, matching reported observations in 
the literature (Kanebratt and Andersson, 2008a; Kanebratt and Andersson, 2008b; 
Turpeinen et al., 2009). The inducibility of HepaRG, which was higher than PHH 
when treated with rifampicin also corroborated with those reported in the literature 
(Kanebratt and Andersson, 2008a; Kanebratt and Andersson, 2008b; Turpeinen et al., 
2009). The effects of increasing concentration of inducers on CYP3A4 activity was 
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most pronounced in the HLC (hFLMPC). However, it should be noted that this might 
have been due to the high variability among experimental replicates as although the 
plated cells consisted of a majority of fully differentiated cells, there would have been 
partially differentiated or undifferentiated cells too. There was also presence of 
fibroblasts after the week long of culture and differentiation. Also, the CYP activity 
was corrected to cell viability which did not circumvent the challenge of having a 
mixed culture but in fact, may have diluted the observed CYP3A4 activity. Despite 
these challenges, the experimental results were still important as they demonstrated 
that the HLC (hFLMPC) possess basal CYP3A4 activity, which is an important trait 
as CYP3A4 is the major CYP isozyme responsible for the metabolism of almost 50% 
of therapeutic drugs (refer Table 7.9) (Guengerich, 2006). The CYP3A4 activity was 
inducible by both rifampicin and dexamethasone, indicating that the PXR machinery 
which regulates the expression of CYP3A4 (LeCluyse, 2001) is intact and functional 
in the HLC (hFLMPC) even though the expression levels of the NR1I2, the PXR 
gene, was lower than Caucasian PHH as seen in the gene expression study.    
 Although CYP3A4 activity was observed for HLC (hFLMPC) using the 
Luciferin IPA assay (Figure 7.4), hydroxytestosterone metabolites could not be 
detected using the LC/MS/MS-based method and hence, a qualitative metabolite 
identification and comparion analyses, similar to Chapter 3, could not be performed. 
The method was not sensitive enough even though 350,000 cells per replicate was 
used versus 62,500 cells per replicate in the luminescence-based assay. As the source 
of HLC (hFLMPC) is limited because it was obtained from the liver of aborted 
fetuses, the current findings underscore the importance of performing the high-
throughput screening assay developed in Section 7.2.5 before proceeding to the 
resource intensive LC/MS/MS-based experiment. The triplex assay was also able to 
maximize the use of the cells by investigating two different CYP functions corrected 
to cell viability. This methodology can be applied for future testing of any 
hepatocytes which also face availability challenges. In the positive control cell line, 
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HepaRG, the hydroxytestosterone metabolite profile obtained (Figure 7.7.B) matched 
those seen in human liver microsomes (Chng et al., 2012) and PHH (Langsch et al., 
2009). Although 6β-hydroxytestosterone has been widely used as a marker of 
CYP3A4 activity in HepaRG cells, a search in the literature did not return any 
previous publications on the profile of the hydroxytestosterone metabolites generated 
from the metabolism of testosterone by HepaRG cells. Therefore, the current data 
adds to the continuously increasing pool of knowledge about HepaRG cells.   
 Between the two different HLCs evaluated in this study, it was not 
unexpected that HLC (hFLMPC) performed better than HLC (hAEC) since it was 
derived from liver progenitor cells which have already been programmed to 
differentiate into hepatocytes while hAECs required more coaxing towards 
differentiation into a functional hepatocyte. Nevertheless, the sample availability and 
ethical challenges in using HLC (hFLMPC) make it less desirable to be developed for 
future applications in drug discovery unless methodologies are developed to improve 
the stemness and immortality of these cells in culture. In contrast, hAECs which are 
isolated from discarded placentas is more abundant. However, much work needs to be 
performed to improve the hepatocytic characteristics of the HLCs derived from 
hAEC. Various differentiation protocols have been tried and tweaked, and an 
improved differentiation protocol modelled after the iPS differentiation protocol (Si-
Tayeb et al., 2010) have now been developed and is currently used in our 
collaborator's laboratory.    
 Based on the current results, one would be inclined to question the value of 
pursuing HLC (hFLMPC) as an alternative model for drug metabolism testing since 
HepaRG performed on par with primary hepatocytes. Despite its poor expression of 
CYP enzymes, HLC (hFLMPC) possess comparable Phase II and transporter genes to 
primary human hepatocytes. The better homogenity, as seen from the PCA scores 
plot, would also mean HLC (hFLMPC) can serve as a better screening model than 
HepaRG. The HLC (hFLMPC) also has an added advantage of not being of 
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cancerous origin, an important consideration if the HLC is to be explored for clinical 
transplant purposes. Understanding the strengths and limitation of this model, one can 
utilize the HLC to fill gaps where the HepaRG cell line is unable to do so. Therefore, 
there is definitely value in pursuing this model as an alternative hepatocyte source for 






 For the first time, a detailed drug disposition transcript profiling study was 
performed on HLCs derived from stem cells. The very different profiles observed 
with the HLCs from two different stem cell sources emphasize the importance of a 
thorough characterization before pursuing any HLCs derived from stem cells for use 
in drug metabolism testing. In addition, understanding the maturity of xenobiotic 
metabolism in these cells is also of clinical significance as HLCs are also explored for 
applications in bioartificial liver devices or transplant. The current study 
demonstrated that HLC (hFLMPC) expressed comparable levels of Phase II and drug 
transporter genes to Caucasian PHH, with the overall profile being better than HuH-7 
but nonetheless still distinct from that of PHH. In addition, it possessed functional 
CYP3A4 metabolic activity which was inducible. On the other hand, the HLC 
(hAEC) did not express many drug disposition-related genes and basal CYP1A and 
CYP3A4 metabolic activities were not detected. Future work should include the 
evaluation of the functional metabolic activities of other DMEs in these HLCs as well 
as transporter assays. Other drug-drug interaction aspects such as enzyme inhibition 
should be assessed as well. Metabolism-mediated toxicities can be evaluated to 
explore the use of these cells as a model for toxicity testing. Finally, continuous 
research efforts into optimizing differentiation or co-culture protocols to produce 
HLCs with better hepatocytic function, immortalizing the HLCs and scaling up the 
manufacture of HLCs should be pursued in tandem to fully realize the potential of 








CHAPTER 8: CONCLUSION AND FUTURE WORK 
8.1. Conclusion 
 
 This thesis aimed to evaluate the alternative in vivo model, zebrafish, and in 
vitro model, hepatocyte-like cells (HLCs) derived from two different stem cell 
sources, for drug metabolism testing in drug discovery. The different drug 
metabolism aspects of these models such as basal gene expression and function (CYP 
inducibility and inhibition) were compared to current gold standards or common 
models using different strategies.  
 Metabolically viable zebrafish liver microsomes (ZLM) were successfully 
isolated in Chapter 2 using an optimized protocol wherein it was shown that bile and 
hemoglobin contamination during dissection of the liver from adult zebrafish affected 
the quality of the isolated ZLM. In Chapter 3, using ZLM, it was shown that zebrafish 
possess Cyp3a functional activity via testosterone 6β-hydroxylation activity. 
Zebrafish was similar to the human model in the types of major hydroxytestosterone 
metabolites formed. However, it was more similar to the rat model in generating a 
variety of hydroxytestosterone metabolites, in which two were metabolites unique to 
zebrafish. Cyp3a and Phase II testosterone glucuronidation activities were also 
observed in five days post fertilization (d.p.f.) larvae. The hydroxytestosterone 
metabolite profile was nevertheless different between the adult ZLM and zebrafish 
larva, underscoring the importance of choosing the suitable developmental stage of 
zebrafish for use in specific assays. For the first time, it was found that zebrafish was 
able to form the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) from 
acetaminophen. Using in silico methods, it was suggested that zfCyp3a65 was likely 
the isozyme responsible for both the Cyp3a activity and NAPQI formation.  
 After establishing that zebrafish possessed Cyp3a functional activity and 
acknowledging the limitations and challenges in the isolation of ZLM for metabolic 
168 
 
testing, a high-throughput luminescence-based in vivo assay for the assessment of 
Cyp3a activity in zebrafish was developed and evaluated in Chapter 4 by coupling 5 
d.p.f. larvae with Luciferin IPA in a 96-well plate. An unexpected finding of atypical 
kinetics involving homotropic effects observed for the first time in an in vivo system 
suggested that the metabolism of the luciferin substrates in zebrafish could likely be 
due to a single, predominant enzyme, hypothesized to be zfCyp3a65 based on the in 
silico experiments in Chapter 3.  
 The optimized assay was then used to assess the effects of hCYP3A4 
inducers and inhibitors on the Cyp3a activity in 5 d.p.f. zebrafish larvae in Chapters 5 
and 6, respectively. Cyp3a activity was inducible by six of the eight compounds 
tested while cyp3a65 was upregulated by all compounds albeit only statistically 
significant for rifampicin, rufinamide and prednisone. Zebrafish was similar to the rat 
model in which Cyp3a activity was not induced by rifampicin but a strong induction 
was observed with dexamethasone. It was also demonstrated that cyp3a65 was 
associated with nr1i2 whereby induction by carbamazepine and dexamethasone was 
mediated via this pathway. The results also suggested that cyp3a65 may not be solely 
regulated through the Pxr pathway. For the inhibition study, a good concordance 
between zebrafish and human was observed when comparing the extent of inhibition 
at a fixed concentration of the six hCYP3A4 inhibitors tested. Carbamazepine, 
rifampicin, pioglitazone, erythromycin, cimetidine, fluvoxamine and verapamil were 
shown to be absorbed into the zebrafish via LC/MS/MS methods, thereby accounting 
for the observed induction or inhibition effects.   
 The findings of this thesis, as summarized above, provides a better 
understanding on the Cyp3a function, related DDI issues and bioactivation potential 
in zebrafish, in comparison with human and rats. Based on the evaluation performed, 
it is the author's opinion that the zebrafish model does hold great potential for 
metabolism testing in early drug discovery. It not only possessed the most important 
Cyp activity in the metabolism of pharmaceutical drugs, but could also be used in a 
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high-throughput manner to assess inducibility or inhibitory potential of compounds, 
with a good degree of concordance to human. Nevertheless, the model requires 
further characterization and validation, and innovation and creativity, before it can 
successfully add value in the drug discovery workflow, when positioned strategically. 
 A more exhaustive validation on the drug metabolizing phenotype of 
zebrafish is required for pharmaceutical scientists to evaluate the suitability of this 
model for not only drug metabolism testing but also applications in other drug 
discovery research. The knowledge gained may also help explain the false-negatives 
and false-positives seen with previous toxicity studies such as QT prolongation, 
developmental toxicity, ototoxicity, visual toxicity and seizure liability which attained 
a level of predictivity ranging from “sufficient” (65 – 75% predictivity) to “good” (75 
– 85% predictivity), based on guidelines established for novel in vitro tests by the 
European Centre for the Validation of Alternative Methods (Redfern et al., 2008; 
Eimon and Rubinstein, 2009). As an example, in a study which evaluated the effects 
of 100 biologically active small molecules on the heart rate of zebrafish embryos at 2 
d.p.f., four of the five false-negatives (N-acetyl-procainamide, pentamidine, 
procainamide, and sotalol) were found to induce bradycardia only after following 
microinjection into the yolk sac, suggesting that the pharmacokinetic factor of poor 
absorption played a role in causing the false-negative results (Milan et al., 2003). 
Hence, it would not be unexpected if some of the other false-negatives observed 
previously may be due to differences in the metabolism of compounds by zebrafish, 
which is not completed understood at this juncture. As such, future work in this 
research area is definitely required and are outlined in the following section. 
 The evaluation of HLCs derived from human fetal liver multipotent 
progenitor cells (hFLMPC) and human amniotic epithelial cells (hAEC) using qRT-
PCR methodology revealed the basal expression of 24 drug disposition-related genes 
in comparison to the gold standard adult Caucasian PHH and Asian liver cells, and 
two commonly used hepatoma cell lines, HuH-7 and HepaRG. The drug disposition 
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transcript profile was different between the two types of HLCs where HLC 
(hFLMPC) expressed a fair number of Phase II and drug transporter genes in levels 
comparable to Caucasian PHH, while many genes were undetected in HLC (hAEC). 
The profile of HLC (hFLMPC) was better than HuH-7 but still distinct from that of 
PHH. It was also shown that HLC (hFLMPC) possessed functional CYP3A4 
metabolic activity which was inducible.  
 The current findings enable scientists to appreciate the strengths and 
limitations of HLCs differentiated from hFLMPC and hAEC and identify areas to be 
improved upon. The HLC (hFLMPC) is promising for screening applications due to 
its relatively homogenous inter-individual metabolic profiles. The experimental 
results will also help facilitate optimization of pharmacotherapy involving 
immunosuppressant drugs if these HLCs are considered for clinical liver transplant 
applications. The systematic and comparative approach adopted in this thesis to 
evaluate the metabolic profile of HLCs derived from stem cells is also novel and 
important. This approach can and should be applied to characterize the drug 
metabolizing profiles of HLCs derived from any stem cell source considered for drug 
metabolism testing.  
 With the rapid advancement and progress in the arena of stem cell research, 
the author is inclined to believe that HLCs derived from stem cells with better 
hepatocytic characteristics, and hence better metabolic profile, would emerge in the 
near future. Therefore, HLCs derived from stem cells do hold promise to be a good 
alternative to PHH and carcinoma cell lines but a thorough evaluation is warranted 
for any HLCs derived from stem cells when they are considered for use in drug 







8.2. Future work 
 
 Specific future work which can be performed were discussed and proposed in 
the Conclusion sections of each chapter. They can be broadly classified to two 
categories: further evaluation of the drug metabolism profile of these two alternative 
models in terms of (1) breadth - evaluation of other DMEs and transporters 
(expression or function), and exploring the different aspects of DDIs, reactive 
metabolite formation and metabolism-related toxicities, or (2) depth - mechanistic 
investigations to explain the similarities, differences and novel findings in the 
metabolic profiles observed. Both angles of investigation are required to expand the 
current limited pool of knowledge about drug metabolism in zebrafish and HLCs 
derived from stem cells.  
 Other existing research gaps, and hence future work, which are pivotal in 
complementing the knowledge gained from drug metabolism studies to realize the 






8.2.1. Alternative in vivo model - zebrafish (Danio rerio) 
 
 The current thesis evaluated the drug metabolism aspect out of the four 
pharmacokinetic pillars (absorption, distribution, metabolism and excretion (ADME)) 
in the zebrafish model. Much remains to be investigated to address the huge research 
gap in understanding the ADME profile of drugs between zebrafish and human or 
other mammalian models. The ADME of a drug is affected by factors such as the 
route of administration, physicochemical properties of the drug and physiology of the 
fish. To fully realize the potential of zebrafish as an alternative model for use in drug 
discovery, a holistic knowledge on the ADME characteristics of zebrafish needs to be 
obtained. Below are research gaps and future work which can be performed to gain 
insight into this model and assess its suitability as an alternative model for use in drug 
discovery. 
 
1) Absorption studies 
 In using zebrafish embryo as a high-throughput screening system, the most 
common route of drug administration is by immersion of embryo into a medium 
which contains the solubilized drug. Researchers should bear in mind that the 
immersion technique for dosing of drugs to zebrafish is analogous to depot injection 
in the mammalian model as there are both absorption and continuous exposure of the 
biological system to the drug. This information is important for selecting a suitable 
mathematical model for pharmacokinetic study in zebrafish. The drug is then 
absorbed by the embryo across the chorion enveloping the embryo (if the drug fails to 
absorb through the chorion, then the chorion can be removed chemically or 
manually).  
 In the larvae or adult fish, drug absorption occurs through the skin, gill and 
gut, out of which dermal uptake may contribute up to 50% of the total uptake of 
compounds that are hydrophobic (Kleinow et al., 2008). Realizing the importance of 
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ascertaining the extent a drug is absorbed by zebrafish to circumvent erroneous 
pharmacokinetic-pharmacodynamic correlation, researchers would benefit if there 
exists a set of rules comprising cut-off molecular weight, log P or polar surface area, 
such as the Lipinski’s rule of five for the determination of drug-likeness of 
compounds (Lipinski et al., 2001), to help predict if a compound can be absorbed into 
the zebrafish embryo, larva or adult fish. In this thesis, an evaluation of the absorption 
of seven compounds into 5 d.p.f. larvae was conducted. The findings were 
nevertheless preliminary as other aspects such as protein binding was not corrected. A 
detailed drug absorption study, evaluating the uptake of a wider range of compounds 
in various developmental stages of the zebrafish would therefore be necessary to 
address this research gap on the prediction of compound absorption. 
 
2) Distribution studies 
 The extent of the distribution of a drug to a particular organ or tissue is of 
importance, especially when studying specific organ toxicity. Distribution of drug is 
affected by blood flow rate, binding to plasma/tissue proteins, permeability across 
membrane barriers and interaction with transporters. It has been shown that the total 
concentration of plasma protein as well as qualitative properties of individual protein 
classes differ between fish and mammals (Kleinow et al., 2008). For adult zebrafish, 
this difference would certainly impact the drug distribution between the plasma and 
tissue compartments in zebrafish compared to mammals. Equilibrium dialysis 
methods may be used to investigate the plasma protein binding of drugs in zebrafish. 
However, one must be mindful of the possible challenges in obtaining sufficient 
volume of blood from adult zebrafish to conduct such experiments.  
 Although these very same factors affect drug distribution in zebrafish embryo 
and larvae as well, it is immensely challenging to study specific organ distribution in 
the embryo or larvae due to their small size. That said, characterization of drug 
binding to proteins in whole tissue can still be made through equilibirum dialysis 
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methods using whole embryo or larvae homogenates albeit requiring large amounts of 
sample. In face of these challenges, scientists must be creative to assess the 
distribution aspect of ADME in the zebrafish using a panel of model drugs with 
diversified physicochemical properties as it is a necessary step forward to obtain 
accurate pharmacokinetic properties of drugs in zebrafish.   
 
3) Drug transporter studies 
 In the past decade, drug transporters have been intensely studied as the 
awareness of their impact on the absorption, distribution, excretion and toxicity of 
drugs has increased (Endres et al., 2006). However, little work has been done in the 
field of drug transporter research in zebrafish. Thus far, forty-one ATP-binding 
cassette (ABC) transporters have been identified in the zebrafish genome (Dean and 
Annilo, 2005). In a proof-of-concept experiment, Scholz et al. demonstrated that 
cyclosporine A inhibition of ABC transporter caused accumulation of rhodamine B in 
zebrafish larvae (Scholz et al., 2008). As seen in Chapter 4, the lack of knowledge on 
drug transporters in zebrafish posed a challenge in choosing suitable P-gp inhibitors 
to assess the contribution of P-gp transporter in the absorption of Luciferin-IPA. 
Therefore, scientists should actively pursue this exciting research area in the zebrafish 
model, not only to understand its role in drug transport, but also to assess its potential 
to be used as a model for drug transport studies in drug discovery.  
 
4) Experimental condition studies 
 The effects of experimental conditions such as temperature, pH of medium 
and choice of solvent/vehicle on the experimental outcomes in the zebrafish should 
be investigated and validated. These factors, often overlooked, are important because 
the zebrafish thrive in an enviroment that is very different from mammalian models 
such as the rodent or even cell culture, and sub-optimal living conditions may affect 
the physiology of the fish, and hence the experimental outcomes.  
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5) Determination of the optimal developmental stage to use for specific assays 
 The developmental stage of the zebrafish at time of experiment initiation is 
yet another important consideration. For instance, if the pharmaceutical scientist is 
using the zebrafish to investigate direct toxicity from parent drug, presence of a 
mature liver may not be crucial. However, a mature metabolizing liver may be critical 
when a toxic electrophilic metabolite is suspected. Similarly, if the zebrafish is used 
for other assays such as cardiotoxicity or neurotoxicity, the right developmental stage 
where the mature organ is present should be chosen.  
 
 It is the author's opinion that resolving these highlighted issues will be 
essential for zebrafish to realize its full potential as an alternative model for drug 
discovery applications. Ironically, the small size of zebrafish embryo and larva, an 
advantage that sets it apart for high-throughput drug toxicity screening, is the greatest 
disadvantage that could well limit ADME investigation. Scientists have to thus 
innovate current available experiments to study ADME in the zebrafish, as was 
performed in this thesis where the Promega P450-Glo™ CYP3A4 assay, designed for 
human liver microsomes and hepatocytes, was optimized and used in zebrafish to 
evaluate its Cyp3a basal activity, inducibility and ability to be inhibited. These 
challenges, nonetheless, can be turned into exciting research opportunities which are 




8.2.2. Alternative in vitro model – hepatocyte-like cells (HLCs) derived from 
stem cells 
 
 The supply of HLC (hFLMPC) and maturity of both types of HLCs were 
constant challenges in this project. While the objective of this thesis was to evaluate 
the metabolic profile of HLC derived from stem cells and demonstrate the importance 
of performing a thorough characterization before utiziling HLCs for drug metabolism 
studies, the HLCs can never fully realize its potential even if they possess a good 
metabolic genotype or phenotype that is comparable to adult PHH unless the 
following research gaps are addressed. 
  
1) Optimization of culture and differentation protocols to produce HLCs with 
better hepatocytic characteristics 
 Various approaches have been utilized by scientists to differentiate a myriad 
of stem cells such as mouse or human embryonic stem cells, Wharton's jelly, 
mesenchymal stem cells or induced pluripotent stem cells to HLCs. The following are 
some of the methodologies that have been employed, either individually, or in 
combination: 
a) Addition of growth factors such as hepatocyte growth factor (HGF) and fibroblast 
growth factor (FGF) among many others, cytokines such as Oncostatin M, and 
additives such as nicotinamide, dimethyl sulfoxide, dexamethasone or insulin, 
transferrin and selenious acid (ITS), into the differentiation medium (Lavon and 
Benvenisty, 2005).  
b) Transfection of transcription factors such as hepatocyte nuclear factor-3β (HNF-
3β) (Ishizaka et al., 2002) or Foxa2 (Liu et al., 2013) into the cells. 
c)  Co-culture with other cell types such as liver non-parenchymal cell lines (Soto-
Gutierrez et al., 2007), embryonic cardiac mesoderm (Fair et al., 2003), liver cells 
(Qihao et al., 2007) or hepatic stellate cells (Nagai et al., 2002). 
177 
 
d) Three-dimensional culture using collagen scaffold (Imamura et al., 2004), ultra-
low cluster dishes (Ogawa et al., 2013) or nanofiber (Ghaedi et al., 2012). 
e) Tweaking culture conditions such as using hypoxic environment (Prasajak and 
Leeanansaksiri, 2013) or conditioned medium (Chen et al., 2007). 
f) Overexpression of microRNAs such as miRNA-122 (Doddapaneni et al., 2013). 
 
 The list of methodologies above is not exhaustive and are examples of 
strategies which have been used on different sources of stem cells. It must be noted 
that every type of stem cell would require a different protocol to direct differentiation 
to HLC and this research area remains to be investigated and improved, especially for 
the two stem cell sources evaluated in this thesis. 
 
2) Exploring methods to prolong self-renewability of stem cells in culture  
 Although the term 'stem cells' imply long term self-renewal and immortality, 
non-embryonic stem cells cannot proliferate for very long in laboratory conditions 
and current culture techniques (Bethesda). This is especially true for the hFLMPC 
used in this thesis where the cells can only be passaged three to four times. Once 
differentiated, de-differentiation of the HLC and overgrowth of fibroblasts posed 
challenges in maintaining them in culture for long periods of time. Scientists have 
employed methods such as overexpressing human telomerase reverse transcriptase 
(hTERT) to reconstitute telomerase activity and extend life span of bone marrow 
stromal cells (Simonsen et al., 2002). Much remains to be researched on in this area 





3) Large scale manufacturing of HLCs from stem cells 
 A huge quantity of cells is required for both pharmaceutical and clinical 
applications. Efforts in pursuing large scale manufacturing of HLCs with good 
hepatocytic characteristics are definitely needed for them to be realistically applied in 
drug discovery or the clinics. Thus far, scalable stirred-bioreactors have been used to 
generate HLCs from human pluripotent stem cells (Vosough et al., 2013). Further 
research in this area is definitely necessary to ensure that it is feasible to use HLCs 
for the promises they hold.  
 
 The above three aspects suggested are but only a few out of the plethora of 
stem cell research investigations which can be performed. These three aspects were 
chosen as the future direction of HLC research as the author is of the opinion that 
they are crucial research gaps to be addressed in parallel with further investigation 
into the drug metabolism profile of HLCs for them to be successfully utilized as an 
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APPENDIX II: SUPPLEMENTARY INFORMATION 
Supplementary Table 1: Nuclear receptor-ligand interaction and their effect 
on the expression of drug metabolizing enzymes (Phase I and II) and ABC 






Phase I Phase II Phase III 
Xenobiotics AhR XRE CYP1A1 (+) UGT1A1 (+) ABCG2 (+) 
CYP1A2 (+) UGT1A6 (+)  CYP1B1 (+) 




CYP2A6 (+) UGT1A1 (+) ABCC2 (+) 
Phenobarbital CYP2B1 (+) 
 
ABCC3 (+) 
CYP2B6 (+) ABCC4 (+) 
CYP2C9 (+)  CYP2C19 (+) 
Bile acids FXR IR-1 CYP7A1 (−) UGT2B4 (+) ABCB4 (+) 




Oxysterols LXRα, β DR-4 CYP2B6 (−) 
 
ABCA1 (+) 




Fatty acids PPARα DR-1 CYP4A1 (+) UGT1A9 (+) ABCA1 (+) 
Fibrates CYP4A3 (+) UGT2B4 (+) ABCC2 (+) 
CYP7A ABCD2 (+) 
ABCD3 (+) 
Fatty acids PPARδ  CYP4A (+) UGT1A (+) ABCA1 (+) 
Carboprostacyclin 
Eicosanoids PPARγ  CYP4AB (+) UGT1A9 (+) ABCA1 (+) Thiazolidinediones ABCG2 (+) 
Retinoic acids RARα, 
β, γ  
CYP2B6 (+)  ABCB1 (+) ABCG4 (+) 
1,25(OH)2-
vitamine D3 
VDR DR-3 CYP2B6 (+) SULT2A1 
(+) 
ABCC2 (+) ? 
ER-6 CYP2C9 (+) 
IR-0 CYP3A4 (+) 
Glucocorticoid GR GRE CYP2C9 (+) 
  CYP2B6 (+) 
CYP3A4 (+) 
ROS Nrf2 ARE 
 
γ-GCS (+) ABCC1 (+)? 
Electrophiles GST (+) ABCC2 (+) 
NQO1 (+) ABCC3 (+) 
UGT (+) ABCG2 (+)? 
HO-1 (+) 




Supplementary Table 2: Summary of the effect of nuclear receptor activation 
on target gene expression (adapted from Urquhart et al. (2007)). 
 
Target gene Nuclear 
receptor 
Nuclear receptor ligands Effect on 
target genes 
CYP3A4 PXR Rifampin, hyperforin, clotrimazole, phenytoin, 
phenobarbital, dexamethasone, zearalenone, 
flucloxacillin, artemisinin, nicotine, nifedipine, 
nicardipine, isradipine, troleandomycin, 
omeprazole, paclitaxel, forskolin, 
carbamazepine, topotecan, etoposide, 
mevastatin, sulfinpyrazone 
↑ 
Ritonavir, ketoconazole ↓ 
CAR Artemisinin, phenobarbital, CITCO ↑ 
GR Dexamethasone ↑ 
HNF4α  ↑ 
VDR 1α,25 hydroxyvitamin D3, 19-nor-1α,25-
dihydroxyvitamin D2, lithocholic acid 
↑ 
FXR Chenodeoxycholic acid, GW4064 ↑ 
CYP2C9 PXR Hyperforin, rifampin, nifedipine, nicardipine, 
isradipine, dexamethasone 
↑ 
CAR Phenobarbital ↑ 
GR Dexamethasone ↑ 
CYP2C19 CAR Phenobarbital ↑ 
GR Dexamethasone ↑ 
CYP2B6 PXR Artemisinin, nifedipine, nicardipine, isradipine, 
rifampin, clotrimazole, phenobarbital, phenytoin 
↑ 
CAR Cerivastatin, fluvastatin, simvastatin, 
atorvastatin, artemisinin, phenytoin, CITCO, 
phenobarbital 
↑ 
UGT1A1 PXR Rifampin ↑ 
CAR Phenobarbital ↑ 
AhR Β-Naphthoflavone, TCDD ↑ 
GST PXR Dexamethasone ↑ 
SULT2A1 PXR Dexamethasone ↑ 
VDR Vitamin D3 ↑ 
FXR Chenodeoxycholic acid ↑ 
MDR1 PXR Flucloxacillin, artemisinin, rifampin, hyperforin ↑ 
CAR Artemisinin ↑ 
MRP2 PXR Rifampin, hyperforin ↑ 
CAR Phenobarbital ↑ 
FXR Chenodeoxycholic acid ↑ 
MRP4 CAR Phenobarbital ↑ 
BSEP FXR Cholic acid, chenodeoxycholic acid ↑ 
 Lithocholic acid ↓ 
BCRP PPARγ Rosiglitazone ↑ 
 GW9662 ↓ 
NTCP GR Dexamethasone ↑ 
OATP8 FXR Chenodeoxycholic acid ↑ 





Supplementary Figure 1: Testosterone docked into (A) hCYP3A4, (B) hCYP2B6, 

















Supplementary Figure 2: Acetaminophen docked into hCYP3A4 (A) reference 
pose 1 and (B) reference pose 2.    
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